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ABSTRACT
The Minor Spliceosome Regulates Alternative Splicing of Minor Introns in Neuronal
Development and Disease
Anouk Olthof, Ph.D.
University of Connecticut, 2020
Expression of ~2% of eukaryotic genes requires the splicing of not just one, but two types of
introns: major, as well as minor, introns. These minor introns contain divergent sequences at their
splice sites which are recognized by the minor spliceosome (U11, U12, U4atac, U6atac and U5).
Since splicing of both intron classes occurs co-transcriptionally, expression of minor introncontaining genes (MIGs) is thought to require the coordinated action of both the major and minor
spliceosome. Proper MIG expression is especially important for nervous system development, as
underscored by multiple diseases linked to pathogenic variants in minor spliceosome
components. To understand this bias of nervous system involvement, I examined tissue-specific
splicing of minor introns. To this end, I identified all minor introns in the mouse and human genome
and developed new bioinformatics pipelines to study their splicing. Moreover, I identified a subset
of MIGs whose aberrant splicing might underlie prevalent symptoms, like microcephaly, observed
in minor spliceosome-related diseases. To determine how disrupted minor intron splicing can
result in microcephaly we then ablated U11 snRNA in the dorsal telencephalon. U11 loss
especially resulted in the death of self-amplifying radial glial cells, through cell cycle defects, DNA
damage and p53-mediated apoptosis. This was due to retention and alternative splicing (AS) of
minor introns found in genes with crucial roles in cell cycle and led me to explore the mechanism
of regulating AS around minor introns. I found that AS is normally repressed through interactions
between minor spliceosome component U11-59K and the major spliceosome. Inhibition of the
minor spliceosome relieves this repression, resulting in elevated AS in individuals with pathogenic
variants in U4atac and U12 snRNA. To test whether disrupted minor intron splicing also plays a
role in amyotrophic lateral sclerosis (ALS), we then ubiquitously ablated U11 in juvenile mice and
found that they recapitulated most of the pathological hallmarks associated with ALS. In all, I show
how the major and minor spliceosome interact to regulate the proper splicing of minor introns in
a tissue-specific manner. Moreover, we found that disrupted minor intron splicing affects survival
of both neural progenitors and motor neurons.
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Chapter 1 Splicing
1.1 Major intron splicing
The central dogma of molecular biology, as first described by Francis Crick in 1958, postulates
that genetic information is transferred from DNA to protein (1). While it was hypothesized that this
transfer of genetic information occurred through RNA, it was not until three years later that the
true “messenger” was established. In 1961, Brenner et al., found that bacteria contained newly
synthesized RNA after infection with bacteriophages, which corresponded to the DNA sequences
of the bacteriophage genome (2). Moreover, they found that this RNA was loaded into pre-existing
ribosomes (2). The identification of this messenger RNA (mRNA) was the key to explain how
protein synthesis is regulated, not only in bacteriophages, but also in prokaryotes.
In contrast, infection of HeLa cells with adenovirus 2, resulted in the detection of mRNA in
the ribosomes that was generally much shorter than the corresponding DNA sequences. Thus,
this suggested that in eukaryotes, there was an additional processing step after transcription, to
obtain mRNA (3, 4). To determine this intermediate step in mRNA production, the laboratories of
Dr. Philip Sharp and Dr. Richard Roberts isolated the mRNA coding for a virion structural protein
from adenovirus 2-infected HeLa cells (3, 4). Incubation of this specific mRNA with fragmented
adenovirus 2 DNA that encoded the mRNA of the virion structural protein, resulted in the formation
of three DNA-RNA hybrids, called R-loops (3, 4). These R-loops are formed when only parts of
the DNA are complementary to RNA, and other segments are not. These complementary regions
in the DNA can only basepair to the contiguous RNA if the non-complementary sequences are
looped out. Therefore, the presence of three R-loops suggested that only three short segments
of the DNA were found in the mRNA, which were separated by non-complementary RNA (3, 4).
As such, it was postulated that after transcription, certain nucleotide sequences were spliced out
from the RNA in eukaryotes (3, 4). These intragenic regions were then called introns, whereas
the regions expressed in the mRNA were termed exons (5). We now know that the process of
1

intron splicing is a major player in the regulation of gene expression for most eukaryotic proteincoding genes. As such, the discovery of introns by Dr. Philip Sharp and Dr. Richard Roberts was
awarded the Nobel Prize in 1993.
1.1.1

Consensus sequences

Subsequent to the discovery of introns in the adenovirus 2 genome, introns were identified in
many eukaryotic genes (6). Analysis of these cloned intronic sequences revealed a remarkable
conservation of nucleotides at the terminal ends of the intron. Particularly, the first two nucleotides
of the intron (+1 and +2 position) were almost always a GT, whereas the last two nucleotides (-1
and -2 position) were exclusively AG (7). While the GT-AG rule proved almost invariably true for
introns of eukaryotic protein-coding genes, it turned out that the consensus sequence at the 5’
splice site (5’SS) and 3’ splice site (3’SS) was longer than two nucleotides. Specifically, the
consensus sequence of the 5’SS consists of a stretch of eight nucleotides spanning from the last
two nucleotides in the exon (-2 and -1 position), to the first six nucleotides of the intron (+1 to +6
position), and can be described by 5’-AG/GTRAGT-3’ (R=purine; /=exon-intron boundary) (Figure
1.2A) (8, 9). The consensus sequence at the 3’SS is four nucleotides long (-3 to +1 position) and
can be described by 5’-YAG/G-3’ (Y=pyrimidine; /=intron-exon boundary) (Figure 1.2A) (8).
Additionally, upstream of the 3’SS, a stretch of at least 11 pyrimidines was observed, which is
now referred to as the polypyrimidine tract (PPT) (Figure 1.2A) (8). Finally, a third, less conserved
consensus sequence can be found in introns, generally located 18-40 nucleotides upstream of
the 3’SS (10, 11). While more degenerate in sequence, this branch point sequence (BPS) has
also proven to be essential for the proper splicing of introns and consists of the five nucleotides
5’-RTNAR-3’ (Figure 1.2A) (9, 12, 13). Overall, ~99% of all known eukaryotic introns are
characterized by these three consensus sequences, and are therefore referred to as major introns
(14, 15).
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1.1.2

Biogenesis of the major spliceosome

Splicing of all major introns is executed by the major spliceosome, a ribonucleoprotein (RNP)
complex, consisting of five small nuclear RNAs (snRNA) that are each associated with many
proteins (9). These snRNAs are ~100bp long and are encoded by several different gene copies
whose expression is both spatially and temporally regulated (16, 17).
Transcription of the genes encoding for the major spliceosomal snRNAs U1, U2, U4 and
U5 (Class I snRNAs) is executed by RNA polymerase II (18). Since these snRNAs do not contain
a poly-A tail, their 3’ end processing depends on the presence of a 3’ box that is located between
9-19 nucleotides downstream of the mature 3’ end (19, 20). Following transcription and addition
of a 7-monomethylguanosine (m 7G) cap, the precursor snRNAs undergo initial 3’end processing
by the integrator complex, which involves endonucleolytic cleavage a few nucleotides upstream
of the 3’ box (21, 22). Afterwards, the Class I snRNAs are exported to the cytoplasm by an export
complex consisting of the cap-binding complex (NCBP1 and NCBP2), the export receptor XPO1,
the snRNA-specific adaptor protein PHAX, and Ran GTPase (23-26). Once in the cytoplasm, the
export complex dissociates from the precursor snRNAs and the SMN protein complex, consisting
of SMN and Gemins2-7, binds to the Sm binding site found in the snRNAs (27, 28). This allows
for the recruitment of seven Sm proteins (SNRPB, SNRNPD1, SNRNPD2, SNRNPE, SNRNPF,
SNRNPG) that form a heptameric ring around the Sm binding site (29). Afterwards, the m7G cap
of the snRNAs is hypermethylated by TGS1 to form a 2,2,7-trimethylguanosine (TMG) cap (30,
31). Additionally, the 3’ end of the snRNAs are trimmed a few nucleotides by a yet unidentified
exonuclease (32). Following this, an import complex consisting of SPN and KPNB1 associate with
the snRNP and allow for its nuclear translocation (33, 34). Here, the snRNPs localize to Cajal
bodies where the snRNAs are 2’-O-methylated and pseudouridylated by scaRNPs, and
additional, snRNP-specific proteins, are loaded onto the complex (35, 36). Afterwards, the mature
snRNPs are assembled into splicing-competent units such as the U4/U6.U5 tri-snRNP (37-40).

3

Finally, the Cajal bodies are also used for the recycling of these splicing-competent units, which
is necessary as the spliceosome undergoes several structural rearrangements during the splicing
reaction (41).
In contrast, U6 snRNA is a Class II snRNA and transcribed by RNA polymerase III (42).
Class II snRNAs do not contain a 3’ box but instead a stretch of uridines which are added by
TUT1 and function as a transcription termination signal (43, 44). The exonuclease USB1 then
removes the last uridine to form a 2’,3’-cyclic phosphate (>P) (45-47). A ring of seven LSm
proteins (LSM2, LSM3, LSM4, LSM5, LSM6, LSM7, LSM8) is then pre-assembled in the
cytoplasm and loaded onto the uridine stretch in the nucleus (48). Additionally, Class II snRNAs
possess a gamma-monomethyl phosphate cap, which is not hypermethylated as they do not leave
the nucleus for their maturation (49). Moreover, 2’-O-methylation and pseudouridylation of Class
II snRNAs does not take place in Cajal bodies, but in the nucleolus by snoRNPs (50, 51). Only
once the Class II snRNPs are fully mature do they move to the Cajal bodies to associate with
other snRNPs (52).
1.1.3

The splicing reaction (intron-definition model)

Since splicing occurs co-transcriptionally, the spliceosome is recruited to the newly synthesized
pre-mRNA to execute the splicing reaction as soon as the first intron of a gene is transcribed (53).
This splicing reaction can be divided into three main steps: 1) intron recognition, 2) the first transesterification reaction that results in the formation of an intron lariat and release of the 5’ exon,
and 3) the second trans-esterification reaction that results in the release of the intron lariat and
ligation of the 5’ and 3’ exon (54, 55). Most of the initial research that focused on intron recognition
took place in yeast, where the average intron length is ~60 nucleotides (56). For these short
introns, intron recognition starts with the recruitment of U1 snRNP to the 5’SS (Figure 1.1) (5759). Specifically, U1 snRNA will base pair with the 5’SS (from -3 to +6 position) while the nonsnRNP protein SF1 interacts with the BPS (Figure 1.1) (57, 60, 61). Finally, the U2AF1 and
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U2AF2, which make up the U2AF complex, interact with the terminal AG dinucleotide at the 3’
end of the intron, and the PPT, respectively (Figure 1.1) (62-64). Together, this early spliceosomal
complex is referred to as the E complex (Figure 1.1). After identification of the BPS by SF1, U2
snRNP is recruited to the BPS by the U2AF complex (62, 65). It then displaces SF1, resulting in
the formation of the spliceosome A complex (Figure 1.1) (66). Initially, the interaction of U2 snRNP
with the BPS is weak, in part because the base pairing of U2 snRNA with the BPS is imperfect,
resulting in the bulging of an adenosine (Figure 1.1) (67, 68). However, this interaction is stabilized
after the protein DDX46 is recruited and binds to both U1 snRNP and U2 snRNP (69). Afterwards,
the U4/U6.U5 tri-snRNP, where U4 and U6 are connected through base pairing of the snRNAs
and U5 is associated through protein interactions, is recruited to the intron, yielding the
spliceosome pre-B complex (Figure 1.1) (70-72). This is followed by several structural
rearrangements within the spliceosome that activate the complex (B complex) (Figure 1.1) (72).
Specifically, U6 snRNP dissociates from U4 snRNP and base pairs with U2 snRNA (Figure 1.1)
(73-76). Moreover, the tri-snRNP protein DDX23 displaces U1 snRNP at the 5’SS such that U6
snRNA can also base pair with the 5’SS, thereby juxtaposing the 5’SS and the BPS (Figure 1.1)
(77-79). Finally, U5 snRNA base pairs with nucleotides in the 5’ exon, as well as in the 3’SS,
thereby further bringing the ends of the intron together (Figure 1.1) (80, 81). The destabilization
of U1 and U4 snRNP results in their exit from the spliceosome, which at this point becomes
catalytically activated (Bact complex) due to the activation of the DEAH-box RNA helicase DHX16
(Figure 1.1) (82-84). This Bact complex can then initiate the first transesterification reaction. Here,
the 2’ hydroxyl group of the bulging adenosine in the BPS acts as a nucleophile and performs a
nucleophilic attack on the phosphodiester bond at the exon-intron boundary (between -1 and +1
nucleotides) (54, 55). This step yields the spliceosome C complex, which contains the free 5’
exon, and an intermediate intron lariat (Figure 1.1) (85). It then undergoes several other ATPdependent rearrangements that involve PRPF8, DHX36 and SLU7, which catalyzes the second
transesterification reaction whereby the free hydroxyl group of the free 5’ exon performs a
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nucleophilic attack on the 3’SS (54, 55, 86). This results in the ligation of both exons and the
formation of an intron lariat (Figure 1.1). Finally, the spliceosomal components dissociate from
the spliced mRNA and are recycled in the Cajal bodies (see section 1.1.2), after which they will
participate in additional rounds of splicing (87). While this splicing reaction, in which the
spliceosome is assembled across the intron, was initially identified in yeast, this intron-definition
model is now thought to describe the splicing of all eukaryotic introns shorter than ~250
nucleotides (88).
1.1.4

The splicing reaction (exon-definition model)

Most vertebrate genes consist of long introns ~1200 nucleotides and short exons of approximately
140 nucleotides (89). Due to the long intron length, there are many putative BPS sequences,
which would complicate the binding of SF1 and U2 snRNP to the correct one. Therefore, splicing
of introns in most vertebrate genes is thought to occur according to the exon-definition model
instead of the intron-definition model (88, 90, 91). The exon-definition model first describes the
binding of U1 snRNP to the 5’SS of the nascently transcribed intron. Other spliceosomal
components are not recruited until the 5’SS of the downstream intron is also transcribed. Then,
another U1 snRNP will be recruited to this 5’SS, which in turn promotes the binding of the U2AF
complex to the PPT and 3’SS of the upstream intron (E complex) (Figure 1.1) (92). These exonspanning interactions are mediated by the U1 snRNP protein SNRNP70, which interacts with
serine-arginine-rich (SR) proteins that have been recruited by splicing enhancer sequences found
in the exon (93). This exon-spanning complex in turn will lead to the recruitment of U2 snRNP to
the correct BPS of the upstream intron (A complex) (Figure 1.1) (62, 65). It was thought that the
spliceosome would then need to be remodeled to disrupt the exon-spanning interactions and
convert them to intron-spanning interactions at some point. One hypothesis was that this occurred
during the A complex formation, such that the exon-spanning complex would be disrupted and
U2 snRNP would start to interact with the U1 snRNP bound to the upstream 5’SS, followed by
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the formation of the intron-defined spliceosome B complex (41). However, other experiments
revealed the presence of the U4/U6.U5 tri-snRNP in the exon-spanning complex, thereby
suggesting that the exon-spanning A complex might be remodeled directly into the intronspanning B complex (94). Recently, these two models were reconciled when it was shown that
the recruitment of the U4/U6.U5 tri-snRNP results in an increased angle between the U1 and U2
snRNP that are bound to the pre-mRNA (95). The short length of vertebrate exons is thought to
hinder this conformational change and therefore stall spliceosome assembly at the pre-B
complex, which is unstable (Figure 1.1) (95). This signal would then allow for the upstream 5’SS
to interact with the tri-snRNP, resulting in the formation of an intron-spanning B-complex without
the need for any spliceosomal rearrangements (Figure 1.1) (95). Once the spliceosome has then
adopted this intron-spanning conformation, the splicing reaction proceeds as described in 1.1.3.
1.2 Minor intron splicing
Initially it was thought that the consensus sequences described in section 1.1.1 were present in
all introns. However, it became clear in the 1990s that introns with other consensus sequences
also existed (96). Comprehensive bioinformatics analyses then revealed that, depending on the
species, approximately 0.5% of all introns shared consensus sequences at the 5’SS and 3’SS
that diverged from major introns (Figure 1.2A) (14, 15). Since the sequences at these splice sites
are crucial for the base pairing with spliceosomal snRNAs, it was hypothesized that an alternative
spliceosome machinery must exist to splice these minor introns (97). Indeed, in 1996 Dr. Joan
Steitz identified the snRNAs that make up the minor spliceosome, followed by the identification of
minor spliceosome protein components in by Dr. Reinhard Luhrmann (98-101).
1.2.1

Identification of minor introns

In 1991, Jackson observed that the intronic splice site sequences of two introns in the genes
cartilage matrix protein (CMP) and nucleolar protein 120 (P120/NOP2) did not conform to the
reported consensus sequences for introns (96). Notably, these introns did not contain the terminal
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dinucleotides GT-AG, but instead contained the sequences AT-AC. Three years later, another
two introns in the mouse gene Rep-3 and Drosophila gene prospero were identified with the
divergent AT-AC terminal dinucleotides (97). Further analysis of these four introns revealed that
more than just the terminal dinucleotides were different than that of major introns, and that these
introns contained an entirely different 5’SS, BPS and 3’SS sequence. The consensus sequence
at the 5’SS of these divergent introns was established as 5’-/ATATCCTTT-3’, at the BPS as 5’TCCTTAAC-3’, and at the 3’SS as 5’-YCCAC/-3’ (102). Besides these conserved and longer
consensus sequences, these introns were also divergent in that they did not contain a PPT (102).
A year later, additional introns were identified with splice sites that mostly corresponded
to the consensus sequences of these AT-AC introns, even though they possessed GT-AG
terminal dinucleotides (103). This led to the refinement of the official consensus sequences of
minor introns to 5’-/RTATCCTTT-3’ (R=purine;/=exon-intron boundary) at the 5’SS, 5’TTCCTTRAY-3’ (Y=pyrimidine) at the BPS, and 5’-YAS/-3’ (S=G or C; /=intron-exon boundary)
at the 3’SS (Figure 1.2A) (9, 15). Since several positions in these consensus sequences are not
100% conserved, introns with splice sites that are not identical to the consensus sequences may
still be identified as minor introns. Therefore, identification of minor introns and the genes that
contain them requires the use of position-weight matrices (PWM) (14, 15). These matrices
represent the probability of a nucleotide to be present at each position within the splice site and
can be generated using a set of known minor introns (104). This approach was used by two
independent groups to identify minor introns across multiple species, which revealed the presence
of ~680 minor introns in the Homo sapiens genome, ~590 minor introns in the Mus musculus
genome, ~17 minor introns in the Drosophila melanogaster genome, and ~220 minor introns in
the Arabidopsis thaliana genome (14, 15). Surprisingly, no minor introns were found in either
Caenorhabditis elegans or Saccharomyces cerevisiae, suggesting there might be an evolutionary
drive to lose them from the genome (14). Notably, the identified minor introns were distributed
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among a similar number of genes, suggesting that most minor intron-containing genes (MIGs)
contain only one or two minor introns, while the remainder are major introns (14, 15).
1.2.2

The minor spliceosome

Since the minor introns contain divergent consensus sequences that would prevent base pairing
with snRNAs of the major spliceosome, it was soon proposed there must exist a parallel splicing
machinery (97). In order to identify these analogous snRNAs, Hall and Padgett analyzed the
sequences of all known snRNA and determined whether they possessed a stretch of nucleotides
complementary to the divergent minor intron 5’SS and BPS. This led to the discovery of U11 and
U12 snRNAs as putative analogs to U1 and U2 snRNA, respectively (Figure 1.2B) (97). However,
unlike U1 and U2, U11 and U12 had been identified as a di-snRNP, suggesting that recognition
of minor introns occurs in a distinct manner from major intron recognition (105, 106). Indeed, in
1996 the presence of the U11/U12 di-snRNP in the minor spliceosome was confirmed, when 2’O-methyl oligonucleotides against U12 snRNA disrupted the splicing of a minor intron (99).
Moreover, disrupted minor intron splicing through mutations in the BPS of a minor intron, could
be rescued by compensatory mutations in the U12 snRNA (102). Surprisingly, mutations in the
BPS of major introns do not abolish binding of U2 snRNP (107). Instead, U2 snRNP binding is
predominately regulated by the U2AF complex, which interacts with the PPT in major introns
(Figure. 1.1) (62, 108). Since minor introns lack a PPT, U12 snRNP binding cannot be promoted
by the U2AF complex and therefore heavily relies on base pairing interactions with the BPS, which
may explain why this sequence is so highly conserved in minor introns (Figure 1.2A) (109).
Because U12 snRNP exists as a di-snRNP with U11, it was assumed that U11 also participated
in the minor intron splicing reaction (106). This hypothesis was further strengthened by the
findings that its secondary structure is highly similar to U1 snRNA, and that it contained a
sequence that was complementary to the +5 to +9 position of the minor intron 5’SS (Figure 1.1,
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1.2B) (97). However, since 2’-O-methyl oligonucleotides were unable to target U11, it took three
more years to prove that it was indeed a part of the minor spliceosome (99, 105, 110).
Since U4 and U6 snRNA initially do not base pair with introns but with each other, the
strategy for the identification of their functional analogs in the minor spliceosome was slightly
different. Instead, the premise was that U6 snRNA is a Class II snRNA, thereby possessing a
unique gamma-monomethyl phosphate cap (49). It was hypothesized that a functional analog of
U6 snRNA would also be a Class II snRNA and therefore contain the same cap (98). Indeed, a
pull-down strategy that targeted the cap of U6 also resulted in the pull-down of two other snRNAs
(98). Based on the secondary structure of these snRNAs, they were identified as analogs of U4
and U6, and named as U4atac and U6atac respectively (Figure 1.1, 1.2B) (98). In order to confirm
that they were also functional analogs to U4 and U6, many biochemical experiments followed.
First, an oligonucleotide against the sequence of U6atac that was complementary to the +4 to +8
position of the minor intron 5’SS disrupted minor splicing (98). The base pairing of U6atac with
the 5’SS of minor introns was then confirmed through 4-thiouridine crosslinking and mutation
analyses (111). Additionally, psoralen crosslinking revealed that U12 and U6atac could base pair
in the presence of minor intron splicing construct (98). Since U4atac did not contain any sequence
complementarity to minor introns, it was hypothesized that it would perform a similar stabilizing
function as U4 that is important for the recruitment of the tri-snRNP. Indeed, oligonucleotidedirected RNase H degradation of U4atac abolished minor intron splicing, underscoring its
importance in the minor spliceosome (98). Finally, 2’-O-methyl oligonucleotides against the
sequences in U5 snRNA that base pair with the 5’ exon during the major splicing reaction also
abolished minor intron splicing, suggesting that U5 snRNP was shared between the two
spliceosomes (99).
The most important difference between the major and minor spliceosome components is
that U11 and U12 exist as a di-snRNP, while U1 and U2 exist as separate mono-snRNPs (105,
10

106). The interaction of U11 and U12 snRNAs is not mediated through base pairing, but instead
through protein interactions. Specifically, there are seven unique proteins in the mammalian
U11/U12 di-snRNP that are not found in the major spliceosome (Table 1.1) (100). These include
U11/U12-65K, which is encoded by the gene RNPC3, U11/U12-59K, which is encoded by
PDCD7, U11/U12-48K (SNRNP48), U11/U12-35K (SNRNP35), U11/U12-31K (ZCRB1),
U11/U12-25K (SNRNP25), and U11/U12-20K (ZMAT5) (Table 1.1) (100). Because the 59K, 48K,
35K and 25K proteins were also identified in U11 mono-snRNP particles, it is thought that these
four proteins interact with U11 snRNA, while the other three interact with the U12 snRNA (Table
1.1) (100). The exact functions of most of these proteins are still unknown, but U11/U12-65K,
U11/U12-59K and U11/U12-48K have been shown to play a role in the formation and
maintenance of the U11/U12 di-snRNP (112, 113). Specifically, U11/U12-65K interacts with the
stem loop II of U12 snRNA via the RRM motif in its C-terminus, whereas its N-terminus interacts
with the C-terminus of U11/U12-59K (112). U11/U12-59K then functions as an anchor in the disnRNP formation by also interacting with the N-terminus of U11/U12-48K (113). Notably,
U11/U12-48K also interacts with the +2 position of minor intron 5’SS through its CHHC zing-finger
motif (113). Finally, based on the presence of similar protein domains, it was hypothesized that
U11/U12-20K may play an analogous role to the U1-C protein, and that U11/U12-35K can function
analogously to U1-70K (100). In support of the latter, U11/U12-35K has been shown to bind SR
proteins in plants, and activate an upstream major-type 3’SS when tethered to a U11 snRNPbinding splicing enhancer (USSE) that consists of a minor-type 5’SS in tandem repeat (114, 115).
However, no data has yet been reported to definitively prove that U11/U12-35K can play a similar
role as U1-70K in maintenance of exon-definition interaction during the splicing reaction. Notably,
while the U11/U12 di-snRNP contains seven minor spliceosome-specific proteins, the protein
composition of the U4atac/U6atac.U5 tri-snRNP is the exact same as that of the U4/U6.U5 trisnRNP (100, 101).
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1.2.3

Co-transcriptional splicing of minor introns
The high number of shared proteins between the two spliceosomes suggests that the two

splicing reactions may also be similar. Indeed, most of the steps of the splicing reaction are
analogous between the major and minor spliceosome, besides an initial difference in intron
recognition. According to the intron-definition model, major intron splicing starts with the
recruitment of U1 snRNP, SF1 and the U2AF complex to the 5’SS, BPS and PPT, respectively,
which allows for the recruitment of U2 snRNP to the correct BPS (see section 1.1.3) (Figure 1.1).
However, U11 and U12 exist as a di-snRNP and therefore do not require the SF1 and U2AF
proteins for identification of the BPS (116). Instead, U11 and U12 simultaneously base pair to the
5’SS and BPS, respectively, in a cooperative manner (117). Afterwards, the U4atac/U6atac.U5
tri-snRNP is recruited to the minor intron. Then, like U6, U6atac dissociates from U4atac and base
pairs with both the 5’SS and U12 snRNA, resulting in the exit of U11 and U4atac from the minor
spliceosome (111, 118). Again, U5 snRNP will bind to the 5’ exon as well as the 3’SS in order to
bring the ends of the intron closer, and allowing for the bulged adenosine of the BPS to perform
the first nucleophilic attack on the phosphate group at the end of the 5’ exon. This then elicits the
second trans-esterification reaction, as described in 1.1.3.
While this describes how minor introns are spliced from an intron-definition perspective,
most minor introns are longer than 200bp, and are therefore predicted to be spliced according to
the exon-definition model (119). However, minor introns are often flanked by major introns and
therefore co-transcriptional splicing of minor introns would require interaction between the major
and minor spliceosome (120). It has previously been shown that the addition of a major-type 5’SS
downstream of a minor intron greatly enhances the splicing efficiency of that minor intron (121).
Thus, this suggests that U1 snRNP can engage in exon-definition interactions with the minor
spliceosome. However, since the minor spliceosome does not contain the U2AF complex, which
is normally involved in these interactions, it is unclear how binding of U1 snRNP to the 5’SS can
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enhance the splicing of minor introns. One possibility would be through an interaction between
U1 and ZRSR2, which has been shown to play a role in the 3’SS selection of minor introns in the
absence of the U2AF complex (122). It is also unknown whether U11 snRNP can engage in exondefinition interactions with the U2AF complex bound to the upstream PPT. It has been shown that
U11 snRNP can engage with SR proteins, similar to U1, but it is not known which proteins mediate
this interaction (114). One hypothesis was U11/U12-35K, as this protein shares homology with
U1-70K, however no experimental evidence exists for this possibility (100). Regardless, the
presence of exon-definition interactions between U11 snRNP and the major spliceosome are
supported by the fact that binding of mono-U11 snRNP to a USSE in the transcripts of SNRNP48
and RNPC3, can activate the use of an upstream major-type 3’SS (115). While this does not
reflect the binding of the U11/U12 di-snRNP to canonical 5’SS and BPS in minor introns, it still
suggests that U11 snRNP can engage with the major spliceosome.
The coordinated action between the major and minor spliceosome add an additional layer
of complication to the splicing of minor introns. This might explain why some minor introns are
less efficiently spliced than major introns in the same gene, as was observed for the MIGs
SNRPE, E2F2 and INSIG1 (123). Moreover, since replacing the minor intron of the MIG NHE3 to
a major intron increased protein production by 6-8-fold, it was hypothesized that the inefficient
splicing of minor introns would create a post-transcriptional bottleneck, thereby regulating gene
expression levels (123). Initially, this steady-state elevated retention of minor introns compared
to major introns was considered to be due to a difference in splicing rates. It was hypothesized
that minor intron splicing would be slower than major intron splicing because the minor
spliceosome snRNPs are present at ~100-fold lower levels than the major spliceosome snRNPs
(105). However, 80-90% reduction of U4atac snRNA levels, which is the least abundant snRNA
of the minor spliceosome, did not affect the splicing of endogenous minor introns (124). Moreover,
while the splicing of three minor introns was almost 2-fold slower than the majority of interrogated
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major introns, a fourth minor intron was spliced just as fast as major introns (125). Thus, these
data suggested that a slower rate of minor intron splicing may not act as a bottleneck in the
expression of MIGs. Regardless, several other manuscripts have reported that minor intron
retention, on average, was higher than the retention levels of flanking major introns (124, 126). It
was then hypothesized that these minor introns were not spliced at a slower rate, but that a subset
of minor introns would be spliced inefficiently, while the remainder of minor introns would be
spliced normally at the same rate as major introns (127). This suggests that the decision to splice
minor introns is actively regulated. One way in which this may occur is through regulation of
U6atac snRNA levels. This snRNA was shown to be highly unstable and inhibiting its function
using antisense morpholino oligonucleotides resulted in widespread minor intron retention (128).
Additionally, this minor intron retention resulted in downregulation of the MIGs they were found
in, likely in part through exosome-mediated degradation (126, 128). Since U6atac snRNA was
then shown to be stabilized by p38MAPK, a kinase activated by cell stress, this supported the
idea of active regulation of minor intron splicing (128).
1.2.4

Model systems to study minor spliceosome function

Accurate splicing of introns is essential for the proper expression of genes, whose function is
otherwise compromised. While minor introns only make up ~0.5% of all introns, disrupted minor
intron splicing in several species could affect the expression of hundreds of genes, and
subsequently result in disease. Since the discovery of the minor spliceosome, several model
systems have been reported that studied the role of minor spliceosome components in
development and disease.
In 2002, two lines of Drosophila melanogaster were identified with P element insertions in
the genes encoding either U12 or U6atac snRNA (129). Disruption of U12 and U6atac in these
lines resulted in embryonic lethality and larval lethality after the third instar, respectively (129).
Notably, expression of U12 or U6atac transgenes in these lines partially rescued these
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phenotypes (129). This suggested that the minor spliceosome was essential for Drosophila
melanogaster development, even though only 17 minor introns have been identified in their
genome (14, 15). To identify the MIGs with disrupted minor intron splicing that might be
responsible for the early lethality, both RT-PCR and microarray analysis have been performed.
While this revealed a progressive reduction in the amount of properly spliced transcripts for a few
MIGs during larval stages, not all minor introns were affected (129, 130). Moreover, even though
intron retention is often predicted to trigger degradation pathways such as nonsense-mediated
decay, only two MIGs were downregulated upon disruption of U6atac, whereas many genes
without minor introns were differentially expressed (130, 131). One of these MIGs was
CG15081/I(2)03709, the fly homolog of PHB2, which stabilizes proteins in the inner membrane of
mitochondria (130, 132). Therefore, it was hypothesized that reduced expression of this MIG
might have been responsible for the disrupted expression of other genes without minor introns
that encode mitochondrial proteins (130).
The importance of minor spliceosomes-specific proteins in development was first
interrogated in Arabidopsis thaliana. Intercrossing of a heterozygote line containing a T-DNA
insertion in the coding region of U11/U12-31K did not yield any homozygotes, suggesting that
complete loss of function of U11/U12-31K was embryonically lethal (133). Similarly, T-DNA
disruption of U11/U12-48K and U11/U12-65K was also embryonically lethal (134, 135). In order
to still study the function of these genes in Arabidopsis thaliana, artificial microRNAs were used
instead to downregulate U11/U12-31K, U11/U12-48K and U11/U12-65K (133-135). This resulted
in several developmental defects, including leaf serration, arrested meristem growth and postbolting rosette leaf production (133-135). Like in the mutant Drosophila lines, knock down of
U11/U12-31K, U11/U12-48K and U11/U12-65K all resulted in elevated minor intron retention, but
not in all MIGs (133-135). Regardless, these studies also underscore the importance of minor
spliceosome-specific proteins in development. Additionally, rough endosperm 3 (Rgh3), the
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homolog of ZRSR2, has been shown to be essential for seed development and plant viability
(136). ZRSR2 is a protein found in both the minor and major spliceosome, although it performs
different functions in either splicing reaction (100, 122). For minor introns, ZRSR2 has been
shown to participate in 3’SS selection, whereas in major introns it facilitates the second transesterification reaction (122). Despite its dual role in splicing, mutant Rgh3 disproportionally
affected the splicing of minor introns, specifically those found in genes that regulate cell cycle
(136). Thus, this suggests that the function of ZRSR2 is especially essential for the minor intron
splicing pathway.
The first study to focus on the role of the minor spliceosome in vertebrate development
leveraged a clbn mutant zebrafish (137). These mutants were characterized by a small head, eye
and lens, as well as several abnormalities in the intestine, liver and pancreas morphology that
started precipitating 4.5 days post fertilization (137). However, within two to five days these
phenotypes resulted in their death (137). Analysis of the clbn locus revealed that these
phenotypes were the result of a mutation in the intron of rnpc3, the gene encoding U11/U12-65K
(137). To determine the effect of this mutation on minor intron splicing, RNAseq analysis of 4.5day post fertilization wild-type and mutant larvae was performed (137). This revealed that a higher
percentage of minor introns was retained than major introns in wild-type larvae, suggesting that
minor introns are less efficiently spliced than major introns (137). Moreover, mutation in rnpc3
resulted in the retention of a quarter of all annotated minor introns in Danio rerio (137). However,
despite the relatively widespread minor intron retention, hardly any downregulation of MIGs was
observed (137).
To further study the role of U11/U12-65K in mammalian development, the Heath group
then produced a knockout mouse for Rnpc3 (138). While germline ablation of Rnpc3 resulted in
embryonic lethality prior to blastocyst implantation, crossing the conditional knockout mouse to a
tamoxifen-inducible UBC-Cre line allowed them to study the role of U11/U12-65K in mouse
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development (138). Tamoxifen induction in early adulthood (8-12 weeks) resulted in rapid
bodyweight loss within 6 days post-injection (138). Additionally, loss of U11/U12-65K had resulted
in leukopenia, anemia and thrombocytopenia (138). Histological analyses then revealed severe
atrophy of the epithelial lining of the gastrointestinal tract, which consists of highly proliferative
stem cells (138). RT-PCR analyses of these epithelial cells revealed elevated minor intron
retention upon loss of U11/U12-65K for all interrogated genes (138). In all, this study revealed
that U11/U12-65K is essential for development, and specifically cell cycle regulation of rapidly
dividing cells. Importantly, this role of U11/U12-65K is conserved between plants, zebrafish and
mice (135, 137, 138).
Another study implicating minor intron splicing in development used mice with nonsense
mutations in the RRM domain of Zrsr1, a retrotransposed copy of the X-linked Zrsr2 (139). Even
though Zrsr1 itself is not found in the minor spliceosome, its paralog Zrsr2 has been shown to
disproportionally affect minor intron splicing (136, 140). Similarly, RNAseq analyses of P15 wildtype and Zrsr1 mutant mouse testis revealed that mutation in Zrsr1 especially affected the
retention of minor introns (139). Consequently, spermatogenesis in these mice was impaired, as
well as muscle and erythrocyte function (139).
Finally, the role of minor spliceosome snRNAs in mammalian development was
established in 2014 (141). Expression analysis of U11, U12, U4atac and U6atac across mouse
development revealed an enrichment in the developing head and central nervous system (141).
Moreover, inhibition of U12 snRNA in the postnatal retina by antisense morpholinos resulted in
apoptosis of differentiating retinal neurons (141). Thus, this data suggested an important role for
the minor spliceosome in nervous system development. This was confirmed with the first
vertebrate model for a minor spliceosome snRNA, where conditional ablation of U11 in the mouse
dorsal telencephalon resulted in microcephaly (142). The results from this U11 conditional
knockout mouse are described in detail in Chapter 5 and 6. Recently, another knockout mouse
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for U11 snRNA was developed by a different group to validate a role of U11 snRNA outside of
minor intron splicing (143). Specifically, U11 snRNA was found to activate Toll-like receptor 7 and
induce arthritis (143). However, since heterozygotes for U11 were not viable, this role of U11 has
not yet been pursued any further (143).
1.2.5

Minor intron splicing in disease

To date, five diseases have been reported that are caused by mutations in minor spliceosomespecific components. Additionally, minor intron splicing has been implicated in several cancers
and motor neuron diseases (see section 2.3). In 2011, two independent groups linked the disease
microcephalic osteodysplastic primordial dwarfism type 1 (MOPD1) to autosomal recessive
mutations in the gene RNU4ATAC, which encodes the U4atac snRNA (144, 145). This rare
developmental disorder often results in death before the age of 2 years, and is characterized by
severe microcephaly, a short stature, intrauterine growth retardation, spondylepimetaphyseal
dysplasia and several other symptoms (see Chapter 4 for more details) (144, 145). Fibroblast
cells derived from individuals with MOPD1 revealed a reduction in splicing efficiency of some
minor introns compared to wild-type cells, which could be rescued by overexpression of wild-type
U4atac snRNA (144). However, the expression of these interrogated MIGs was either unchanged
or upregulated (144). RNAseq analysis performed on different tissues from seven individuals with
MOPD1 resulted in similar findings: while minor intron retention was observed in the majority of
MIGs, allowing for a clear separation of patients and healthy individuals in PCA analysis, MIG
expression was mostly unaltered (146). Most studies interrogating the effect of U4atac mutations
on minor intron splicing focused on individuals with G>A mutations at nucleotide 51 (144, 146).
However, several different mutations in RNU4ATAC have been described in individuals with
MOPD1, with the majority of them located within the 5’ stem loop (nucleotides 26 to 57) of U4atac
snRNA (147-150). In order to determine how mutations in this 5’ stem loop specifically affect
minor intron splicing, several biochemical assays have been performed. The 5’ stem loop normally
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interacts with the U4atac/U6atac di-snRNP protein 15.5K, which is required for the binding of
additional proteins such as PRPF31 in order to form the U4atac/U6atac.U5 tri-snRNP (151, 152).
The mutations at nucleotides 50 and 51 of RNU4ATAC that were observed in individuals with
MOPD1 have been shown to drastically reduce binding of 15.5K to U4atac snRNA, and in turn
also binding of PRPF31 (147). This resulted in a reduction of U4atac/U6atac.U5 tri-snRNP
formation, which is necessary for the formation of the spliceosome B complex (147, 153). In
contrast, other mutations in the 5’ stem loop did not affect the binding capacity of 15.5K at all or
only very little (147). These results may explain why few individuals with MOPD1 have survived
into childhood. For instance, a 9-year old and 18-year old individual with MOPD1 were both
homozygous for the 55G>A mutation (144, 149, 154). Moreover, two siblings with MOPD1 who
were 17 and 24 at the time of publication were both heterozygous for the 40C>T mutation and an
85bp insertion at position 100, which is predicted to disrupt the 3’ stem loop of U4atac snRNA
(155). While deletion of this entire 3’ stem loop inhibited minor intron splicing, deletion of the distal
part of the 3’ stem loop (nucleotides 92-105) did not affect splicing, suggesting this region does
not interact with essential proteins or RNAs (156). Thus, disease severity in individuals with
MOPD1 may be dependent on the location of the mutation, whereby mutations at positions 50
and 51 in the 5’ stem loop of U4atac snRNA result in very severe phenotypes due to disrupted
formation of the U4atac/U6atac.U5 tri-snRNP.
This hypothesis is further supported by the identification of another disease associated
with mutations in RNU4ATAC: Roifman syndrome (RS) (157). Symptoms of individuals with RS
are very similar to those of individuals with MOPD1, with a few exceptions (See Chapter 4 for
more details). Specifically, individuals with RS have mild microcephaly, a short stature, multiple
epiphyseal dysplasia and intrauterine growth retardation (157). While most of these symptoms
are less severe or less common in individuals with RS compared to individuals with MOPD1,
retinal dystrophy is more commonly associated with RS than MOPD1 (Table S1) (158). Moreover,
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reduced antibody levels have almost exclusively been observed in individuals with RS (Table S1)
(158). All individuals with RS are compound heterozygotes for mutations in RNU4ATAC, whereby
one mutation is found in the stem II (nucleotides 1 to 19) of U4atac snRNA, which is a region
involved in the base pairing with U6atac snRNA (157, 159-163). Interestingly, one individual with
RS is compound heterozygous for the mutations 16G>A and 51G>A, the latter of which has also
been observed in homozygosity in individuals with MOPD1 (144, 145, 157). Biochemical
experiments have revealed that mutations in the stem II of U4atac snRNA affect base pairing
capacity to U6atac snRNA, thereby affecting minor intron splicing (156). In agreement with this,
elevated minor intron retention has been observed in individuals with RS, while MIGs were not
changed in expression (157, 161). The milder symptoms observed in individuals with RS suggest
that these splicing defects are less detrimental than those caused by homozygous mutations in
the 5’ stem loop. However, they may underlie the retinal and immunological phenotypes
predominately observed in RS.
Finally, in 2018, a third disease was associated with mutations in RNU4ATAC (164).
Individuals with Lowry-Wood syndrome (LWS) present similar cardinal symptoms as individuals
with MOPD1, although to a less severe extent (See Chapter 4 for more details) (158). Accordingly,
individuals with LWS have been reported to survive into adulthood (158). Like individuals with RS,
all reported individuals with LWS are compound heterozygotes often with one mutation in the 5’
stem loop and the other mutation in either stem II, the 3’ stem loop, or the Sm binding region (158,
164). The effect of these specific mutations on minor intron splicing has not been reported so far,
but will be addressed in Chapter 6.
Besides U4atac snRNA, U12 snRNA has also been implicated in disease. An 84C>T
autosomal recessive mutation in the gene RNU12 was observed in six individuals with early-onset
cerebellar ataxia (EOCA) (165). These individuals all had delayed motor milestones in early
infancy and had an ataxic gait (165). Magnetic resonance imaging revealed cerebellar hypoplasia,
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while the cerebral cortex appeared normal (165). The mutation resulting in these symptoms was
found at the base of stem loop III, whereas the terminal region of this loop is used to bind the
U11/U12-65K protein (112). Regardless, RNAseq analysis on PBMCs of individuals with earlyonset cerebellar ataxia showed that approximately 25% of all minor introns were retained at
significantly higher levels in these affected individuals compared to healthy controls, suggesting
that nucleotide 84 in RNU12, is also important for proper minor intron splicing (165).
The fifth disease that has been directly associated with mutations in minor spliceosome
components is isolated growth hormone deficiency (IGHD), which is characterized by reduced
growth hormone levels that result in a short stature, as well as mild microcephaly (166). To date,
three individuals have been reported with mutations in the gene RNPC3, which encodes
U11/U12-65K (166). These mutations result in either a P747T or R502X substitution in the Cterminal RRM domain, which is essential for binding to U12 snRNA (112). Indeed, biochemical
analyses has revealed that the mutations observed in individuals with IGHD result in reduced
stability of the U11/U12 di-snRNP, either due to disrupted RRM folding or a reduction in U11/U1265K protein levels as a consequence of NMD activation (167). As has been observed in other
individuals with minor spliceosome-related diseases, PBMCs of individuals with IGHD showed
elevated levels of minor intron retention and cryptic splicing around minor introns, however this
was restricted to only a subset of MIGs (166). In all, mutations in the different minor spliceosome
components result in a range of disorders that all affect the central nervous system. However, the
different symptoms observed in each disease suggest that disruption of each component results
in transcript-specific splicing defects.
Even though not always directly, minor spliceosome components have recently also
begun to be implicated in cancer. For example, a somatic A>G mutation at nucleotide 5 of RNU11,
which normally base pairs with the +7 position of the minor intron 5’SS, has been implicated in
Sonic hedgehog medulloblastomas (168). Moreover, mutations in ZRSR2, the protein involved in
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3’SS recognition in minor introns, have been linked to myelodysplastic syndrome (MDS) (122,
140). Even though ZRSR2 is also found in the major spliceosome, fibroblasts from individuals
with MDS showed widespread splicing defects around minor introns (140). This included not only
retention of minor introns, but also alternative splicing around minor introns, thus implicating minor
intron splicing as a key player in MDS progression (140). Other examples of cancers with minor
spliceosome implications include acute myeloid leukemia (AML), a malignancy of hematopoietic
stem cells. While molecular mechanisms underlying the progression of AML are unclear, PDCD7
was found to be expressed at significantly higher levels in cytogenetically normal AML patients
compared to healthy controls (169). Moreover, high levels of PDCD7 were associated with a
reduced survival rate, accompanied by a decreased relapse-free survival (169). Thus, these
studies implicate U11/U12-59K in aggressive AML associated with a poor prognosis. In contrast,
oral squamous cell carcinoma tumors were associated with reduced levels of PDCD7 (170). Here,
miR-134 was shown to downregulate PDCD7, which normally transactivates E-cadherin
expression, thereby resulting in increased neck nodal metastasis in mice (170). Additionally,
RNPC3 was identified as a prognostic marker for survival of individuals with lung adenocarcinoma
(171). Finally, serum from individuals with the autoimmune rheumatic disease scleroderma that
also had cancer was positive for antibodies against the minor spliceosome-specific proteins
U11/U12-65K, U11/U12-59K, U11/U12-35K and U11/U12-25K (172, 173). Notably, the sera were
negative for autoantibodies that are known to increase the risk of cancer in scleroderma (173).
Thus, the presence of these minor spliceosome antibodies may define a distinct subtype of
scleroderma that is associated with an increased risk of cancer. While most of these studies
require follow-up experiments to determine whether minor intron splicing is actually affected in
these different cancers, it does suggest a connection between the minor spliceosome and cell
cycle regulation, which has been reported previously and will be elaborated on in Chapter 5 (174).
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1.3 Alternative splicing
The splicing of introns is essential for the proper expression of genes, as mutations in splice sites
often result in disease. However, the presence of introns in most eukaryotic protein-coding genes
also provides a regulatory advantage: through alternative splicing many transcripts (and proteins)
can be created from the same gene. Indeed, it is now known that at least 95% of all protein-coding
genes are alternatively spliced in humans (175, 176). On average, it has been estimated that a
single multi-exon gene produces four different mRNA transcripts (also called isoforms) (177).
However, in extreme cases, a gene like Dscam in Drosophila melanogaster can be alternatively
spliced into 38,016 different isoforms, which is more than the total number of genes in the
Drosophila genome (178, 179). Not all isoforms will be expressed at the same level; research has
shown that most genes contain a ‘dominant’ isoform (180, 181). Regardless, for 86% of all genes
the second most abundantly expressed isoform contributed at least 15% of the overall gene
expression and thus is likely to play a biological role (175). While the extent to which these
different isoforms contribute to the vast diversity observed at the proteome level is still a matter
of debate, it is clear that alternative splicing is an important mechanism to regulate gene
expression (182, 183). This is especially the case in tissues such as the brain, heart and skeletal
muscle, in which the most alternative splicing takes place (184, 185). Besides the expression of
tissue-specific isoforms, alternatively splicing can also regulate gene expression in a brain-region
specific manner, or within cortical layers (186, 187). Moreover, alternative splicing has been
shown to regulate development (188). For instance, alternative splicing of Ninein causes the
protein to translocate to non-centrosomal loci in neural progenitor cells, resulting the
differentiation of these NPCs into neurons (189). Similarly, genes like Titin and Serca1 are
alternatively spliced between P2 and P20, allowing for the remodeling of skeletal muscle (190).
The importance of this regulation is underscored by the fact that the expression of these neonatal
alternatively spliced isoforms in adulthood underlies the disease myotonic dystrophy (191). Thus,
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while alternative splicing of genes can result in a wide variety of different isoforms that can perform
tissue-specific functions, it must be tightly regulated to prevent disease.
1.3.1

Types of alternative splicing

Alternative splicing events are often divided into five main categories (Figure 1.3A). These include
the selection of a 5’SS that is different from the constitutive 5’SS (alternative 5’SS) and the
selection of a different 3’SS than the constitutive 3’SS (alternative 3’SS) (192). Combined, these
two forms were estimated to make up ~25% of all known AS events (193). More common is the
inclusion of an exon (cryptic exon) or the exclusion of an entire exon (exon skipping), which is
predicted to occur in a third of all alternative splicing events (193). Many of these events are not
mutually exclusive and are in fact commonly observed in conjunction (194). For instance, an
alternative 5’SS can be combined with an alternative 3’SS, or skipping of an exon can result in
the use of an alternative 3’SS. This combination of AS events allows for the maintenance of the
open reading frame, which would normally be disrupted for instance if the length of a skipped
exon is not a multiple of three. Finally, intron retention, while initially considered an outcome of
failed splicing, is now appreciated as the fifth form of alternative splicing (195, 196). It has been
suggested that intron retention is the most common form of alternative splicing, although it often
results in the introduction of a premature stop codon (131, 197).
1.3.2

Mechanism of alternative splicing

The parameters that influence the decision to utilize a certain splice site involve the strength of
the splice site (i.e. how similar the sequence is to the consensus sequence), the presence of cisregulatory sequences in the intron and flanking exon, and finally the expression levels of transacting alternative splicing factors (198). Strong splice sites are often easily recognized by the
spliceosome and result in constitutive splicing (199). However, not all splice sites are strong, and
their recognition may depend on the presence of cis-regulatory elements that can enhance its use
(intronic or exonic splicing enhancers; ISE or ESE) (192). In absence of these, the flanking exon
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could be skipped or the intron could be retained. In contrast, exons may contain sequences that
resemble splice sites, but their use would result in the (partial) exclusion of the exon. The use of
these splice sites can be repressed by either intronic or exonic splicing silencers (ISS or ESS)
(192). All cis-regulatory sequences are recognized by trans-acting alternative splicing factors, of
which at least 70 have been identified so far (Figure 1.3B) (200). These can broadly be divided
into one of three groups: serine/arginine-rich (SR) proteins, heterogeneous nuclear
ribonucleoproteins (hnRNPs), and tissue-specific alternative splicing factors (201). SR proteins
generally recognize ESEs and promote splicing and exon inclusion, while hnRNP proteins
generally bind to ESSs, resulting in exon skipping (202, 203). Binding of SR proteins to ESEs
allows for its binding to U1 snRNP and U2AF1, thereby establishing an exon-definition complex
that results in the constitutive splicing of an intron (see section 1.1.4) (204). However, the binding
of SR proteins to intronic cis-regulatory elements has also been described, which can result in
the repression of splicing (205). Similarly, few hnRNP proteins have been reported to activate
splicing (206). Finally, the third group of AS factors are often expressed in a tissue-specific
manner and can bind either enhancer or silencer elements within the pre-mRNA, often acting
antagonistically to one another (192, 207). Some examples include NOVA proteins,
polypyrimidine tract-binding (PTB) proteins, RBFOX proteins and proteins of the muscleblind
(MBNL) and CUG-BP and ETR3-like factor (CELF) family (207-211).
1.3.3

Detection of alternative splicing by RNAseq

The extent of alternative splicing in eukaryotic organisms was first determined with the use of
expression sequence tags (ESTs) and splicing-sensitive microarrays (212). However, both
technologies produce results with high noise levels and are relative low throughput (213). The
advance of RNA sequencing allowed for the true appreciation of the transcriptome complexity
generated through alternative splicing. However, not every library and analysis tool is amenable
to the discovery of novel alternative splicing events. Most importantly, the detection of alternative
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splicing by RNAseq is complicated by the length of reads produced by most sequencing platforms,
such as Illumina. Reads generally do not surpass 400 nucleotides, while the median length of
mature mRNA transcripts is greater than 2500 nucleotides (177, 214). Thus, it is impossible to
unambiguously determine whether two alternative splicing events occur in the same transcript, or
are found in two separate transcripts. This limitation is overcome by the development of thirdgeneration sequencers such as those from Pacific Biosciences and Oxford Nanopore
Technologies (215, 216). These sequencers can produce reads up to tens or hundreds of
kilobases long, allowing for full coverage of the mRNA transcript (214). However, the sequencing
error rate of these machines is still relatively high, thereby complicating the alignment (217).
Moreover, the sequencing depth is generally speaking lower, which would prevent the capture of
low abundant alternatively spliced transcripts (216, 218). Consequently, the majority of alternative
splicing analyses still rely on the use of short reads with a high sequencing depth.
Quantification of alternative splicing can either be done at the exon-level or at the
isoform-level (219). While exon-based analysis is easier and can allow for the detection of de
novo events, it does not provide insight into the combination of alternative splicing events in a
transcript. Conversely, isoform-level analyses can improve the accuracy of gene expression
quantification, but are commonly restricted to annotated alternative splicing events due to
computational difficulties (220). Some examples of exon-based analyses algorithms include
HTSeq, DEXSeq, and MISO, which rely on the quantification of reads to a specific exon or splice
junction (221-223). Many transcript-based algorithms however include several iterations of
expectation-maximization (EM) algorithms in order to assign reads to a specific isoform. These
include: RSEM, eXpress, Cufflinks, and IsoEM2 (224-227). There are many advantages and
disadvantages that can be listed for each of these computational tools, and thus there remains
no golden standard in the field for the detection and quantification of alternative splicing events
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(228). As such, RNAseq analysis of alternative splicing still heavily relies on validations by RTPCR.
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1.4 Figures and tables

Figure 1.1. The splicing reaction according to the exon and intron definition model.
Schematic of major intron splicing reaction according to the intron definition model (left) and exon
definition model (right). Base pairing interactions between snRNAs and pre-mRNA are shown in
the bottom right.
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Figure 1.2. Minor introns and the minor spliceosome snRNAs.
(A) Frequency logos of major and minor intron consensus sequences. Letters in black represent
consensus sequence. Grey line marks the exon-intron boundary. (B) Secondary structures of the
snRNAs in the minor spliceosome.

29

Figure 1.3. Mechanisms and types of alternative splicing.
(A) Schematic representation of five different types of alternative splicing. (B) Schematic
representation of alternative splicing mechanism with trans-acting factors binding to cis-acting
elements. ISS=intronic splicing silencer; ESS=exonic splicing silencer; ESE=exonic splicing
enhancer; ISE=intronic splicing enhancer.
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Table 1.1 Minor spliceosome-specific proteins.
Gene name
RNPC3
PDCD7
SNRNP48
SNRNP35
ZCRB1
SNRNP25
ZMAT5

Protein name
65K
59K
48K
35K
31K
25K
20K

snRNP component
U12 snRNP
U11 snRNP
U11 snRNP
U11 snRNP
U12 snRNP
U11 snRNP
U12 snRNP
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Chapter 2 Central nervous system
2.1 Cortical development
Symptoms observed in individuals with minor spliceosome-related diseases often include
congenital microcephaly and other brain abnormalities, such as agenesis of the corpus callosum,
hypoplasia of cortical lobes and abnormal gyrification patterns (see also Chapter 4) (145, 154,
229, 230). This suggests that disrupted minor intron splicing severely affects the development of
the cerebral cortex. This critical structure of the brain has been studied for many years, yet much
is still to be discovered about the diversity of cell types within the cortex and the connections
between neurons of different cortical areas.
2.1.1

Formation and expansion of the dorsal telencephalon

Early embryonic brain development in the mouse starts at E8 with the development of part of the
neural tube into three main vesicles: the prosencephalon (forebrain), mesencephalon (midbrain)
and the rhombencephalon (hindbrain) (231). By E9, the prosencephalon will be further divided
into an anteriorly located telencephalon and a caudal diencephalon (232). While the diencephalon
will eventually form the thalamic and hypothalamic structures in the brain, the telencephalon will
give rise to the cerebral cortex and the basal ganglia (233, 234). Indeed, the telencephalon will
bulge laterally at this timepoint to form two symmetrical vesicles, which is the beginning of the two
cerebral hemispheres (232). The secretion of morphogens such as bone morphogenic proteins
(BMPs) and sonic hedgehog (Shh) then causes the telencephalon to undergo dorsoventral
patterning (232, 235, 236). This results in the formation of a dorsal telencephalon, which can be
marked by the transcription factor Emx1 and will eventually develop into the cerebral cortex, as
well as a ventral telencephalon, which differentiates into the basal ganglia (234, 237). Additionally,
the ventral telencephalon produces neurons that tangentially migrate dorsally, which will become
the inhibitory interneurons (238). The dorsal telencephalon can be further subdivided into an

32

anterior and lateral region that gives rise to the neocortex, and a posterior and medial area that
develops into the hippocampus, cortical hem, and choroid plexus (234).
Once the dorsal telencephalon, which is also referred to as the pallium, is formed, it
consists of a single layer of pseudostratified neuroepithelial cells (239, 240). The cell body of
these cells is positioned near the apical (ventricular) edge and is anchored by its apical endfoot,
thereby forming the ventricular zone (VZ) (239, 240). At the same time, these neuroepithelial cells
also contact the basal (pial) edge through a cellular process (239). This polarized morphology of
neuroepithelial cells allows for interkinetic nuclear migration during cell cycle (241). Here, the
nucleus migrates from the apical edge to the basal edge during G1 of the cell cycle (241). At the
basal edge, S-phase occurs, and then the nucleus migrates back down to the apical edge during
G2 phase, where mitosis eventually takes place (241). Until E10, these neuroepithelial undergo
symmetric proliferative divisions to produce two new neuroepithelial cells, in order to exponentially
amplify the progenitor pool (240). After E10, Notch and Fgf10 signaling cause neuroepithelial cells
to transform in another type of neural progenitor cells (NPCs), called radial glial cells (RGCs)
(242). These RGCs possess a similar polarized morphology as neuroepithelial cells, with
processes contacting both apical and basal edges, and are characterized by the expression of
the transcription factor Pax6 (240, 243). Similar to neuroepithelial cells, RGCs can undergo
symmetric proliferative divisions to produce two new RGCs (244, 245). While this is the
predominant type of cell division for RGCs in the E10 dorsal telencephalon, around E11 they also
start to undergo asymmetric differentiative divisions, resulting in one RGC and one differentiative
cell (246). These differentiative cells can either be another type of NPC called intermediate
progenitor cells (IPCs), which is marked by the expression of transcription factor Tbr2, or an
immature excitatory neuron, which can be identified by expression of Tubb3 (246-251). Since
IPCs do not have long processes like RGCs, but instead short multipolar processes, they do not
undergo interkinetic nuclear migration (240, 246). Instead, they divide in the subventricular zone
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(SVZ), the region just above the VZ, where they migrate to after birth (247, 248). Here, they will
mostly undergo symmetric neurogenic divisions to produce two excitatory neurons, that will use
the processes of nearby RGCs to migrate to the basal edge (247, 248, 252, 253). During their
migration, these neurons start the formation of an axon and reorient their Golgi and centrosome
to the basal edge, allowing for the formation of a leading process (254). These processes all occur
in the intermediate zone (IZ), which is found above the SVZ, and once completed result in the
migration of the neuron to their terminal location close to the basal edge (254, 255). Excitatory
neurons born from asymmetric RGCs divisions are thought to migrate in a similar manner (253,
254). Bromodeoxyuridine (BrdU) pulse studies revealed that their final location at the basal edge
of the dorsal telencephalon is dependent on the timepoint of their birth: the pioneering neurons
that are born between E11.5 and E12.5 form the preplate (256). The migration of excitatory
neurons born after E12.5 into the preplate then splits this region up into an outer marginal zone
(MZ) and an inner subplate (SP), while forming the cortical plate (CP) (256, 257). Finally, besides
the symmetric neurogenic division that IPCs can undergo, a small percentage of IPCs will undergo
symmetric proliferative divisions, to produce two daughter IPCs (247). These proliferative
divisions are then followed by terminal symmetric differentiative divisions, such that the majority
of excitatory neurons in the cortex are produced by IPCs (248, 258).
2.1.2

Neurogenesis and cortical layers

Neurogenesis begins at E11 with the first differentiative divisions of NPCs, and ends around E18
when RGCs transform into astrocytes (259, 260). The neurons that are born within this window
of time will migrate up in an inside-out fashion, i.e. earlier born neurons form lower layer neurons,
whereas later-born neurons migrate up and produce the upper layer neurons (261, 262). Overall,
there are six distinct neuronal layers in the adult mammalian cortex, of which layers II-VI are
formed from neurons located in the CP (263). In contrast, layer I is formed by neurons from the
MZ and for a large fraction by inhibitory neurons that have migrated into the neocortex (264, 265).
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Layer I remains relatively sparse in cell number throughout development, and consists of
Cajal-Retzius cells that originated in the cortical hem, inhibitory interneurons that have migrated
from the ventral telencephalon and the apical dendrites of excitatory pyramidal cells of deeper
cortical layers (266, 267). Cajal-Retzius cells express the neurochemical marker Reelin, which
was found to be essential for the lamination of neurons in the CP (268). However, they gradually
degenerate in early postnatal development, leaving the GABAergic interneurons that start
expressing Reelin from P8 onwards (269, 270). These interneurons receive input from
corticocortical axons and axons from thalamic nuclei among others, which is what makes layer I
so dense in horizontal fibers (271-273).
In rodents, layers II and III are hard to distinguish solely based on their cytoarchitecture,
and are therefore commonly referred to as layer II/III (274). These layers consist of commissural
projection neurons that are born from E15.5 to E17.5 (275, 276). The majority of these neurons
sends axons that cross the midline through the corpus callosum in order to integrate information
from the two cerebral hemispheres, and are called callosal projection neurons (CPN) (275, 276).
Besides their contralateral projections, they also send collateral axons to pyramidal neurons in
layers II/III, V, and VI (277). They are marked by the expression of the transcription factor Cux1
(278). Layer IV predominately consists of excitatory granular neurons that are born between E14
and E15 (263, 276). They are the primary target of sensory input received from the thalamus and
project up into layer II/III (279, 280). Initially, it was thought that the primary motor cortex lacked
a layer IV (281). However, optogenetic tools revealed its presence in the motor cortex, similar to
that of the somatosensory cortex (282). Due to the dense network of neuronal dendrites from
layer V in the motor cortex, this layer has been hard to distinguish without the use of specific
markers, such as Rorb (281, 283).
Layers V and VI mostly consist of corticofugal projection neurons, a type of output
projection neuron that transmits signals to subcortical regions such as the thalamus, brain stem,
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and spinal cord (276). Specifically, layer V neurons are subcerebral projection neurons (SCPN)
that project to different regions depending on the cortical region they are located in (276). For
instance, SCPN in the motor cortex project to either the spinal cord (corticospinal motor neurons)
or motor nuclei in the brainstem (corticobulbar motor neurons) (276, 284, 285). In contrast, SCPN
in the primary somatosensory cortex project to the trigeminal principal sensory nucleus and dorsal
column medullary nuclei (corticobulbar projection neurons), whereas SCPN in the visual cortex
project to the optic tectum (corticotectal projection neurons) (276). On the other hand, layer VI
neurons include corticothalamic projection neurons (CThPN), which, as the name suggest, project
to specific thalamic regions depending on the location of their soma (286). For CThPN in the
primary motor cortex these include ventral lateral and ventral anterior nuclei, whereas CThPN in
the primary somatosensory cortex project to the ventral posterior nucleus, and the CThPN in the
visual cortex connect with the lateral geniculate nucleus (276). Layers V and VI can both be
marked by expression of Ctip2, whereas Foxp2 specifically marks layer VI (287, 288). Neurons in
these layers are born early: the SCPN of layer V are born between E13 and E14, while the CThPN
in layer VI are born a day earlier, from E12 to E13 (263). Notably, layers V and VI also contain
CPN, which unlike the CPN in layer II/III are both between E12.5 and E14.5 (276).
In conclusion, the excitatory pyramidal neurons that make up almost 80% of all cortical
neurons can be found in all layers, with the exception of layer I (289, 290). The remaining 20% of
cortical neurons are inhibitory neurons that have migrated into the neocortex from the ventral
telencephalon (290). While they are found in all cortical layers, they are enriched in layers I, II and
V, where they modulate the activity of excitatory neurons (291).
2.2 Spinal cord development
Minor intron splicing has clearly been implicated in CNS development through the cortex, but the
spinal cord has also been associated with disrupted minor intron splicing (292). Specifically, the
neurodegenerative diseases spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis
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(ALS) are characterized by a loss of motor neurons in the spinal cord (293). Like the brain, the
spinal cord is a highly structured tissue that consists of both grey and white matter (294). Due to
the association with minor intron splicing, this Chapter focusses on the development and function
of spinal neurons. However, it must be noted that these neurons are outnumbered approximately
6-fold by glia such as oligodendrocytes, astrocytes and microglia, which play essential roles in
the modulation of neuronal function (295, 296).
2.2.1

Structure of the adult mammalian spinal cord

The adult spinal cord is made up of butterfly-shaped gray matter containing the cell bodies,
encased by white matter consisting of the myelinated axons (294). Generally, the spinal cord can
be divided into 34 segments, that each generate a bilateral pair of spinal nerve roots (297). In the
mouse, the cervical segments of the spinal cord consisting of C1-C8 spans from the C1 vertebrae
to C7 (298). The thoracic segments of the spinal cord (T1-T13) can be found between vertebrae
T1 and T10 and the lumbar segments of the spinal cord (L1-L6) are found from vertebrae T11-L1
(298). Finally, the sacral (S1-S4) and coccygeal (Co1-Co3) segments of the spinal cord
correspond to the lumbar vertebrae (298). Like the Brodmann areas in the brain, the grey matter
of the spinal cord can be further divided into Rexed laminae (I-X) based on the cellular structure
(299). Generally, laminae I-IV are referred to as the dorsal horn, which is involved in sensory
processing, while laminae VII-IX make up the ventral horn, which is essential for motor function
(300). Laminae V and VI form the intermediate zone, which is thought to integrate sensory and
descending information in order to fine tune motor output (300). Finally, lamina X encompasses
the cells surrounding the central canal, which contains the cerebrospinal fluid (CSF) (301).
The dorsal horn predominately receives input from primary afferents that innervate the
skin and deeper tissues of the body (302). Depending on their sensory modality, they terminate
in specific laminae. For example, most of the small afferents with fine myelinated (Aδ) and
unmyelinated (C) axons are nociceptors and synapse onto excitatory and inhibitory interneurons
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in laminae I and II (302). In turn, these interneurons synapse onto projection neurons in lamina I
that send ascending projections to the brain, specifically to areas such as the thalamus and lateral
parabrachial nucleus in the midbrain (303). Alternatively, certain interneurons play a role in the
local reflex pathway (304, 305). In contrast, cutaneous afferents (Aβ) synapse onto projection
neurons in laminae III-VI and function as low-threshold mechanoreceptors (302). Finally, both
serotonergic and noradrenergic neurons from the nucleus raphe magnus and locus coeruleus
respectively send descending projections diffusely to the dorsal horn (302).
The ventral horn of the spinal cord mostly consists of motor neurons and a large network
of interneurons that regulate their firing (305). Motor neurons are distributed in columns that span
specific spinal segments depending on the muscles they innervate (306). They receive most of
their input from the upper motor neurons located in layer V of the motor cortex (see section 2.1.2),
and terminate at neuromuscular junctions (NMJs) (307). Motor neurons controlling smooth
muscles and glands are referred to as visceral motor neurons and form the preganglionic column
(306, 308). This column is positioned intermedio-laterally from spinal segment T1 to L2 and
innervates sympathetic ganglia (306). Conversely, skeletal muscles responsible for movement
are innervated by somatic motor neurons, which are located in lamina IX (306). They are
organized into five columns: the median motor column, the hypaxial motor column, the spinal
accessory column, the phrenic motor column, and the lateral motor column (306). Motor neurons
organized in the median motor column, which is localized ventro-medially, innervate the axial
musculature (309). As such, this column is not restricted to a specific spinal segment, but spans
the entire spinal cord (306, 309). The hypaxial motor column is located ventro-laterally in thoracic
spinal segments, where motor neurons innervate intercostal and abdominal skeletal muscles
(306, 309). Moreover, the spinal accessory column is located intermedio-laterally in spinal cord
segments C1-C5, where motor neurons innervate mastoid and several neck muscles (306, 310).
Motor neurons in the phrenic motor column are located in C3-C5 where they rhythmically fire in
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order to innervate the diaphragm (311, 312). Finally, motor neurons of the lateral motor column
are positioned most laterally in the ventral horn, and innervate the skeletal muscles of the limbs
(313). As such this column can be found in C1-C5, where it innervates the forelimbs, and in L1L5, where it innervates the hindlimbs (306). Thus, lower motor neurons are organized in a
topographic manner depending on the specific muscles they innervate.
Each motor neuron can innervate multiple muscle fibers within a muscle, which is referred
to as a motor unit (314). Depending on the specific muscle fiber type that these lower motor
neurons innervate, they can be further divided into alpha motor neurons, beta motor neurons and
gamma motor neurons (306). Alpha motor neurons are characterized by their large cell body and
combined expression of NeuN and ChAT, and innervate extrafusal muscle fibers (slow-twitch
fatigue-resistant, fast-twitch fatigue-resistant and fast-twitch fatigable) (315, 316). These fibers
generate force within muscle, and therefore alpha motor neurons are considered to be the main
cell type responsible for muscle contraction (306). In contrast, gamma motor neurons possess
smaller cell bodies and can be characterized by expression of ChAT, but not NeuN (316). They
exclusively regulate the sensitivity of muscle spindles, thereby contributing to the modulation of
muscle contraction (306). Finally, beta motor neurons innervate both extrafusal and intrafusal
muscle fibers, but are generally less well characterized (317).
2.2.2

Embryonic development of the spinal cord

The topographic localization of neurons in the adult spinal cord is the result of distinct progenitor
pools that are found along the dorsal-ventral axis in the embryonic spinal cord (318). Like the
brain, the spinal cord is derived from the neural tube and consists of a layer of pseudostratified
neuroepithelium (319). These cells are transformed to RGCs around E9, which can then undergo
similar cell divisions through interkinetic nuclear movements as described in section 2.1.1 (319,
320). The RGCs in the spinal cord are then prespecified by levels of diffusing morphogens (318).
Specifically, the rostral-caudal axis of the spinal cord is defined by opposing gradients of retinoic
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acid and FGFs respectively (321, 322). Moreover, diffusion of the morphogens Shh from the
floorplate, and BMPs and Wnts from the roofplate, establish the dorsal-ventral axis (236, 323326). The gradients that are formed by these morphogens result in the activation of different
transcription factors, thereby specifying the identities of 13 progenitor pools (327, 328). Eight of
these are dorsal interneuron progenitors, named pd1-pd6 and pdILA and pdILB (318). Moreover,
there are four ventral interneuron progenitor pools, named p0-p3 and one motor neuron progenitor
pool, called pMN (318).
The pd1-pd3 NPCs are located most dorsally, and are dependent on BMP signaling from
the roofplate (329, 330). This results in the expression of Olig3 in all progenitors, as well as
expression of Math1 in pd1 progenitors, Ngn1 and Ngn2 in pd2 progenitors, and Mash1 and Gsh2
in pd3 progenitors (331-333). These NPCs undergo several proliferative divisions, before
differentiating into dorsal interneurons between E10.5 and E12.5 (318, 334). These interneurons
start expressing different transcription factors and will then migrate ventrally to laminae III-V (318).
In contrast, pd4-pd6 and pdILA and pdILB are independent of roof plate signals (335, 336). Both
pd4 and pd5 NPCs can be characterized by expression of Gsh1 and Gsh2, whereas pd6 NPCs
express Dbx2, Ngn1 and Ngn2 (318, 337). Differentiation of these progenitors into dorsal
interneurons occurs between E10.5 and E12.5, which is followed by their migration into the deep
dorsal horn and the ventral spinal cord (336). The progenitors of the pdIL domains differentiate
later than the other dorsal progenitors, around E12.5, which results in the production of
interneurons that migrate into the laminae I-III (336, 338).
The p0 NPCs can be marked by combined expression of Dbx1 and Dbx2, which starts at
E10 (339, 340). They then differentiate into different commissural interneuron subtypes that
synapse contralaterally onto motor neurons (341). NPCs in the p1 domain also express Dbx2, but
not Dbx1, and are positioned ventrally to p0 NPCs (339, 340). They give rise to different types of
V1 interneurons, such as v1 Renshaw cells, that modulate motor neuron output (318, 342). More
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ventrally is the p2 domain, that consists of Lhx3+ NPCs (343). These NPCs undergo symmetric
differentiative divisions, resulting in one v2a and one v2b neuron, which are glutamatergic and
GABAergic respectively (344-346). The final progenitor domain producing interneurons is p3,
which consists of NPCs positive for Nkx2.2 (347). These p3 NPCs give rise to glutamatergic
interneurons that synapse onto V1 interneurons, some V2 interneurons, and motor neurons in the
lateral motor column (348).
Finally, the pMN domain is located between the p2 and p3 domain and contains
progenitors that give rise to cholinergic alpha motor neurons, gamma motor neurons,
preganglionic motor neurons of the autonomous nervous system, and finally oligodendrocytes
(318). The pMN NPCs are prespecified from E9.5 onwards after the activation of transcription
factor Isl1, which is dependent on Shh signaling (323, 349). During the final cell division of pMNs,
Hb9 is expressed, which results in the expression of ChAT and others, thereby establishing
independence from Shh signaling (318, 350).
2.3 Neurodegenerative disease
Neurodegenerative diseases are debilitating, and often incurable, diseases characterized by
neuronal loss. While the two most prevalent neurodegenerative diseases are Parkinson’s disease
and Alzheimer’s disease, this section will specifically focus on motor neuron degeneration (351).
Motor neuron diseases are characterized by loss of motor neurons, resulting in muscle atrophy
and often early death after disease onset (352). The most common motor neuron disease in adults
is amyotrophic lateral sclerosis (ALS), which currently affects ~1 in 50,000 people worldwide
(353). In contrast, spinal muscular atrophy (SMA) is the most prevalent motor neuron disease in
children, affecting ~1 in 10,000 births (354). Both these motor neuron diseases have been
associated with disrupted minor intron splicing, which will be discussed below.
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2.3.1

Spinal muscular atrophy

SMA is an autosomal recessive disease caused by mutation in SMN1 (355). Loss-of-function
mutations in SMN1 result in a reduction of the full-length SMN protein, which is important for the
maturation of both major and minor spliceosomal snRNPs (see section 1.1.2 and 2.1.2) (356,
357). While chromosomal duplication in humans has led to a second copy of the gene encoding
for SMN, called SMN2, this gene differs from SMN1 by one nucleotide (356, 358). This C>T
transition in exon 7 of SMN2 does not directly affect the amino acid sequence, but it does disrupt
an ESE sequence, resulting in the skipping of exon 7 (356, 358). As such, translation of 80%90% of SMN2 transcripts results in a truncated protein that is only partially functional (359-361).
Therefore, SMN2 cannot compensate for the production of fully functioning SMN, when mutations
in SMN1 occur. However, the disease severity of SMA can be modulated by the copy-number of
SMN2 (362). Specifically, one copy number of SMN2 is predicted to result in SMA type 0, the
most severe type that precipitates prenatally and is characterized by a life expectancy of less than
6 months (362). The presence of two copy numbers of SMN2, have been associated with SMA
type I, which is characterized by a life expectancy of less than 2 years (362). In contrast, four or
more copy numbers of SMN2 has been linked to SMA type III and IV, which allows individuals to
survive into adulthood (362).
In order to understand the molecular mechanisms underlying the disease pathogenesis in
SMA, several mouse models have been created (363). Since the chromosomal duplication of the
SMN1 locus is specific to humans, mice only contain a single Smn gene. Ubiquitous loss of this
gene results in early embryonic lethality and thus does not recapitulate the human phenotypes
(364). As such, several mouse models were created where the human SMN2 was expressed in
a Smn-null background (365, 366). Other SMA mouse models contain the human SMN2 cDNA
with the skipped exon 7 in a null-background (367). Regardless of the specific genetical
background, these mouse models result in a mean lifespan of approximately a month (363).
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Moreover, while these mice are indistinguishable from their wild-type littermates at birth, they are
characterized by loss of lower motor neurons (specifically alpha-motor neurons), as well as
muscular atrophy soon thereafter (363). Because SMN plays a role in the biogenesis of all Class
I snRNPs, it was predicted that splicing would be affected in SMA. However, formation of major
spliceosome snRNPs is unaffected in mouse models for SMA (368). In contrast, minor
spliceosome components have been shown to be reduced in the brain and spinal cord of these
mice (368). Notably, this reduction was not observed in unaffected tissues such as the kidney and
skeletal muscle (368). Thus, this suggests that minor intron splicing may be disproportionally
affected in SMA. Indeed, minor intron retention has been elevated in SMA mouse models (369).
Similarly, elevated levels of minor intron retention have been reported in SMA patients (370). In
addition, the formation of the minor spliceosome tri-snRNP is affected in lymphoblasts derived
from SMA patients, resulting in aberrant splicing of minor introns (370). Thus, disrupted minor
intron splicing may contribute to the lower motor neuron loss observed in SMA patients.
2.3.2

Amyotrophic lateral sclerosis

ALS is a severe neurodegenerative disease affecting both upper and lower motor neurons, and
is characterized by death within 2-5 years after disease onset. Most ALS cases are sporadic
(sALS) and do not have a known genetic association, but ~10% of ALS cases are familial (fALS)
(371). These cases of fALS have been linked to mutations in over 40 different genes, of which
C9ORF72, SOD1, TARDBP, and FUS are the four most common (372). While RNA processing
roles have been demonstrated for all four genes, FUS and TARDBP specifically play a role in
splicing (373). Mutations in the nuclear localization of these two genes result in their cytoplasmic
aggregation and concomitant depletion in the nucleus (373). Therefore, it has been debated in
the field whether the pathogenesis in these ALS patients is due to loss of function or gain of
function of these proteins. To address this question, several mouse models have been created to
recapitulate the ALS phenotypes observed in patients.
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To test whether the nuclear depletion of FUS was the underlying cause of ALS, several
knockout mice have been developed for Fus. In 2000, Hicks et al. created a constitutive knockout
mouse for Fus that displayed perinatal lethality and therefore could not be studied for age-related
neurodegeneration (374). Another Fus knockout mouse made by Kuroda et al. lived longer, but
the neurodegenerative phenotype was not assessed (375). The Fus knockout mice made by
Hicks et al. were then outcrossed by another group, which prolonged their survival (376).
However, since these mice did not show an ALS-like phenotype, a gain-of-function mechanism
was favored (376). Similarly, constitutive knockout mice for Tardbp, which encodes the protein
TDP43, were embryonically lethal, and therefore could not be studied for neurodegenerative
symptoms (377-379). Embryonic lethality was circumvented by ablating Tardbp in motor neurons,
which did result in motor dysfunction (380).
In contrast to the loss-of-function hypothesis, the gain-of-function hypothesis postulates
that the cytoplasmic aggregates are toxic and cause disease. This hypothesis was tested by the
production of transgenic mice that express human FUSR521C and FUSP525L, in the WT Fus
background (381, 382). These mice developed ALS-like phenotypes, thereby strongly supporting
the toxic gain-of-function model (381, 382). Moreover, transgenic mice that mimic commonly
found human mutations in TARDBP, like TARDBPA315T, TARDBPG348C, TARDBPQ331K and
TARDBPM337V, showed motor deficits at 10 months of age accompanied with lower motor neuron
death (383-385). Thus, a toxic gain-of-function model is also invoked for ALS caused by mutations
in TARDBP.
The mechanism by which cytoplasmic FUS aggregates manifest toxicity is not clearly
understood. In 2013, it was shown that several mutations in FUS result in cytoplasmic aggregates,
which trap spliceosomal components in the cytoplasm (386). While this group only interrogated
the localization of major spliceosome components, it was later reported that both nuclear and
cytoplasmic FUS protein
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also

interact

with minor spliceosomal components

(387).

Immunoprecipitation of wild-type FUS protein especially enriched for minor spliceosome-specific
proteins and the U11 and U12 snRNA (387). Importantly, it was shown that cytoplasmic
aggregates of mutant FUS co-localized with U11 and U12 snRNA (387). Consequently, nuclear
levels of these snRNAs, which are normally low, would be reduced, thereby inhibiting the
formation of functional minor spliceosomes. This hypothesis is consistent with the reduced
splicing efficiency of the minor intron in the reporter gene P120 (387). While this mechanism was
specifically tested for P525L mutations in the NLS of FUS, it is possible that any mutant FUS that
retains RNA-binding capacity and forms cytoplasmic aggregates, may ultimately inhibit the minor
spliceosome.
Besides the sequestration of minor spliceosomal components, aberrant minor
spliceosome levels have been observed in sALS patients (388, 389). The primary mutation in
these patients was unknown, but cytoplasmic TDP43 + aggregates were found in the motor cortex
and spinal cord (389). In these same tissues, the expression level of U11 and U12 snRNA was
significantly reduced compared to those of controls (389). Similarly, the expression of U11/U1259K, was reduced in sALS patients, concomitant with an increase in cytoplasmic localization
(389). Importantly, RT-PCR for a few minor introns revealed a reduction in the levels of properly
spliced MIG transcripts in these sALS patients (389). Thus, disrupted minor intron splicing might
underlie forms of both fALS and sALS, since FUS+ and TDP43+ cytoplasmic aggregates have
also been observed in sALS patients (390-392).
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Chapter 3 Identification of minor introns and regulation of their splicing
In order to study minor intron splicing, one must know which genes contain minor introns. This
chapter describes how I identified minor introns in the mouse and human genome using positionweighted matrices. Moreover, it discusses the regulation of minor intron splicing and alternative
splicing in MIGs across different tissues, an area that had been up to debate. The analysis of
minor intron splicing required the development of new bioinformatics pipelines, which are
described in this chapter. The results of this study were published in BMC Genomics, in a
manuscript entitled: “Minor intron splicing revisited: identification of new minor intron-containing
genes and tissue-dependent retention and alternative splicing of minor intron.” (120)
3.1 Introduction
Splicing of introns is required for the expression of most eukaryotic genes. A subset of mammalian
genes contains both major and minor introns, therefore requiring both the major (U1, U2, U4, U6
and U5) and the minor (U11, U12, U4atac, U6atac and U5) spliceosome, respectively (393). In
these minor intron-containing genes (MIGs), the majority of introns are usually spliced by the
major spliceosome, with only one or two introns being spliced by the minor spliceosome.
Regardless, mis-splicing of these few minor introns can have detrimental consequences, as
highlighted by diseases caused by mutation in minor spliceosome components. For example,
mutation in RNU4ATAC, which encodes for U4atac snRNA, has been linked to microcephalic
osteodysplastic primordial dwarfism type I (MOPD1), Roifman syndrome and Lowry-Wood
syndrome (144, 145, 157, 164). Since U4atac snRNA is ubiquitously expressed, mutation in this
gene is expected to result in systemic inhibition of the minor spliceosome. Consequently, the
expectation is that all tissues of the developing embryo would be affected. Instead, the cardinal
symptoms that characterize these diseases include microcephaly and skeletal dysplasia,
suggesting that the developing brain and bone are more prone to the loss of minor splicing than
other tissues (144, 145). One way to explain this paradox of systemic minor spliceosome inhibition
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resulting in tissue-specific phenotypes would be that the MIGs are expressed, spliced and/or
alternatively spliced in a tissue-specific manner. As a consequence, certain tissues might be more
susceptible to loss of minor spliceosome function. Indeed, there is evidence that cell-types are
differentially affected by loss of minor spliceosome. For instance, we recently reported a mouse
model for microcephaly, in which we inactivated the minor spliceosome through ablation of U11
snRNA in the dorsal telencephalon (142). We found that loss of minor spliceosome function
affected symmetrically dividing radial glial cells more severely than intermediate progenitor cells
and neurons, underscoring cell type-specific susceptibility to loss of minor splicing. Moreover,
RNAseq revealed that expression of MIGs was generally not affected, despite elevated retention
of many minor introns (142). On the other hand, splicing of several minor introns was not affected
in the U11-null dorsal telencephalon (142). This dynamic response to loss of minor splicing in a
cell-type specific manner suggests that minor intron splicing and MIG expression might also be
highly regulated in WT tissues. Therefore, we here wanted to determine whether minor intron
splicing and MIG expression showed tissue-specific regulation.
3.2 Results
3.2.1

Identification of new minor introns in the mouse and human genome.

Historically, minor introns were defined based on their divergent terminal dinucleotides (AT-AC)
(96). However, since the initial discovery of minor introns, several AT-AC introns were shown to
be spliced by the major spliceosome (103, 394). As such, not only the terminal dinucleotides, but
the entire 5’ and 3’ splice site, as well as the branch point sequence are now taken into account
in order to define minor introns. In 2006, a comprehensive analysis of all annotated introns was
performed by two independent groups (14, 15). By employing position-weighted matrices of the
consensus sequences of all annotated introns, they were able to classify introns as major or
minor. However, these studies are over ten years old, and the genome annotation has been
significantly updated since. Thus, we first wanted to obtain an updated comprehensive list of all
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minor introns in the mouse and human genome (Ensembl assembly 95). Using position-weighted
matrices, we identified 722 minor introns in canonical mouse nascent transcripts and 770 minor
introns in canonical human nascent transcripts. (Figure 3.1A-B). Of the mouse minor introns, 184
(25%) were not previously identified by the U12DB, whereas 7 (1%) minor introns were identified
by the U12DB, but not found in our analysis (Figure 3.1A). These 722 mouse minor introns were
distributed across 666 genes, of which 172 MIGs were not previously reported in the U12DB
(Figure 3.1A). For humans, we newly identified 153 (20%) minor introns, while 23 (3%) minor
introns from the U12DB were not classified as such in our analysis (Figure 3.1B). The 770
identified minor introns were found in 714 MIGs, of which 145 were not previously reported in the
U12DB (Figure 3.1B). Several of the newly identified minor introns were part of gene families that
already had members identified as MIGs. For instance, we now identified a minor intron in E2f4,
which is part of the E2F family that already had E2f1, E2f2, E2f3, E2f5 and E2f6 listed as MIGs
in the U12DB (Figure 3.1C). Similarly, our analysis identified new minor introns in other gene
families known to consist several MIGs, such as the mitogen-activated protein kinases, guanylate
binding proteins, DOCKs, and voltage-gated calcium and sodium channels (Figure 3.1C).
Next, we investigated the terminal dinucleotides of all the identified minor introns, and
found that ~72% of the minor introns were of the GT-AG type, whereas only ~24% and ~22% was
of the AT-AC type in mouse and human, respectively (Figure 3.1D-E). The distribution of minor
introns across MIGs was similar between mouse in human in that for both genomes there were
50 MIGs that contained 2 minor introns, and 3 MIGs that contained 3 minor introns, while the
remaining MIGs only contained a single minor intron (Figure 3.1F-G). Following this analysis, we
wanted to interrogate the type of genes in which these minor introns were found. Interestingly, we
found that while the majority of MIG transcripts were protein-coding, 8 MIGs in mouse were
predicted to be pseudogenes (Figure 3.1H). Moreover, 15 MIGs were long intergenic non-coding
RNAs (lincRNAs) (Figure 3.1H). Similarly, in the human genome, 34 MIGs were predicted to be
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pseudogenes, as well as 15 MIGs as lincRNAs (Figure 3.1I). In all, we have identified ~150 new
MIGs compared to previous minor intron annotations (Figure 3.1A-B) (14, 15).
Finally, we wanted to compare the identity of MIGs between mouse and human. To this
end, we curated the orthologs listed in the Ensembl and NCBI database, and found that 586 genes
contained a minor intron in both mouse and human genome (14). As such, there were 80 mousespecific MIGs and 128 human-specific MIGs.
3.2.2

MIGs show dynamic expression across mouse and human tissues.

With our updated list of minor introns, we next wanted to characterize the expression of MIGs
across tissues. To this end, we interrogated RNAseq data from eleven different adult WT mouse
tissues and eight different tissues from healthy human adults (395, 396). By setting the expression
threshold at 1 TPM, we found that the fewest MIGs were expressed in the mouse liver (434 out
of 666; 65%), whereas the most MIGs were expressed in the testis (585 out of 666; 88%) (Figure
3.2A). Furthermore, there were 396 MIGs (59%) expressed in all of the eleven mouse tissues
(Figure 3.2A). Next, we wanted to determine whether tissues with a high number of expressed
MIGs, such as the cerebrum and testis, also expressed these MIGs at a high level. Indeed, we
found that not only many MIGs were expressed in the testis and cerebrum, but they were also
expressed at relatively high levels (Figure 3.2B). Moreover, we found that MIGs were expressed
at high levels in the mouse spleen and thymus (Figure 3.2B). In contrast, heart and liver, the two
tissues that had the least number of MIGs expressed, also had low levels of MIG expression
(Figure 3.2B). Thus, it is not only the number of expressed MIGs, but also the level at which these
MIGs are expressed that differs between tissues. Importantly, this finding is conserved in humans,
where we analyzed MIG expression in eight different tissues (Figure 3.2C). Like in mouse, we
also found that MIGs were expressed at the lowest levels in the human heart and liver, and at the
highest levels in the cerebral cortex and testis (Figure 3.2D).
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Next, we wanted to determine whether the specific MIGs that were expressed in each
tissue were the same in mouse and human. For this, we used the 586 MIGs that were conserved
across both genomes to interrogate MIG expression across eight tissues. Overall, we found that
if a MIG was expressed in a mouse tissue, it was also expressed in that same tissue in human
(Figure 3.2E). Only few MIGs showed differences in expression between mouse and human
tissues. For example, we found 18 MIGs that were expressed in the mouse lung, but not in the
human lung. Similarly, there were 22 MIGs expressed in the human lung, but not in mouse.
Regardless, the majority (512) of MIGs were expressed in both the mouse and human lung
(Figure 3.2E). We observed a similar trend in most other tissues, except for the liver where there
was a relatively high number of MIGs (79) exclusively expressed in humans (Figure 3.2E). In all,
we found that MIG expression is mostly conserved between mouse and human and shows
dynamic changes across tissues.
3.2.3

Tissue-enriched MIGs participate in specific biological functions.

To determine which tissues were most similar in their MIG expression pattern, we performed
hierarchical clustering of the mouse tissues based on the expression of all 666 MIGs (Figure
3.3A). The analysis revealed that testis was an outlier, followed by thymus and spleen, which
were closely paired (Figure 3.3A). Similarly, the heart and skeletal muscle were closely related,
as well as bone and lung. The heatmap of MIG expression showed several clusters of MIGs that
were highly expressed in one tissue compared to the other tissues (Figure 3.3A). To identify the
MIGs that were specifically enriched in one tissue, and thus form the expression signature of that
tissue, we employed a bioinformatics pipeline which we named SignatureCalc. Here, we extracted
all MIGs that were significantly upregulated (>2FC) in one tissue compared to all other samples
to generate the UpSignature (Figure 3.4). Similarly, we extracted all MIGs that were significantly
downregulated (>2FC) in one tissue compared to all others (DownSignature) (Figure 3.4). Using
this approach, we found 228 MIGs that were upregulated in one tissue compared to all others
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(Figure 3.3B). Most of these were enriched in the testis (109) and cerebrum (54), but each
interrogated tissue showed enriched expression of at least one MIG (Figure 3.3B). To determine
whether their expression would contribute to a tissue-specific function, we submitted all
UpSignature gene lists for functional annotation analysis by DAVID, g:Profiler and Toppgene
(397-399). Only those functions that were identified as significant enrichments by all three tools
were reported. We found that the 109 testis-upregulated MIGs significantly enriched for functions
including centriole and cilium assembly (Figure 3.3B; Table S1). Moreover, submission of the 54
MIGs in the UpSignature of the cerebrum to functional annotation tools showed several significant
enrichments, including voltage-gated ion channel activity and neuronal cell body (Figure 3.3B;
Table S1). This is in keeping with the upregulation of the several members of the Cacna, Scn and
Slc gene family in the cerebrum compared to the other ten tissues (Figure 3.3B). Submission of
the remaining UpSignature lists revealed only one more significant enrichment: MIGs enriched in
bone are important for calcium ion binding (Figure 3.3B; Table S1). Next, we determined the
DownSignature, i.e. MIGs specifically downregulated in one tissue compared to all others, for
each sample. Several tissues did not have a DownSignature, or in other words, did not express
MIGs at a significantly lower level than all other tissues. However, we did find 23 MIGs expressed
at >2FC lower in bone marrow, 20 MIGs in testis, and 108 MIGs in the liver (Figure 3.5B).
Submission of the MIGs downregulated in the liver enriched for functions including voltage-gated
ion channel activity and cilium morphogenesis (Table S1). In sum, we found tissue-enriched
expression of many MIGs, which often encode for proteins important for the function of the tissues
in which they are upregulated.
3.2.4

Shorter minor introns are retained at a higher level in a tissue-specific manner.

Besides being regulated at the transcriptional level, MIGs are thought to be regulated at the level
of splicing, specifically minor intron splicing. Currently, the model for minor intron splicing
postulates that minor introns are generally spliced inefficiently resulting in retention and
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introduction of a premature stop codon (123). This would then either activate the nonsensemediated decay (NMD) pathway or result in the production of an aberrant protein isoform.
However, this model has emerged from analysis performed on few MIGs, such as P120, PROX1,
SCN4A, INSIG2, SNRPE and E2F2 (99, 123, 394, 400, 401). We wanted to investigate whether
this form of regulation extends to all MIGs or whether it is intron-specific, as suggested by recent
RNAseq analyses. Notably, RNAseq from zebrafish, maize, our U11 cKO mouse, Roifman
syndrome and myelodysplastic syndrome patients has shown that there is a wide range of minor
intron retention levels in absence of a fully functioning minor spliceosome (136, 137, 140, 142,
157). These reports highlight that inefficient minor intron splicing as a means to regulate MIG
expression might not extend to all MIGs.
To test which MIGs showed minor intron retention at steady-state in WT tissues, and thus
could be regulated through inefficient minor intron splicing, we next employed the method
described by Madan et al. (140). Briefly, we quantified the exon-minor intron boundary reads to
determine minor intron retention levels, which were reported as a mis-splicing index (MSI) (Figure
3.6A) (140). Using our filtering criteria (Figure 3.6A), we found that 150 minor introns were
retained in all three replicates of at least one tissue, 105 minor introns were retained in 1 or 2
replicates in at least one tissue, while 467 minor introns did not show any retention at all in any of
the eleven tissues (Figure 3.7A). Next, we wanted to interrogate whether the retained minor
introns contained specific features, making them more susceptible to retention. First, we
interrogated the effect of intron length on the level of minor intron retention. Here, we found that
the 150 retained minor introns were significantly shorter than the 467 minor introns that did not
show any retention (Figure 3.7A). Since minor introns were initially identified based on their
divergent AT-AC consensus sequences, we next wanted to determine whether retained minor
introns contained different splice sites than those minor introns that were not retained. However,
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analysis of the 5’ splice site (SS), branch point (BP) and 3’ SS sequences revealed similar
consensus sequences regardless of the retention status (Figure 3.8).
To establish whether minor introns were subject to tissue-specific splicing, resulting in
dynamic retention across tissues, we determined the number of retained minor introns in each
tissue. To this end, we made conservative calls by limiting ourselves to minor introns that showed
evidence of retention in all three replicates. Only one of these 150 minor introns showed retention
in all interrogated tissues (Figure 3.7B). In fact, most minor introns showed dynamic use of
retention across tissues. Specifically, only 9 minor introns were retained in the liver, while there
were 93 minor introns retained in the thymus (Figure 3.7B). To exclude the possibility that this
variability was caused by tissue-specific expression of MIGs, we focused only on those minor
introns that were found in MIGs expressed >1 TPM in all eleven tissues. Of the remaining 120
retained minor introns, none showed retention across all interrogated tissues (Figure 3.7C).
Moreover, only three minor introns were retained in 10 tissues, and for a large portion of the 120
minor introns retention was only observed in a single tissue (Figure 3.7C). Furthermore, we found
that the level of retention for the same minor intron varied across different tissues (Figure 3.7D).
For example, Pcyt2 showed intron retention in ten tissues, but at significantly different levels.
Notably, it was retained at the highest MSI levels in kidney, lung, spleen, and thymus, which was
significantly higher than the retention levels in heart, skeletal muscle and testis (Figure 3.7D). In
contrast, Tcp1, which showed retention in six tissues, had significantly higher MSI values in the
liver compared to its retention levels in bone, bone marrow, lung, spleen and thymus (Figure
3.7D). Thus, MIGs are not only differentially expressed across tissues, but their minor intron is
also spliced in a tissue-specific manner.
Importantly, splicing of minor introns also occurred in a tissue-dependent manner in
humans. Like in mouse, few minor introns showed retention in at least 3 replicates in one tissue
(Figure 3.9A). In fact, hardly any minor intron retention was detected in the human cerebral cortex,
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heart, kidney and liver, which were also tissues with low minor intron retention in mouse (Figure
3.7B; 3.9B). It must be noted however that some of these human tissues had a low sequencing
depth, which could contribute to the fact that we detected so few retained introns (Table S2).
Moreover, for most retained minor introns we only detected minor intron retention in one or two
tissues, specifically testis and bone marrow (Figure 3.9B-C). This is unlike mouse, where spleen
and thymus contained the most retained minor introns (Figure 3.7B). In addition, the minor introns
that are retained in the bone marrow, spleen and testis are mostly distinct between mice and
human (Figure 3.9D). Thus, while the expression patterns of MIGs seemed conserved between
the two species, retention of minor introns did not. However, we did find that shorter introns were
also more often retained than longer minor introns in human (Figure 3.9A)
3.2.5

Minor intron splicing can be efficient.

While major intron retention used to be considered the consequence of mis-splicing, it is now
considered an actively regulated form of alternative splicing (AS) that often serves a physiological
function (402). However, in the case of minor introns, retention is still thought to be the result of
inefficient splicing caused by low levels of minor spliceosome snRNPs or slower splicing rates
(123, 393). As such, at steady-state, one might expect the splicing of major introns flanking the
minor intron to be more efficient than that of the minor intron. Indeed, this was the finding reported
by Patel et al., where they analyzed the rate of major intron versus minor intron retention for three
MIGs through qRT-PCR analysis (123). Since the model was based on a small sample size, we
wanted to extend this analysis to all MIGs.
Of the 722 minor introns in the mouse genome, 582 minor introns are flanked by both an
upstream and downstream major intron (Figure 3.10). The remaining minor introns were either
found as the first or last intron in the gene (122), flanked by a major and a minor intron (12), or
were the only intron in the gene (6) (Figure 3.10). One such MIG that contains a minor intron
without any major introns, is Coa3. This suggests that splicing and indirectly expression of these
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MIGs solely relies on the minor spliceosome, yet retention of this single minor intron was tissuespecific (Figure 3.7D). Next, we wanted to analyze the MSI values for the upstream and the
downstream major intron flanking the minor intron, and perform statistical analysis to compare
these levels to that of minor intron retention. Thus, for this analysis we were limited to the 582
minor introns that were flanked by two major introns. We first wanted to establish for how many
of the retained minor introns in each tissue there was no retention of the flanking major introns,
as this would be consistent with the model of inefficient minor intron splicing. We found that, if a
minor intron was retained in a tissue, the flanking major introns were frequently not retained
(Figure 3.11A; Bin I). However, for most minor introns we did not detect retention, while in several
cases the flanking major introns were retained (Figure 3.11A; Bin V-VI), which suggests that minor
intron splicing is not always inefficient. For example, in thymus, a tissue with the most retained
minor introns, we also found nine minor introns that were spliced efficiently, yet in those cases
both of the flanking major introns showed retention (Figure 3.11A; Bin VI). In addition, we found
that even when a minor intron is retained, its levels are not always higher than that of the flanking
major introns (Figure 3.11B). For instance, Pcyt2, which has a minor intron of 379bp and flanking
major introns of similar size, showed significantly elevated minor intron retention compared to that
of the flanking major introns in the thymus. However, in the cerebrum this elevated minor intron
retention is not significant (Figure 3.11C), which would be in agreement with a model of dynamic
regulated minor intron splicing. A more extreme example is Tcp1, which contains a minor intron
of 350bp. In the thymus, this minor intron was retained at low levels (Figure 3.11C). However,
when we compared it to the retention levels of the flanking major introns, we found that the
upstream major intron had significantly elevated retention compared to the minor intron (Figure
3.11C). Again, this effect is tissue-specific as we did not find similar significant changes in the
liver (Figure 3.11C). In all, our analysis showed that in vivo, minor intron retention as a
consequence of inefficient splicing might not apply to all MIGs.
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3.2.6

Minor introns are alternatively spliced in a tissue-dependent manner.

Our discovery that minor intron retention is a dynamically regulated event across tissues, supports
the idea that minor intron retention is not just the result of inefficient splicing. Instead, we propose
to consider it as a type of alternative splicing, as is now accepted for major intron retention (131).
As such, we next wanted to determine whether other forms of AS events would occur across
minor introns in a tissue-specific manner. Previous reports have detected few AS events across
minor introns (393), which may be explained by the bioinformatics tools employed for detection
of AS event. For example, a widely used tool to detect AS events is MISO (126, 128, 139), which
detects AS events that have been annotated previously, thereby missing new AS events (222).
Here we did not want to limit our search to annotated AS events, so we curated all spliced reads
that mapped around the minor intron. We then quantified the number of reads that would support
constitutive splicing (CAT1, Figure 3.12A) or any of the eight different AS events (Figure 3.12A).
It must be noted that we interrogated each of these events separately. However, because these
events are not necessarily mutually exclusive, a single read can support multiple AS events. We
then determined the level of each AS event for each minor intron in each tissue, represented as
an MSI value (Figure 3.6B). Using this approach, we found that most of the eight AS categories
were utilized in all eleven tissues (Figure 3.12B).
The most prominent form of AS that was observed around minor introns involved cryptic
splicing. Specifically, CAT6 and CAT7 (Figure 3.12B), which represent an alternative 5’SS and
3’SS (Figure 3.12A), respectively, were used at a high level in all tissues. In contrast, exon
skipping (CAT2-4) was detected at lower levels in most tissues and was often employed in a
dynamic manner across tissues (Figure 3.12B). For instance, five MIGs showed evidence of exon
skipping in the testis, while not a single exon skipping event around minor introns was observed
in the bone, cerebrum, heart and skeletal muscle (Figure 3.12B). Finally, the introduction of a
cryptic exon within the minor intron (CAT9) was observed in several MIGs, albeit at lower levels
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(Figure 3.12B). Again, the dynamic usage of this form of AS was illustrated by the fact that it was
utilized by 15 MIGs in the thymus, yet by only 4 MIGs in the skeletal muscle (Figure 3.12B).
Overall, we detected very few AS events across minor introns in the heart, liver and skeletal
muscle, which is similar to our observation of low levels of minor intron retention in these tissues
(Figure 3.7B; Figure 3.12B). In contrast, many AS events were observed in the spleen and
thymus, the tissues that also possessed the most retained minor introns (Figure 3.7B; Figure
3.12B). Finally, despite having detected only few retained minor introns in testis, we did observe
the most AS events in this tissue compared to other tissues (Figure 3.7B; Figure 3.12B). In all,
these results show that AS across minor introns is utilized in a tissue-dependent manner and that
these AS events are more common than previously thought (393). Consistent with these
observations, is our finding that ~8% of the annotated isoforms of MIGs in the Ensembl database
employ AS events across the minor introns (Figure 3.13A-B) (403). Moreover, we identified a
positive correlation between alternative splicing and the length of the minor intron, such that
alternatively spliced minor introns were significantly longer than those that were not alternatively
spliced (Figure 3.13C).
3.2.7

Identification of alternatively spliced MIGs.

Since multiple AS events can be used in conjunction in a single MIG, we next took a MIG-centric
approach. This analysis revealed that utilization of a cryptic 5’SS (CAT6) was often coincident
with a cryptic 3’SS (CAT7) (Figure 3.14). There were 12 minor introns where CAT6 was not used
along with CAT7, while nine minor introns used a cryptic 3’SS (CAT7) but not CAT6 (Figure 3.14).
Similarly, a cryptic 5’SS resulting in a truncation of the upstream exon (CAT5) was often utilized
in combination with a cryptic 3’SS resulting in extension of the downstream exon (CAT8) (Figure
3.14). Types of AS that were generally employed as a single event in a MIG included all forms of
exon skipping. Specifically, skipping of both the upstream and downstream exon (CAT2) was the
sole AS event found in eight MIGs (Figure 3.14). Moreover, we found ten MIGs that expressed
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an isoform in which the upstream exon was skipped (CAT3). These included mitogen-activated
protein kinases, and Tmem87a and Tmem87b (Figure 3.14). Especially the skipping event in the
mitogen-activated protein kinases was tissue-specific, as it was highly upregulated in the
cerebrum compared to other tissues (Figure 3.12B; Figure 3.14). While the AS around the minor
introns of mitogen-activated protein kinases had previously been described (404), many other AS
events were undescribed so far. For instance, the AS event around the minor intron of Tmem87b,
which is located between exons 11 and 12, was a novel event. We observed skipping of exon 11
(CAT3) in the cortex and the kidney (Figure 3.14). In addition, we detected the presence of a
cryptic exon 11a within the minor intron of Tmem87b (Figure 3.14). Sashimi plots revealed that
these events were not resulting in separate isoforms but were connected, such that when exon
11 is skipped, the cryptic exon 11a is utilized (Figure 3.12C). Moreover, we did not observe any
spliced reads spanning exon 11 and exon 11a, which suggested that these two exons are mutually
exclusive (Figure 3.12C). We performed RT-PCR to confirm that in the cortex, the most robustly
expressed transcript of Tmem87b is the one that skips exon 11 and utilizes exon 11a (Figure
3.12D). However, both exon 11 and 11a are 72 bp, which with the primer pairs we designed
resulted in PCR-products of identical size. Therefore, we used the unique AvaI restriction site
found in exon 11a to determine the presence of isoforms containing exon 11a but not exon 11,
which is resistant to this digest. These results support the RNAseq analysis in that the
predominant isoform expressed in the cortex is the one with exon 11a (Figure 3.12D). Importantly,
the minor spliceosome is also required to splice intron 11a, as supported by the U12-type 5’SS,
despite the fact that the annotated minor intron is skipped. In addition, we validated several other
AS events around minor introns. For example, in the testis, we detected skipping of exons flanking
the minor intron in Pdpk1 and Tctn1 by RNAseq (Figure 3.14). RT-PCR analysis confirmed the
robust presence of these isoforms in the testis, as well as low levels in several other tissues, such
as the cerebrum (Figure 3.12E). Similarly, we had detected skipping of both exons flanking the
minor intron of Dram2 (CAT2) in bone marrow, kidney and thymus by RNAseq (Figure 3.14).
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Analysis by RT-PCR confirmed the presence of the isoform in these tissues, but also showed low
expression of isoforms generated by different alternative splicing events around the minor intron
of Dram2 (Figure 3.12E). Thus, besides confirming RNAseq results, we were also able to detect
several additional isoforms expressed at low levels. In other words, our RNAseq analysis was
conservative in the identification of AS events around minor introns, in order to minimize false
positives. Overall, we identified several novel AS events around minor introns that were often
used in conjunction and resulted in the expression of tissue-specific isoforms.
To test whether these isoforms could also result in the production of tissue-specific
proteins, we performed bioinformatics analysis to predict the fate of alternatively spliced
transcripts. RNA transcripts are under tight quality control, such that aberrant splicing can result
in activation of several degradation pathways. For instance, intron retention can result in nuclear
retention of the transcript and subsequent degradation by the exosome (405). Alternatively,
aberrant transcripts are exported to the cytoplasm where they can be degraded via pathways
such as NMD and/or non-stop decay (NSD) (406). It has been predicted that transcripts containing
a premature stop codon >50 nt upstream of an exon-exon junction are subjected to NMD, whereas
transcripts lacking a stop codon before the polyA-signal would be subject to NSD (407, 408).
Thus, we used these criteria to predict whether the alternatively spliced isoforms would be
translated into protein, or degraded via NMD or NSD. We found that the majority of alternative
splicing events would introduce a premature stop codon, resulting in truncation of the open
reading frame (ORF) and most likely degradation via NMD (Figure 3.12F). In contrast, only one
transcript was predicted to result in NSD (Figure 3.12F). Lastly, ~22% of the AS events are
predicted to result in transcripts that could be translated into proteins. Of these, the vast majority
would result in truncation of the protein, compared to the canonical isoform (Figure 3.12F). Only
four AS events were predicted to result in an extension of the protein, potentially resulting in novel
protein domains (Figure 3.12F).
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Finally, we also wanted to determine the prevalence of AS around minor introns in
humans. Again, we found that cryptic splicing of minor introns (CAT6 and CAT7) was used at the
highest levels in all tissues (Figure 3.15A). In addition, we observed dynamic usage of AS across
minor introns in the investigated tissues (Figure 3.15A). Specifically, we detected exon skipping
(CAT2) in many MIGs in the bone marrow and testis, but not in other tissues (Figure 3.15A).
Moreover, skipping of the downstream exon (CAT4) was used for more minor introns in the bone
marrow than in any other tissue (Figure 3.15A). In addition, we found that the usage of a cryptic
exon (CAT9) was used for a varying number of minor introns across the tissues, suggesting that
AS across minor introns is also a regulated event in humans (Figure 3.15A). Overall, the most
minor introns were alternatively spliced in the bone marrow and the testis (Figure 3.15A).
Comparison of alternatively spliced MIGs between mouse and human revealed that 46 MIGs were
alternatively spliced in both mouse and human, whereas 36 MIGs were alternatively spliced in at
least one tissue in mouse, and 81 MIGs were only alternatively spliced in human (Figure 3.15B).
Thus, even though AS across minor introns also occurs in humans, the specific AS events for
each individual minor intron do not seem to be conserved and its prevalence varies between the
species. However, we cannot exclude the possibility that this difference stems from a difference
in age between the two species.
3.3 Discussion
The field of minor intron splicing is gaining prominence with discoveries of diseases linked to
mutations in genes encoding the components of the minor spliceosome (157, 164-166). In order
to understand the mechanism of disease pathogenesis in these syndromes, one must have a
detailed overview of the MIGs that could have been altered by the inhibition of the minor
spliceosome. In this regard the U12DB has served a valuable role in providing an easily
accessible list of minor introns and MIGs. However, the U12DB has not been updated since 2007,
while several new genome assemblies have been released since (14, 403). Here, we present a
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new list of minor introns, which was generated using PWMs as described by Sheth et al. (15).
The new list of MIGs captures 99% and 97% of all MIGs reported in the U12DB for the mouse
and human genome, respectively and thus is not expected to fundamentally change the results
of previous studies. However, the identification of new MIGs, which is likely the result of new
genome assemblies that refined the exon/intron boundary coordinates, does expand the list of
target genes that may underlie phenotypes created by minor spliceosome-related diseases. As
such, it would be interesting to see whether any of the newly identified minor introns are affected
in these diseases.
Given that we identified 666 MIGs in the mouse genome, it is not surprising that MIG
expression is tissue-specific. However, when MIG expression was used to cluster tissues, the
relationships between these tissues were different than when total gene expression was used to
perform the same analysis (Figure 3.3A; Figure 3.5A). This tissue-specific MIG expression might
be one of the contributing factors to the tissue-specificity observed in the diseases caused by
mutation in the various minor spliceosome components (140, 144, 145, 165, 166, 387). Since
cerebrum and testis expressed the most MIGs at the highest levels (Figure 3.2A-D), one may
predict these tissues to be most susceptible to loss of minor intron splicing. Indeed, one of the
cardinal symptoms of MOPD1 and Roifman syndrome, which are caused by mutation in the
U4atac snRNA, is microcephaly (144, 145, 157). Defects in testis development have not been
reported in MOPD1 patients, but mutation in the RRM of Zrsr1, a retrotransposed copy of Zrsr2,
has been shown to result in impaired spermatogenesis (139). Specifically, Zrsr1-mutant testis
contain seminiferous tubules arrested at the spermatocyte stage, as well as sperm with abnormal
tail development, which suggests defects in their cilium assembly (139). Interestingly, MIGs
upregulated in the testes significantly enriched for cilium assembly (Figure 3.3B), which
underscores the importance of understanding tissue-specific expression of MIGs. Indeed, tissues
with low MIG expression such as liver and heart have not been reported in patients and/or animal
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models with inactivated minor spliceosome. Thus, it appears that liver and heart manage without
a functioning minor spliceosome and aberrant MIG expression. Together, these finding suggest
that the differential transcriptional regulation of MIGs might contribute to tissue-specific
phenotypes in minor spliceosome-related disease.
While we observed tissue-specific transcriptional regulation of MIG expression, the more
widely investigated mechanism for the regulation of MIG expression is through retention of their
minor intron(s) (123). The inherent complexity of coordinating both the major and the minor
spliceosome to splice introns co-transcriptionally, combined with the inefficient splicing of minor
introns is thought to result in the retention of minor introns (123). In keeping with this model, our
RNAseq analysis of WT tissues showed 150 minor introns that were retained in at least one tissue
(Figure 3.7A). However, we only observed retention for one minor intron in all tissues (Figure
3.7B), which raises the possibility that minor intron retention is not a stochastic output of inefficient
splicing, but rather an actively regulated process. For example, we found that the minor intron in
Pyct2 is retained at a high level in cerebrum, but retention was not detected in bone marrow
(Figure 3.7D). In all, these data support a model of active minor intron splicing regulation.
We favor such a model, which would mean that splicing and/or retention of minor introns
can behave like the splicing of major introns. This model is in contrast to the previous model of
stochastic or inefficient minor intron splicing resulting in prevalent retention of minor introns. The
latter ideas were based on comparison of minor intron retention levels to that of the flanking major
introns. Briefly, Patel et al., employed this comparison to test the hypothesis that minor introns
are excised more slowly than the upstream and/or the downstream major introns (123). They
showed by qPCR analysis that for three human MIGs (SNRPE , E2F2, INSIG1) minor introns
were retained at a higher level than the flanking major introns (123). Afterwards, the Frilander
group used RNAseq of Hep-2 cells to show that, on average, minor introns are indeed retained
at higher levels than their flanking major introns, thereby supporting this finding (126). However,
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the variability of retention of individual minor introns was not addressed in this study; even though
a wide spread of minor intron retention was observed (126). While we detected few minor introns
that could support the idea of inefficient minor intron splicing, our model is supported by the
observation that retention of several minor introns is lower than their upstream and/or downstream
major introns (Figure 3.11). Thus, the model of inefficient minor intron splicing does not apply to
all MIGs and the decision to retain an intron, be it major or minor, is a highly regulated process in
MIGs.
The apparent differences in our findings and the subsequent models could be explained
by the choice of MIGs that were interrogated. We found that retention of shorter minor introns was
detected at a higher level than the longer introns (Figure 3.7A). This finding is in line with a recent
report by Pieczynski et al., who showed that splicing efficiency of the minor intron in the
Arabidopsis gene CBP20 became progressively more efficient by increasing the length of the
intron (409). Together, these findings suggest that efficiency of minor intron splicing, as reported
by intron retention, is inversely proportional to the intron length, which has been reported
previously for major introns (197). The elevated levels of retention in shorter minor introns is
especially relevant in light of the knowledge that most of the MIGs used to study minor intron
retention contained short introns, as they are amenable to RT-PCR analysis. Indeed, in one of
the first papers on minor intron splicing where a P120 splicing substrate was used, the authors
mentioned that: “This particular minor class intron was selected because of its small size” (99).
Since then, P120 has served as a golden standard for studying the efficiency of minor intron
splicing. Thus, the confluence of a naturally occurring preference for retention of shorter minor
introns and the choice of minor introns that were studied for technical reasons might have led to
the minor intron retention as a model for regulating all MIGs.
Given our observation that splicing of minor introns is highly regulated, it stands to reason
that it is also tissue-specific. Indeed, we found dynamic levels of minor intron retention across
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different mouse tissues (Figure 3.7D). For example, we found that minor introns were most often
retained in the mouse thymus and spleen, and in human bone marrow (Figure 3.7B; Figure 3.9C).
This is in agreement with previous reports that discovered that immune cells and neuronal cells
generally have the highest intron retention levels (197). Since lymphoid organs already possess
high levels of minor intron retention normally, this suggests that these tissues would experience
highly elevated minor intron retention in disease states. Support for this idea is evidenced by the
fact that the lymphatic system is commonly affected in patients with minor spliceosome-related
diseases such as myelodysplastic syndrome (MDS) and Roifman syndrome (140, 157). In
addition, systemic inhibition of the minor spliceosome in mouse through loss of the protein Rnpc3,
also resulted in immunological defects (138). Specifically, Doggett et al showed that systemic
postnatal ablation of Rnpc3 resulted in leukopenia and a severely reduced thymus lacking
medullary or cortical regions (138). Together, actively regulated, tissue-dependent minor intron
retention, could contribute to the tissue-specific phenotypes observed in diseases with systemic
inhibition of the minor spliceosome.
If minor intron retention is an actively regulated process, one might predict that it would
respond to stress or other environmental cues. Interestingly, Mauger et al. showed that neurons
contain large amounts of stable intron-retained transcripts in their nucleus that are not rapidly
degraded by nuclear decay mechanisms (410). Upon activation of the neural network by
incubation with bicuculline, these introns were spliced out and the transcripts were loaded onto
ribosomes, thus allowing for a rapid increase in protein production. Several activation-dependent
splicing events of introns were validated by RT-PCR, including intron 19 of the gene Ahctf1 (410).
Interestingly, this intron is a minor intron, thus supporting the model of actively regulated minor
intron retention. Moreover, the Dreyfuss group has showed that stress can enhance minor intron
splicing. By using anisomycin to activate the stress-induced protein kinase Mapk14, U6atac
snRNA levels were increased, and splicing of several minor introns found in MIGs involved in
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stress physiology was enhanced (128). Based on these findings, they proposed a model where
minor introns can act as molecular switches through retention and alternative splicing (128).
However, the extent to which AS across minor introns occurs remained unclear (393).
Here we have shown that for a subset of MIGs there are extensive tissue-specific AS
events (Figure 3.12). For example, the skipping events observed for Tmem87b (Figure 3.12C-D)
bring to light the coordinated action of both the major and the minor spliceosome to use the major
5’ SS of intron 10 in conjunction with the 3’SS of an exon found embedded within the annotated
minor intron 11a. For this to occur, the immediate major 3’ SS that is available in intron 10 was
not used, which suggests an active regulation of AS by the minor spliceosome or an alternative
splicing factor. Indeed, Mapk9, which has a similar gene arrangement as Tmem87b, with a minor
intron between exons 7 and 8, also shows mutually exclusive usage of exon 7 and 7a. The isoform
that skips the upstream exon, but splices into the cryptic exon has been shown to be enriched in
the cortex and regulated by the cortex-specific AS factor Nova2 (Figure 3.14) (411). Interestingly,
although Tmem87b and Mapk9 both employ mutually exclusive exons around the minor intron,
and both show exclusive expression of one of the isoforms in the cortex (Figure 3.12C; Figure
3.14), Tmem87b was not found to be a target of Nova2 by CLIPseq (411). This suggests that
there are multiple AS factors that may interact with the minor and major spliceosome in a tissuespecific manner, to regulate AS of MIGs. Moreover, we found that the spleen, testis and thymus
contained the most alternative spliced MIGs. This is in contrast with the AS of major introns, which
is most frequent in the central nervous system (412). Thus, the regulation of AS across the minor
intron is independent of the frequency of AS across major introns in the same gene. In summary,
our investigation provides a new avenue to explore tissue-specific MIG expression through
transcription, minor intron retention and other forms of alternative splicing.
3.4 Materials and Methods
Bioinformatics analysis
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Classification of minor introns
To identify additional minor introns, we scored the splice sites of all annotated introns against
position-weighted matrices of major and minor introns, as reported previously by Sheth et al. (15).
Briefly, all annotated intron in the mouse and human genome were curated from Ensembl (v.95).
We then isolated the consensus sequences at the 5’ and 3’ splice sites for all introns. Here, we
used a stretch of 12 nucleotides for the 5’SS (-3 to +9), and 14 nucleotides for the 3’SS (-13 to
+1). The branch point sequence (BPS) of minor introns has been shown to be closely positioned
to the 3’SS, with an optimal distance of 11-13 nucleotides (413). As such, we curated a sequence
up to 40 nucleotides upstream of the 3’SS (-40 to -1) and then isolated 29 windows of 12
nucleotides in length, thus resulting in 29 putative BPS.
Position probability matrices (PPMs) for the 5’SS and 3’SS of minor introns (AT-AC and GT-AG
type) and major introns (GT-AG and GC-AG type) were downloaded from SpliceRack (15).
Moreover, two different PPMs for the BPS of minor introns were curated, one with the adenosine
at the 9th, and one with the adenosine at the 10th position. Each element M in these matrices was
then transformed to create a position weight matrix (PWMs) using the following formula: 𝑀𝑘,𝑗 =
log 2

𝑀𝑘,𝑗
0.25

. Any 0 values in the PPMs were replaced by a pseudo count of 0.0001.

The curated splice sites of all introns were then scored against the PWMs for minor introns and
major introns by adding the scores of each individual element (𝑚 = ∑𝑛𝑗=1 𝑀𝑘,𝑗 ). The obtained
scores for each intron were then rescaled to a scale from 0 to 100 using the following formula for
negative scores: 𝑥 = 50 ∗

𝑚−𝑚𝑚𝑖𝑛
−𝑚𝑚𝑖𝑛

and for positive scores: 𝑥 = 50 + 50 ∗

𝑚
𝑚𝑚𝑎𝑥

. This way negative

values were transformed to be from 0 to 50, and positive values were transformed to be on a
scale from 50 to 100.
For the identification of minor introns we employed similar criteria as mentioned by Sheth et al.
(15). As such, an intron was classified as a minor intron if it met any of the following 4 criteria:
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1) The score for the minor intron AT-AC 5’SS PWM was over 50, and at least 10 points
higher than the score for any other 5’SS PWM.
2) The score for the minor intron GT-AG 5’SS PWM was over 50, and at least 25 points
higher than the score for the major intron GT-AG 5’SS PWM, as well as 10 points
higher than the score of the other 5’SS PWMs
3) The score for the minor intron GT-AG 5’SS PWM was over 50, and at least 10 points
higher than the score for any other 5’SS PWM. Moreover, the score for the minor intron
BPS PWM was over 65.
4) The sum of the scores for the minor 5’SS, BPS and 3’SS PWM was over 150.
We then isolated those minor introns that would need to be spliced out in order to generate the
canonical transcript. For this we used the Ensembl definition of the canonical transcript. In other
words, the CCDS translation, or otherwise Ensembl/Havana translation, with the longest CDS
would be considered the canonical translation. If these were not present, then any transcript with
the longest CDS would be considered the canonical isoform. If there was no CDS, then the longest
non-protein coding transcript was assigned as the canonical transcript.
Data accession
Data analyzed in this study was downloaded from the DDBJ and EMBL database. They can be
accessed using the following accession numbers: Mouse WT tissues (DRA005768; DDBJ
database) (395); Human tissues (E-MTAB-2836; EMBL database) (396). Information on number
of replicates and sequencing depth can be found in Table S2.
Gene expression analysis
Reads from the human pan tissue were aligned to the hg38 genome (UCSC genome browser)
using Hisat2 as described previously (142, 414). Reads obtained from mouse pan tissue were
aligned to the mm10 genome (UCSC genome browser). Gene expression was then determined
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by IsoEM2, as described previously (142, 415). Hierarchical clustering was performed using
average linking with Genesis (416).
SignatureCalc
Differential gene expression analysis was conducted using IsoDE2, as described previously (142,
415). Genes were considered differentially expressed if the fold-change was >2 with P<0.01.
Using this method, 55 pairwise comparisons were performed between all mouse tissues.
Afterwards, the intersect was taking of all the upregulated genes. Genes that were binned as
upregulated in all pairwise comparisons, were classified as being part of that tissue’s
UpSignature. Conversely, genes that were binned as downregulated in one tissue compared to
all other tissues were classified as being part of that tissue’s DownSignature.
Minor intron retention analysis
Coordinates of flanking major introns from the canonical transcript were determined using
Ensembl (v.95) and utilized for the splicing efficiency analysis in Figure 3.11. To determine minor
and major intron retention in mouse and human tissues, we employed the strategy previously
described by Madan et al. (140). Here, retention is described as the mis-splicing index (MSI),
which was calculated for each intron using BEDTools (417). Only introns that passed the filtering
criteria (>4 exon-intron boundary reads, ≥1 read aligning to both the 5’ and 3’ splice site, >95%
intron coverage) in all replicates of a condition were considered to be retained (Figure 3.6A).
Alternative splicing analysis
To detect AS across minor introns, we extracted all uniquely mapped spliced reads spanning the
minor intron. Reads mapping with only one nucleotide on either side of the junction were excluded.
The remaining spliced reads were then binned into one of 9 splicing categories (Figure 3.12A)
using BEDTools (417). First, spliced reads supporting the canonical exon-exon junction were
binned as CAT1. This was followed by binning the spliced reads supporting one of the three exon
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skipping categories. Reads spanning the minor intron and flanking exons but not mapping to
either, were classified as CAT2. Reads skipping the upstream exon but aligning to the minor intron
and/or downstream exon were classified as CAT3. Similarly, reads skipping the downstream
exon, but mapping to the minor intron and/or upstream exon, were binned as CAT4. Then,
BEDTools was employed to extract all reads supporting cryptic splice site usage. To this end,
only reads mapping to one exon and supporting a cryptic splice site >2nt from the canonical splice
site at the other exon were included. Afterwards, the specific coordinates for these novel exonexon junctions were utilized as bait to extract additional spliced reads that mapped to this cryptic
splice site but not the opposite exon. Finally, spliced reads mapping within the minor intron and
also mapping to either of the flanking exons were binned as CAT9, cryptic exon usage. We then
calculated the relative AS usage for each AS event for each minor intron as the mis-splicing index
(MSI). This was determined as the percentage of reads supporting an individual AS event (Figure
3.6B). To reduce false positives, we only considered minor introns to be alternatively spliced if
the average MSI of all replicates for a given condition was >10% (Figure 3.6B). Moreover, a
threshold for the average number of reads supporting an AS event was employed by normalizing
to the sequencing depth. Specifically, only AS events with >1 read per 3 million uniquely mapped
reads were included (Figure 3.6B).
Functional enrichment analysis
UpSignature lists for each tissue were submitted for functional enrichment analysis to DAVID,
ToppGene and g:Profiler (397-399). Significant GO-Terms (Benjamini-Hochberg adjusted Pvalue<0.05 for DAVID; FDR-corrected P-value<0.05 for ToppGene; g:SCS threshold<0.05) were
isolated. Only GO-Terms that were significant according to all three functional annotation tools
are reported in Figure 3.3 and Table S1. Similar analysis was performed for the DownSignature
lists.
Open Reading Frame (ORF) analysis
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For all alternatively spliced MIGs, we determined the new exons of the canonical transcript
depending on the specific AS event that was observed. If multiple AS events were observed
around a minor intron, these were treated as separate events. Moreover, if the read filter was
passed for an AS event, but this was the result of multiple coordinates being employed, of which
no single coordinate passed the read filter separately, the event was excluded from this analysis.
An example would be the use of a cryptic 5’SS in a minor intron (CAT6) which was supported by
20 reads, however this was the sum of reads all supporting different coordinates being employed
as a cryptic 5’ SS. The transcripts of the remaining protein-coding genes were then translated in
silico and the open reading frame was predicted. The location of the stop codon was compared
with the annotated stop codon to determine whether the AS event had resulted in a truncation or
extension of the ORF. If the new stop codon was found >50 nt upstream of an exon-exon junction,
the alternatively spliced isoform was predicted to be degraded by NMD. If no stop codon was
identified, then the transcript was predicted to be degraded by NSD. In all other cases, the
transcript was predicted to give rise to a protein.
Annotated isoform analysis
To determine whether AS events across minor introns had been annotated, we downloaded the
exon coordinates of all MIG transcripts from Ensembl (v.95). Exon coordinates of each transcript
were then compared to the minor intron coordinates and transcripts were binned into one of four
categories: 1) transcripts that supported constitutive splicing of the minor intron, 2) transcripts that
were truncated before the minor intron coordinates, 3) transcripts with their first/last exon within
the minor intron coordinates, and 4) transcripts with AS across the minor intron.
Statistical analyses
To determine whether the median length of retained vs. spliced minor introns were statistically
different, we performed a Kruskal-Wallis test, followed by post-hoc Dunn test. A one-way ANOVA,
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followed by post-hoc Tukey test was employed for determining dynamic levels of retention for
individual minor introns across tissues. To determine whether minor introns were retained at
significantly higher levels than their flanking major introns, we also performed one-way ANOVA,
followed by post-hoc Tukey test. Finally, to determine whether there was a significant difference
in the median length of alternatively spliced vs. canonically spliced minor introns, we performed
a Mann Whitney U-test.
Transcardial perfusion
Eight week old C57/Bl6J male mice (N=3) were obtained from The Jackson Laboratory and
anesthetized using isoflurane, and perfused using 0.125M NaCl as described previously (418).
All mouse procedures were performed according to protocols that conformed to NIH guidelines
for the use and care of animals in research, which were approved by the University of
Connecticut Institutional Animal Care and Use Committee (IACUC).
RNA extraction and cDNA preparation
Ten tissues were dissected from 8-week-old C57/Bl6J perfused male mice (N=3). Cortex, heart,
kidney, liver, lung, and testis were homogenized in 1mL TRIzol (#15596018); skin, spleen, thymus
and tibialis anterior (skeletal muscle) were homogenized in 500ul TRIzol. RNA was extracted
using the DirectZOL RNA Miniprep kit (#R2062, Zymo Research), per the manufacturer’s
instructions. 1ug of total RNA was then used for cDNA synthesis, as described previously (419).
RT-PCR
25ng of cDNA prepared from total RNA was used for all reverse-transcriptase PCR (RT-PCR)
analyses. For AS analysis in pan tissue, cDNA from three replicates was pooled. MSI values were
determined by quantification of band intensity by ImageJ.
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3.5 Figures and tables

Figure 3.1. Identification of new minor introns in the mouse and human genome.
(A-B) Stacked bargraph showing the number of minor introns and MIGs identified in the mouse
(A) and human (B) genome by the U12DB and MIDB. (C) Overview of mouse gene families that
contain MIGs (black text) and were newly identified in MIDB (underlined). (D-E) Piechart showing
the distribution of mouse (D) and human (E) minor introns based on their terminal dinucleotides.
(F-G) Piechart showing the distribution of mouse (F) and human (G) MIGs with one, two or three
minor introns. (H-I) Piechart showing the gene types of all mouse (H) and human (I) MIGs.
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Figure 3.2. Expression of minor intron-containing (MIG) is dynamic across mouse and
human tissues.
(A) Venn diagram showing the overlap of MIGs expressed >1 TPM in eleven mouse tissues. (B)
Boxplots representing the 10 th-90th percentile of MIG expression in TPM across mouse tissues.
(C) Venn diagram showing the overlap of MIGs expressed >1 TPM in eight human tissues. (D)
Boxplots representing the 10 th-90th percentile of MIG expression in TPM across human tissues.
(E) Stacked bargraph showing the number of MIGs expressed (>1 TPM) in each tissue in mouse
(blue), human (red), or both (grey). TPM=transcripts per million.
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Figure 3.3. Tissue-enriched MIGs participate in specific biological functions.
(A) Hierarchical clustering of mouse tissues based on MIG expression. Heatmap represents TPM
values of all 500 MIGs. (B) Venn diagram showing the number of uniquely upregulated (>2FC;
P<0.01) MIGs in each tissue. Genes enriched in each tissue are listed as well as the biological
processes that were significantly enriched for. MIGs participating in any of the biological
processes are underlined.

74

Figure 3.4. SignatureCalc pipeline.
Schematic describing the pipeline to determine the UpSignature and DownSignature for bone.
This pipeline was run iteratively to determine these signatures for the other ten mouse tissues.
NonDE=non-differentially expressed.
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Figure 3.5. Functional enrichment of Up- and DownSignatures.
(A) Dendogram showing the hierarchical clustering of mouse tissues based on overall gene
expression. (B) Venn diagram showing the number of uniquely downregulated (>2FC; P<0.01)
MIGs in each tissue.
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Figure 3.6. Bioinformatics analysis strategy for detection of retention and AS of minor
introns.
(A) Schematic describing the pipeline to detect minor intron retention, including filtering criteria.
(B) Schematic describing the pipeline to detect novel AS events across minor introns, including
filtering criteria. Adopted from Madan et al., 2015 (140). See also Methods. MSI=mis-splicing
index; SS=splice site; M=million.
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Figure 3.7. Minor introns are retained in a tissue-dependent manner.
(A) Piechart with number of minor introns that show retention in number of replicates of at least
one tissue. Boxplots reflect the 5 th-95th percentile of minor intron length in each of the three
categories. Significance was determined by Kruskal-Wallis rank sum test, followed by post-hoc
multiple comparison using Dunn method. ***=P <0.001; *=P<0.05. (B) Venn diagram showing the
overlap of retained minor introns across eleven mouse tissues. Only minor introns that passed
filtering criteria in all three replicates of a tissue were included. (C) Histogram of the number of
tissues that minor introns were retained in. (D) Heatmap of MSI values across eleven mouse
tissues for eight minor introns. White cells denote that a minor intron did not pass the filtering
criteria for retention in that tissue. See also methods. MSI=mis-splicing index; marr.=marrow.
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Figure 3.8. Minor intron retention is not dependent on consensus sequence.
Frequency plots of the annotated 5’SS, BPS and 3’SS of minor introns that are retained in 3 (top),
1 or 2 (middle), or 0 (bottom) replicates of at least one tissue.
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Figure 3.9. Minor intron retention is tissue-specific in human tissues.
(A) Piechart with number of minor introns that show retention in number of replicates of at least
one tissue. Boxplots reflect the 5 th-95th percentile of minor intron length in each of the three
categories. Significance was determined by Kruskal-Wallis rank sum test, followed by post-hoc
multiple comparison using Dunn method. **=P <0.001; n.s.=not significant. (B) Histogram of the
number of tissues that minor introns were retained in. (C) Venn diagram showing the overlap of
retained minor introns across eight human tissues. Only minor introns that passed filtering criteria
in at least three replicates of a tissue were included. (D) Stacked bargraph showing the number
of retained minor introns in each tissue in mouse (blue), human (red), or both (grey).
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Figure 3.10. Location of minor introns within canonical transcript.
Piechart showing the percentage of minor introns that have flanking major introns.
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Figure 3.11. Minor intron splicing can be efficient.
(A) Table showing the number of retained minor introns and flanking major introns across eleven
mouse tissues. Above are schematics exemplifying the 6 different categories. (B) Heatmap of
MSI values for minor introns, upstream major introns, and downstream major introns across
eleven mouse tissues. (C) Bargraphs showing retention levels for the minor intron, upstream and
downstream major introns of Pcyt2 and Tcp1 in different tissues as determined by RNAseq. Data
are represented as mean±SEM. Above is the gene schematic with intron sizes. Minor intron is
depicted by the red line. MSI=mis-splicing index. E=exon. Significance was determined by oneway ANOVA, followed by post-hoc Tukey test. *=P<0.05; **=P<0.01; n.s.=not significant.
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Figure 3.12. Minor introns are alternatively spliced in a tissue-dependent manner.
(A) Schematic of the nine interrogated AS events. Red line denotes the minor intron. (B)
Bubbleplot reflecting AS usage across minor introns in eleven mouse tissues. Size of the circle
represents the number of introns that passed the filtering criteria, the color represents the type of
AS. See also Methods. (C) Sashimi plot of Tmem87b showing tissue-dependent usage of a cryptic
exon within the minor intron. Only arcs representing >10 reads were included. (D) Gel image of
RT-PCR products for Tmem87b across different tissues. Products were cut with AvaI restriction
enzyme to determine tissue-specific isoform usage. Predicted product sizes are shown below the
gene schematic. Red line denotes the minor intron. %MSI was calculated using ImageJ by
quantifying respective band intensity. (E) Gel images of RT-PCR products for Dram2, Tctn1 and
Pdpk1 across different tissues. Schematic of identified transcripts on the right. (F) Bargraph
representing the number of alternatively spliced transcripts predicted to be translated into protein,
or targeted for non-sense mediated decay (NMD) or non-stop mediated decay (NSD). MSI=missplicing index.
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Figure 3.13. Alternative splicing across minor introns is annotated in the Ensembl
database.
(A) Bar graph showing the number of annotated isoforms in the Ensembl database which resulted
from AS across the minor intron. (B) Venn diagram showing the combined usage of AS events in
isoforms that are alternatively spliced across the minor introns. (C) Boxplots reflect the 5th-95th
percentile of minor intron length in minor introns that are and are not alternatively spliced.
Significance was determined by Mann Whitney U test. **=P <0.01. Transcr. = transcription.
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Figure 3.14. Multiple AS events around the minor intron are employed within the same
MIG.
Table showing the minor introns that are alternatively spliced. Colors indicate the tissue that a
specific AS event was detected in for a minor intron.
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Figure 3.15. Alternative splicing across minor introns in human tissues is dynamic.
(A) Bubbleplot reflecting AS usage across minor introns in 8 human tissues. Size of the circle
represents the number of introns that passed the filtering criteria, the colour represents the type
of AS. (B) Venn diagram revealing the overlap of MIGs that are alternatively spliced in at least
one tissue between mouse and human. MSI=mis-splicing index.
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Chapter 4 Minor intron splicing and disease
This chapter discusses the diseases and symptoms resulting from disrupted minor intron splicing
using bioinformatic approaches that include the use of medical databases. It focuses on the
phenotypes observed in individuals with pathogenic variants in minor spliceosome components,
and aims to identify a subset of MIGs that may underlie the molecular pathogenesis in minor
spliceosome-related diseases. Moreover, it describes the presence of pathogenic variants in
minor introns that can result in disrupted splicing and/or expression of MIGs, which is much more
prevalent than previously thought.
4.1 Introduction
The human genome contains two types of introns, major (99.5%) and minor (<0.5%), that diverge
in the consensus sequences at the 5’ splice site (5’SS), branch point sequence (BPS) and 3’SS
(14, 120). The splicing of these two classes of introns therefore requires two separate splicing
machineries, the major and minor spliceosome, which are made up of five small nuclear RNAs
(snRNAs). Specifically, the major spliceosome consists of U1, U2, U4, U5 and U6 snRNAs,
whereas the minor spliceosome contains the analogous snRNAs U11, U12, U4atac, U6atac and
shares U5 with the major spliceosome (98, 99). Moreover, the minor spliceosome contains seven
unique proteins associated with U11 and U12 snRNA (100). To date, the only known diseases
associated with germline variants in snRNAs affect the minor spliceosome. Specifically,
pathogenic variants in RNU4ATAC are linked to microcephalic osteodysplastic primordial
dwarfism type 1 (MOPD1), Roifman syndrome and Lowry-Wood syndrome (144, 145, 157, 164).
Moreover, pathogenic variants in RNU12, which encodes the U12 snRNA, have been linked to
early onset cerebellar ataxia (165). Finally, variants in RNPC3, a minor spliceosome-specific
protein that is part of the U12 small nuclear ribonucleoprotein (snRNP), have been associated
with isolated growth hormone deficiency (IGHD) (166). Together, these diseases are rare, which
might explain why the minor spliceosome is somewhat understudied.
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The autosomal recessive inheritance pattern of minor spliceosome-related diseases suggests
that these pathogenic variants result in a loss-of-function (144, 145, 157, 164-166). Consequently,
this would result in the aberrant splicing and expression of minor intron-containing genes (MIGs).
Indeed, these molecular defects were observed in peripheral blood mononuclear cells (PBMCs)
from individuals with Roifman syndrome and cerebellar ataxia (157, 165). However, not all MIGs
were affected in these individuals, suggesting that aberrant splicing of only a subset of MIGs
underlies the symptoms associated with these diseases. Here we analyzed previous reports to
determine shared symptoms amongst individuals with minor spliceosome-related diseases. We
then identify a subset of MIGs that, when disrupted, result in similar phenotypes and therefore
may underlie the pathogenesis of minor spliceosome-related diseases. Finally, we identify
pathogenic variants in minor introns that are predicted to result in disrupted minor intron splicing
and result in diseases commonly affecting the nervous system.
4.2 Results
4.2.1

Pathogenic variants in disparate components of the minor spliceosome result in
overlapping symptoms affecting many different tissues.

Pathogenic variants in different minor spliceosome components have all been shown to inhibit
minor spliceosome activity and affect the splicing and/or expression of its targets, the MIGs. Since
both the minor spliceosome and MIGs are ubiquitously expressed, these pathogenic variants
were predicted to affect all tissues. To determine the footprint of disrupted minor intron splicing
on tissue development, we curated all symptoms that have been associated with MOPD1,
Roifman syndrome, Lowry-Wood syndrome, early onset cerebellar ataxia and IGHD, using the
HPO database (420). The use of generalized nomenclature to describe all symptoms allowed us
to compare the phenotypes associated with each disease, which is usually complicated by the
varying terminology used in primary literature. The frequency of each symptom was then
determined by manual curation of the primary literature to ensure it was reported in at least two
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individuals (Table S3). This resulted in a list of 64 symptoms associated with MOPD1, 41
symptoms for Roifman syndrome, and 17 for Lowry-Wood syndrome (Figure 4.1). Moreover, we
identified 11 symptoms in cerebellar ataxia, and 7 symptoms characteristic of individuals with
IGHD (Figure 4.1). No symptoms were shared between all five diseases. However, microcephaly
(HP:0000252), short stature (HP:0004322) and delayed skeletal maturation (HP:0002750) were
observed in four of the five minor spliceosome-related diseases (Figure 4.1). Additionally, seven
symptoms were shared in all three of the RNU4ATAC-related disorders, but not reported for
individuals with IGHD or cerebellar ataxia. These included brachydactyly (HP:0001156),
aplasia/hypoplasia involving bones of the hand (HP:0005927), clinodactyly of the 5th finger
(HP:0004209), a premature birth (HP:0001622), and retinal dystrophy (HP:0000556). Moreover,
muscular hypotonia (HP:0001252) and seizures (HP:0001250) were reported in individuals with
MOPD1, Roifman syndrome and cerebellar ataxia, but not in individuals with Lowry-Wood
syndrome (Figure 4.1). Relating these commonly observed symptoms to the affected organ
system revealed the pleiotropic nature of the minor spliceosome-related diseases. For example,
the aforementioned phenotypes were indicative of defects in limbs, head and neck, eye,
musculature, growth, nervous system, as well as the skeletal system.
Given that MOPD1, Roifman syndrome and Lowry-Wood syndrome all result from
pathogenic variants in RNU4ATAC, we expected the most overlap of phenotypes between these
diseases. Indeed, several symptoms were shared between individuals with MOPD1 and Roifman
syndrome, such as abnormal bone ossification (HP:0011849), intrauterine growth retardation
(HP:0001511), and an abnormal form of the vertebral bodies (HP:0003312) (Figure 4.1).
Moreover, symptoms such as flexion contracture (HP:0001371) and a sloping forehead
(HP:0000340) were commonly observed in MOPD1 as well as Lowry-Wood patients. However,
the majority of the phenotypes were unique to one condition. Specifically, symptoms associated
with the integumentary system like dry skin (HP:0000958), hyperkeratosis (HP:0000962), and
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sparse hair (HP:0008070), were prevalent in individuals with MOPD1 (Figure 4.1). Similarly,
several facial dysmorphisms were characteristic of individuals with MOPD1, such as
abnormalities of the pinna (HP:0000377) and the mandible (HP:0000277) and proptosis
(HP:0000520). On the other hand, immunological defects like a decreased antibody level in the
blood (HP:0004313) and recurrent infections (HP:0002719) were exclusively reported for
individuals with Roifman syndrome (Figure 4.1). Interestingly, pathogenic variants in RNU12 and
RNPC3 did not result in any overlapping symptoms, even though they are both predicted to disrupt
U12 snRNP function. Together, these data reveal that variants in the same minor spliceosome
components can result in diseases with disparate phenotypes.
4.2.2

Disruption of MIG function predominantly affects the nervous system.

Loss-of function variants in the minor spliceosome components result in the aberrant
splicing/expression of MIGs, which ultimately cause the disease (146, 157, 165). To identify a
subset of MIGs whose aberrant splicing might underlie the pathogenesis of minor spliceosomerelated diseases, we curated diseases resulting from independent pathogenic variants in all
known MIGs. The rationale here was that shared symptomology between these diseases could
provide insight into the effect of aberrant splicing/expression of each MIG. We identified variants
in 225 MIGs, of which 211 were associated with a total of 753 clinical manifestations recorded in
the HPO database. These ranged from rare multi-system diseases like Yunis-Varón syndrome
(ORPHA:3472) and PHACE syndrome (ORPHA:42775), to more prevalent clinical manifestations
like attention deficit hyperactivity disorder (HP:0007018) or neoplasms. Several of the identified
clinical manifestations were associated with variants in not just one, but multiple MIGs. Therefore,
we curated all known genes linked to each disorder and determined whether MIGs were
significantly enriched in this list. We found that there was a significant enrichment of proteincoding MIGs among all protein-coding genes that have been correlated to the cardiac diseases
Brugada syndrome (ORPHA:130), Long QT syndrome (OPRHA:101016) and Wolff-Parkinson-
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White Pattern (OMIM:194200) (Table 4.1). Moreover, a significant enrichment of MIGs was
observed among all known causes of Jeune syndrome (ORPHA:474) (Table 4.1). Finally, several
MIGs have been linked to neurological disorders: we identified significant enrichments of MIGs
for epileptic encephalopathy (ORPHA:1934), Joubert syndrome (ORPHA:2754), Charcot-MarieTooth disease (ORPHA:166) and congenital disorder of glycosylation (ORPHA:137) (Table 4.1).
These findings underscore the importance of proper MIG expression for the functioning of the
nervous system.
Next, we established the organ systems that were most commonly affected upon
pathogenic variants in MIGs. Of all 211 MIGs with known symptoms, disruption of the function of
119 MIGs would result in neurological defects (Figure 4.2). This enrichment was driven by global
developmental delay (62 MIGs), intellectual disability (49 MIGs) and seizures (40 MIGs) (Figure
4.2). Many of these symptoms were due to variants in any of the voltage-gated ion channels or
solute carrier transporters that contain a minor intron. The second most affected organ system
was the head and neck (80 MIGs), where the symptom microcephaly was prevalent (39 MIGs)
(Figure 4.2). Finally, variants in 79 MIGs have been linked to eye-related symptoms such as
nystagmus and strabismus (Figure 4.2). It is of note that symptoms like microcephaly,
macrocephaly, spasticity, hypotonia and strabismus, can also be viewed as a defect in the
development of the nervous system, thereby increasing the number of phenotypes associated
with that system, even though they are classified as a symptom of another organ system by HPO.
In contrast to these commonly affected organ systems, the respiratory system (29 MIGs) and
immune system (26 MIGs) were only affected in conditions associated with few MIGs.
To test whether the low prevalence of immunological and respiratory symptoms was
specific to MIGs, or whether these systems are generally less affected in case of pathogenic
variants, we determined the percentage of all genotype-phenotype relationships listed in HPO
that would involve each organ system. For example, of the 31,039 genotype-phenotype
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relationships listed in the HPO database, 2,903 involved genes that affected the nervous system
when mutated, which is 9.4% of all relationships documented. Using a Fisher Exact test, we then
compared this percentage to the percentage of MIGs that would result in a neurological phenotype
when disrupted. This showed that a significantly higher proportion of MIG-phenotype relationships
affect the nervous system compared to all known genotype-phenotype relationships (Table 4.2).
Besides the nervous system, we found no other enrichment of MIGs in genotype-phenotype
relationships. However, we did observe a significantly lower number of MIG-phenotype
relationships that affected the digestive system, cardiovascular system and connective tissue
(Table 4.2). Thus, this analysis underscores the importance of proper MIG functioning for nervous
system development and function.
4.2.3

Identification of candidate MIGs involved in the pathogenesis of minor
spliceosome-related diseases.

Several of the commonly identified symptoms in MIG-associated diseases were also observed in
minor spliceosome-related diseases, such as microcephaly and seizures (Figures 4.1 and 4.2).
This suggests that it is indeed the aberrant expression of a subset of MIGs, that underlies the
symptoms observed in the minor spliceosome-associated diseases. To determine which MIGs
are most likely playing a role in the pathogenesis of minor spliceosome-related diseases, we
focused on nine symptoms that were shared between at least three of the minor spliceosomerelated disorders (Figure 4.1). We found that variants in fifty-one MIGs resulted in at least two of
these nine phenotypes (Figure 4.3). Functional annotation of these MIGs using DAVID revealed
that they significantly enrich for cilium morphogenesis (P=1.5E-03), which was driven by CEP164
(Nephronophthisis), IFT122 (Cranioectodermal dysplasia), IFT80 (Short rib polydactyly
syndrome), TCTN1 (Joubert syndrome and others), TCTN3 (Orofaciodigital syndrome),
TMEM107 (Joubert syndrome and others), TMEM231 (Joubert syndrome and others). Cilia have
been shown to play a role in cortical and cerebellar morphogenesis, and have been hypothesized
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to participate in the pathogenesis of Roifman syndrome (421, 422). Thus, disrupted ciliogenesis
may underlie some of the phenotypes observed in minor spliceosome-related diseases. Variants
in 23 of the 51 MIGs resulted in at least three of the phenotypes also commonly observed in minor
spliceosome-diseases, due to the association with a single disease (Figure 4.3).
Finally, variants in eight MIGs resulted in four or five of the nine symptoms also observed
in minor spliceosome-related diseases (Figure 4.3). These MIGs include DNA2 (DNA replication
helicase/nuclease 2) and TRAIP (TRAF interacting protein), which both have been linked to
Seckel syndrome (423, 424), SMC3 (Structural maintenance of chromosomes 3) which is linked
to Cornelia de Lange syndrome and TBCE (Tubulin folding cofactor E), which has been linked to
Sanjad-sakati syndrome (Figure 3) (425, 426). While variants in most of these MIGs result in
different diseases, they all share the common symptoms of microcephaly, short stature, and
delayed skeletal maturation (Figure 4.3). Interestingly, Seckel syndrome, together with MeierGorlin syndrome, MOPDI and MOPDII, make up a spectrum of microcephalic primordial dwarfism
disorders (427). As such, MIGs related to these diseases are prime candidates to be affected in
minor spliceosome-related disorders.
4.2.4

Pathogenic variants in minor intron splice sites reduce the splice site strength.

Our analysis revealed a subset of MIGs whose disruption could contribute to the symptoms
observed in the minor spliceosome-related diseases. However, the MIG-associated diseases we
identified do not necessarily have to be due to disrupted minor intron splicing. Thus, it only reveals
the importance of the function these MIGs execute and not whether its loss is linked to defect in
minor intron splicing, which is the expected outcome in minor spliceosome-related diseases.
Therefore, we next curated diseases resulting from variants in the minor introns of MIGs. ClinVar
revealed 186 variants in 63 minor introns, found among 58 MIGs (Figure 4.4A). Of these, 68
variants were found in one of the three consensus sequences of the minor intron. Specifically, we
identified 33 variants in the 5’ SS (+1 to +9 position), 19 variants in the BPS, and 16 variants in
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the 3’SS (-1 to -3 position) (Figure 4.4A). While the remaining variants were located outside of
the splice sites, the majority was within close proximity (<20 nucleotides) of the 5’ and 3’ ends of
the minor intron. Especially, the -5 position at the 3’ end of the intron was relatively frequently
mutated, as reflected by the presence of 12 variants, identified in nine different MIGs (Figure
4.4B). We found that the most frequently mutated nucleotide within the 5’SS was the +1 position
(Figure 4.4B). The nucleotide change at this position was relatively consistent, as all nine
identified variants were either a G>A or A>G conversion (Figure 4.4B). Additionally, the variants
at the +3 position of the 5’SS and the -2 position of the 3’SS were all A>G transitions (Figure
4.4B).
Of the 68 minor intron splice site-associated variants listed in ClinVar, 28 were considered
pathogenic, 17 were considered benign, whereas the pathogenicity for the remaining 23 was
uncertain. Since pathogenic variants tend to have a lower allelic frequency in the population due
to natural selection, we cross-referenced the 68 variants with all variants listed in gnomAD, a
database describing allelic frequencies in control populations. Most of the variants classified as
pathogenic by ClinVar were indeed not observed in gnomAD, whereas several benign variants
were observed at a frequency >0.1%. Finally, for the 23 variants with uncertain pathogenicity, the
allelic frequency was either lower than 0.05%, or they were not listed at all in gnomAD, suggesting
that these may also be pathogenic. Based on these results, we focused on the 51 variants that
were likely pathogenic, of which 39 were associated with a clinical manifestation (Table S4). Since
several variants were found within the same MIG (e.g. PTEN, STK11, SCN1A), the overall
number of affected MIGs was 25 (Table S4). These included several well-characterized ion
channels and transporters such as members from the CACNA, SCN, and SLC gene family (Table
S4). Next, we assessed the effect of the 51 pathogenic variants on the splice site strength by
scoring the sequence against a minor intron-type PWM (resulting in a score ranging from 0-100)
(15). We found that 96% of pathogenic variants resulted in a reduction of the PWM score (Figure
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4.4C). On average, pathogenic variants in the 5’SS decreased the PWM score by 25.4 points,
variants in the BPS lowered the PWM score by 17.5 points, and variants in the 3’SS reduced the
PWM score by 29.5 points. Importantly, 41% of the likely benign variants in the consensus
sequences actually enhanced the PWM score, suggesting an increased splice site strength and
potentially enhanced splicing (Figure 4.4C).
Finally, we wanted to determine the specific phenotypes that were observed in diseases
associated with variants in these consensus sequences. We found that the most prominent
symptoms included a global developmental delay (7 MIGs), intellectual disability (7 MIGs),
seizures (6 MIGs), and microcephaly (3 MIGs) (Figure 4.4D). Thus, variants specifically identified
in the splice sites of minor introns also heavily affect the nervous system.
4.3 Discussion
The moniker, “minor spliceosome” refers to the relatively few (<0.5%) introns spliced by this
machinery and not its biological significance. Most of the 699 MIGs in the human genome contain
one or two minor introns, while the other introns are major introns (120). Since minor introns
cannot be spliced by the major spliceosome, minor intron splicing has a disproportionately large
regulatory impact on the expression of MIGs. As such, pathogenic variants in minor spliceosome
components that inhibit the function of the minor spliceosome, wield a large effect on the many
biological processes MIGs execute. This is reflected by the multisystemic diseases such as
MOPD1, Roifman syndrome, and Lowry-Wood syndrome (144, 145, 157, 158, 164). Given that
all of the pathogenic variants in these diseases ultimately inhibit the minor spliceosome function,
it is not surprising that they result in overlapping symptoms such as short stature and
microcephaly. However, these symptoms are found along a spectrum of severity in patients, such
that the most severe microcephaly and growth retardation is associated with individuals with
MOPD1 and the least severe with individuals with Lowry-Wood syndrome (158). This gradation
may be explained by the level of minor intron mis-splicing that resulted from the individual variants
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in RNU4ATAC. It was reported that MOPD1-associated variants resulted in a 90% loss of minor
spliceosome activity as 100% loss would likely result in embryonic lethality (144). Moreover,
individuals with Roifman syndrome and Lowry-Wood syndrome experience fewer symptoms, as
well as less severe growth retardation and microcephaly than individuals with MOPD1. Therefore,
we hypothesize that minor spliceosome activity in Roifman syndrome and Lowry-Wood syndrome
might be affected to a lesser extent (Figure 4.1). Interestingly, individuals with Roifman syndrome
are also characterized by several immunological phenotypes that are absent in individuals with
MOPD1 and Lowry-Wood syndrome, which suggests that different MIGs may be affected upon
the different variants in RNU4ATAC (Figure 4.1). This is likely not the complete explanation, as
the same 51 G>A pathogenic variant has been discovered in individuals with Lowry-Wood
syndrome, as well as individuals with Roifman syndrome and MOPD1 (144, 157, 164). These
findings suggest that there are modifiers in the genome to these RNU4ATAC variants that can
reduce the severity and/or penetrance of the phenotype in a tissue-specific manner. Since most
patients are compound heterozygotes, another explanation may be that the severity of disease is
influenced by the pathogenic variant in the other RNU4ATAC allele. Indeed, variants uniquely
found in individuals with MOPD1 were found to be more likely deleterious than those in individuals
with Roifman syndrome and Lowry-Wood syndrome (158).
Even though the majority of minor spliceosome-related diseases result in pleiotropic
phenotypes, most of the symptoms are indicative of defects in the nervous system or skeletal
system (Figure 4.1). The source of these tissue-enriched symptoms might be the tissue-specific
expression, splicing, and/or alternative splicing of MIGs that we reported previously (120). The
tissue-specific regulation of MIGs is underscored by our findings that variants in MIGs commonly
affect the nervous system (Figure 4.2). The most prevalent symptoms resulting from pathogenic
variants in MIGs included a global developmental delay, intellectual disability and microcephaly
(Figure 4.2). This is consistent with some of the cardinal sympotms observed in minor
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spliceosome-related diseases. Together, the overlap of symptoms resulting from disrupted MIG
function and minor spliceosome-related diseases might shed light onto the molecular mechanism
of pathogenesis underlying these syndromes. However, further investigation is required to
understand how exactly the regulation of minor intron splicing contributes to the pathogenesis of
minor spliceosome-related diseases.
Since all minor spliceosome-related diseases are inherited in an autosomal recessive
manner, it is likely that the pathogenic variants result in a loss-of-function of the minor
spliceosome. This was modeled in two different mouse models, through knockout of Rnpc3 and
Rnu11 (138, 428). Germline ablation of both Rnpc3 and Rnu11 resulted in embryonic lethality,
again suggesting that the variants observed in minor spliceosome-related diseases such as IGHD
are hypomorphic (138, 166, 429). Ablation of Rnpc3 in adult mice resulted in severe
gastrointestinal defects, as well as a reduction of peripheral lymphocytes and platelets (138).
While the latter phenotype resembles some of the immunological symptoms that individuals with
Roifman syndrome experience, gastrointestinal defects are generally not found in individuals with
IGHD (166). This may be due to a change in the expression pattern of Rnpc3 from embryonic
development to adulthood. Therefore, it would be interesting to determine whether spatially
restricted loss of Rnpc3 during embryonic development would recapitulate more minor
spliceosome-related phenotypes. Finally, loss of Rnu11 in the dorsal telencephalon resulted in
severe microcephaly at birth, through disrupted splicing of a subset of MIGs (428). As such, this
mouse can be used to provide more insight into the molecular etiology of the microcephaly
phenotype observed in individuals with minor spliceosome-related diseases.
Of particular interest for the identification of targets affected in minor spliceosome-related
diseases are variants in splice sites of minor introns, which compromise the splicing process,
thereby revealing the regulatory importance of minor intron splicing in proper MIG expression.
Thus, the symptoms observed in diseases associated with splice site variants in minor introns
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can reveal the tissue types in which these MIGs are expressed and where they perform nonredundant functions. These diseases are often being investigated by researchers who might not
be aware of the fact that the primary defect underlying the disease is aberrant minor intron
splicing. Moreover, variants in splice sites have been shown to result in alternative splicing of
flanking exons and the use of cryptic splice sites, which means that variants in minor introns may
also result in alternative splicing (430). Therefore, the aberrant expression of alternatively spliced
isoforms of MIGs might contribute to the pathogenesis of these disease through a gain-offunction. To date, only the minor introns of STK11 and TRAPPC2 were known to contain
pathogenic variants resulting in disease (431, 432). Here, we report that at least another 28 minor
introns are also associated with pathogenic variants in their splice sites (Figure S3). The number
of aberrant minor intron splicing events that can result in disease might be much larger than this,
as most variant detection is done through exome sequencing and advanced bioinformatics tools
are required to detect variants in non-canonical splice sites (433). Moreover, variants in other
positions of the minor intron can also induce alternative splicing, thereby resulting in the
production of aberrant isoforms (434). We hope that further studies on the intronic variants that
we report here can reveal the role of aberrant minor intron splicing in disease pathogenesis.
Together these findings expand the impact of minor intron splicing beyond pathogenic variants in
the minor spliceosome components.
Finally, we found that the most common variant in the 5’SS of minor introns was located
at the +1 position and involved a G>A or A>G change (Figure 4.4B). Minor introns can be
classified based on their terminal dinucleotides as AT-AC introns or GT-AG introns and either
contain an A or G at the +1 position, while the rest of their splice site sequence is the same. The
presence of these two nucleotides normally does not hinder the recognition and splicing capacity
of the minor spliceosome. Instead, the pathogenicity of the G>A and A>G conversion may come
from the fact that the -1 position at the 3’SS is not mutated alongside these variants, as this
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combination of terminal dinucleotides has been shown to reduce canonical splicing using an in
vitro splicing assay (103).
Several pathogenic variants in splice sites of minor introns have been shown to result in
alternative splicing. In the case of STK11, the variants in the 5’SS resulted in the occasional use
of a cryptic 5’SS in conjunction with several cryptic 3’SS (431). Moreover, pathogenic variants in
the 5’SS of TRAPPC2 were shown to result in the utilization of a cryptic 5’SS and skipping of the
downstream exon (432). Several of the 5’SS variants listed in ClinVar also had associated
manuscripts that described the effect on splicing. For instance, a +1G>T variant in the 5’SS of the
minor intron in AP4M1 has been shown to result in skipping of the upstream exon and the minor
intron (435). Moreover, a +6delC variant in the 5’SS of the minor intron in DNA2 resulted in the
use of a cryptic 5’SS in combination with several cryptic 3’SS (423). Finally, a +1G>A variant in
the 5’SS of the minor intron in TMEM107 was shown to result in the inclusion of a single basepair, thereby resulting in a frameshift (436). These results highlight the potential of minor intron
splice site variants to affect alternative splicing and regulate gene expression and/or protein
production. Since all evidence has currently resulted from variants in the 5’SS, it would be
important to determine the effect of variants in the BPS and 3’SS on alternative splicing around
minor introns. This would require experimental validation using patient samples and/or in vitro
splicing constructs mimicking the human pathogenic variants. These results will be important for
the identification of therapeutic strategies. Recently, antisense oligonucleotides have been a
commonly used method to target specific splicing events and have been shown effective at
treating splicing diseases (437-439). Moreover, expression of U1 snRNA with compensatory
mutations has been shown to rescue splicing defects in mutant mice (440, 441). The rise in
splicing-targeted therapeutics therefore increases the importance of being cognizant of the
splicing pathway that is affected by the specific splice site variants.
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In all, our study was designed to interrogate the true impact of minor intron splicing defects
on human diseases from both perspectives, i.e., the minor spliceosome dysfunction and its
targets, the MIGs. Here we report that the combined effect of minor spliceosome-related diseases
as well as MIG-related diseases is significantly larger than has been appreciated. The field of
minor spliceosome research has remained small because most diseases caused by loss of minor
spliceosome function are rare. However, if one considers the MIGs and the associated diseases,
the field of minor intron splicing expands. This study was aimed to create awareness among other
scientists, that inherent to studying MIG-related diseases is the understanding of a crucial form of
gene regulation, i.e. minor intron splicing. In all, we expanded the spectrum of minor splicingrelated disorders, thereby providing additional insight into the pathways that may be affected in
minor spliceosome-related diseases.
4.4 Materials and Methods
Curation of variants and associated clinical manifestations in MIGs.
All human MIGs from the Minor Intron DataBase (MIDB) were queried in ClinVar to identify
associated variants listed as ‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’ and
‘conflicting results of pathogenicity’. Variants labelled as ‘uncertain significance’ or ‘conflicting
results of pathogenicity’ were cross-referenced with gnomAD to ensure the allelic frequency was
<0.01%. Clinical manifestations associated with each variant were then curated, and filtered to
create a list of unique clinical manifestations associated with pathogenic variants in each MIG
(120, 442). Clinical manifestations linked to variants found in MIGs and overlapping non-MIGs
were excluded. The Human Phenotype Ontology (HPO) database was then used to curate
symptoms associated with each clinical manifestation (420). Here, the ORPHA code was used to
extract symptoms listed as very frequent (>80%). If no ORPHA code was available, an OMIM
code was used to extract the symptoms for the corresponding disease. Since these codes are
not associated with a frequency, all phenotypes listed on HPO were included, regardless of their
100

prevalence. Few variants were associated with diseases and ORPHA codes that were ‘in
progress’ or not recognized at all. These were excluded from further analysis.
Curation of symptoms linked to minor spliceosome-related disorders.
The Human Phenotype Ontology (HPO) database was used to curate symptoms associated with
minor spliceosome-related diseases (420). Here, both the symptoms associated with the OMIM
and ORPHA code were extracted. The frequency of these symptoms in minor spliceosomerelated disorders was then determined by manual curation of the primary literature. Only primary
literature describing individuals for which the pathogenic variants were known, were included.
Symptoms reported in at least two individuals were included in Figure 1. Some of the isolated
symptoms were part of the same root but indicated different degrees of severity (e.g. Intellectual
disability, mild (HP:0001256) and Intellectual disability, moderate (HP:0002342)). For these
terms, we condensed the symptoms to the shared root (e.g. Intellectual disability (HP:0001249))
in Figure 1.
Identification of (pathogenic) variants in minor introns.
Minor intron coordinates from MIDB were cross-referenced with all variants reported by ClinVar
(both pathogenic and benign) (120, 442). Variants within the first 9 nucleotides of the intron were
considered part of the 5’SS and variants within the last 3 nucleotides of the intron were classified
as 3’SS. Finally, variants located within the BPS coordinates listed at MIDB were recorded as
BPS, whereas the remainder was classified as ‘elsewhere in intron’. Three variants absent in
ClinVar, but previously published in peer-reviewed journals have also been included in Table S4.
The allelic frequency and homozygosity of variants was determined by cross-referencing of the
coordinates with gnomAD (443). The associated clinical manifestations and symptoms were
curated the same way as was done for MIGs.
Impact of variant on splice site strength.
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The strength of minor intron splice sites was based on their score against minor intron-type PWMs
and previously reported on MIDB (15, 120). The splice sites including the variant were rescored
against the same AT-AC type PWM or GT-AG type PWM as listed in (15). LOD scores were then
rescaled to be on a scale from 0-100 as described previously (120).
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4.5 Figures and tables

Figure 4.1. Pathogenic variants in disparate components of the minor spliceosome result
in overlapping symptoms affecting many different tissues.
Network of phenotypes associated with minor spliceosome-related diseases according to HPO.
Color of symptom outline corresponds to the affected organ system.
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Figure 4.2. Pathogenic variants in MIGs predominately affect the nervous system.
Doughnut charts of the affected organ systems due to variants in MIGs. Size of doughnut charts
represents the number of MIGs that can result in a symptom related to the respective organ
system when affected. If variants in MIGs were associated with several diseases that contained
overlapping symptoms, then these symptoms were only counted once. Moreover, if different
variants within the same gene were associated with the same symptoms, this symptom was also
only included once. The three most prevalent phenotypes are listed in the ring based on their
relative occurrence. Color-coding of the organ systems is the same as in Figure 1.
IUGR=intrauterine growth retardation; FS=focal segmental; HI=hearing impairment;
DSM=delayed skeletal maturation.
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Figure 4.3. Pathogenic variants in MIGs result in similar phenotypes as minor spliceosomerelated diseases.
Chart with MIGs that, when mutated, result in at least two of the commonly shared minor
spliceosome-related disease phenotypes. Diseases that are associated with the listed
phenotypes are shown on the right. *=-short stature-facial dysmorphism-hypergonadotropic
hypogonadism syndrome.
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Figure 4.4. Identification of 51 pathogenic variants in splice sites of minor introns.
(A) Bar graph with the number of variants observed in each of the splice site, as well as the
number of minor introns and MIGs affected. (B) Frequency logo of 5’SS and 3’SS of all minor
introns, generated using WebLogo. Below is a bar graph of the number of variants observed at
each position and the type of variant. (C) Scatterplot with PWM score for splice sites with
associated benign and pathogenic variants. (D) Wordcloud with symptoms resulting from
diseases associated with variants in splice sites of minor introns.
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Table 4.1. Overview of conditions that are associated with genes that contain a
significant enrichment of minor introns.
Condition

Brugada
syndrome

Primary
affected
organ system
Cardiovascular
system

# of
associated
MIGs
4

# of total
associated
genes
28

Fisher
Exact Pvalue
P=0.0073

Long QT
syndrome

Cardiovascular 8
system

112

P=0.0134

WolffParkinsonWhite pattern
Jeune
syndrome
Epileptic
encephalopathy

Cardiovascular 4
system

46

P=0.0391

Skeletal
system
Nervous
system

4

25

P=0.0048

14

105

P<0.00001

Joubert
syndrome

Nervous
system

9

47

P<0.00001

Charcot-MarieTooth disease

Nervous
system

6

87

P=0.035

Congenital
disorder of
glycosylation

Nervous
system &
Digestive
system

8

49

P=0.00001

Affected MIGs

CACNA1C;
CACNA2D1;
SCN10A;
SCN5A
CACNA1C;
CACNA2D1;
DNA2;
HNRNPM;
INTS8;
RALGAPA1;
SCN5A; TCTN3
CACNA1C;
CACNA1E;
MYH11; SCN5A
C2CD3; IFT74;
IFT80; IFT88
ACTL6B;
ATP6V1A;
CACNA1A;
CACNA1E;
CACNA2D2;
CAD; MAPK10;
PLCB1; SCN1A;
SCN2A; SCN3A;
SCN8A;
SLC12A5;
TRIT1
ARMC9;
C2CD3; CEP41;
KIAA0556;
PDE6D; TCTN1;
TCTN3;
TMEM107;
TMEM231
FIG4; GARS;
HARS; SCN9A;
SLC12A6;
SPG11
ALG12; ALG3;
ALG6; ALG8;
COG6; HMBS;
MAGT1; TUSC3
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Table 4.2. Distribution of affected organ systems in case of MIG- and total gene-related
pathogenic variants.
Organ system highlighted in orange are significantly more affected by pathogenic variants in
MIGs compared to all human genes.
Organ system

Associated MIGs

Nervous system
Head and Neck
Eye
Growth
Musculature
Genitourinary system
Limbs
Ear
Skeletal system
Skin, Hair and Nails
Digestive system
Metabolism
Cardiovascular system
Respiratory system
Immunology
Blood and blood-forming
tissues
Others
Endocrine
Neoplasm
Connective tissue
Prenatal and birth

119
80
79
66
64
64
56
52
50
45
42
42
33
29
26
24
23
22
20
18
11
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Fisher Exact

11.6%
7.8%
7.7%
6.4%
6.2%
6.2%
5.5%
5.1%
4.9%
4.4%
4.1%
4.1%
3.2%
2.8%
2.5%
2.3%

Associated Total
Genes
2903
9.4%
2274
7.3%
2238
7.2%
1964
6.3%
2031
6.5%
1600
5.2%
1361
4.4%
1600
5.2%
1652
5.3%
1481
4.8%
1827
5.9%
1422
4.6%
1662
5.4%
1111
3.6%
882
2.8%
863
2.8%

2.2%
2.1%
2.0%
1.8%
1.1%

1257
874
613
878
546

P=0.0026
P=0.2465
P=1.000
P=0.0423
P=0.1133

4.0%
2.8%
2.0%
2.8%
1.8%

P=0.0168
P=0.543
P=0.5397
P=0.8451
P=0.7482
P=0.1322
P=0.1043
P=1.000
P=0.5715
P=0.6543
P=0.0146
P=0.5424
P=0.0017
P=0.2296
P=0.6324
P=0.497

Chapter 5 The role of the minor spliceosome in mouse cortical development
Microcephaly is one of the most frequent symptoms observed in individuals with disrupted minor
spliceosome function. In order to understand how minor spliceosome inhibition can result in
microcephaly, we disrupted minor intron splicing by ablating U11 snRNA. This was also the first
mammalian model system for minor spliceosome function and allowed us to identify the molecular
and cellular mechanisms that underlie microcephaly upon disruption of the minor spliceosome.
Notably, especially self-amplifying radial glial cells were susceptible to U11 loss. The results of
this study, which I co-authored with Marybeth Baumgartner, were published in Development, in a
manuscript entitled “Minor spliceosome inactivation causes microcephaly, owing to cell cycle
defects and death of self-amplifying radial glial cells.” (142)
5.1 Introduction
RNA splicing, the removal of non-coding introns from pre-mRNA transcripts, is an essential step
in eukaryotic gene expression. This process is performed by one of two distinct spliceosomes,
the major or the minor type (9). The minor spliceosome is comprised of four unique snRNAs (U11,
U12, U4atac, and U6atac) and the U5 snRNA, which it shares with the major spliceosome (98,
99). In the mouse genome, <0.5% of introns require the minor spliceosome for their removal;
hence, they are called minor introns (14). The importance of minor intron splicing in development
is underscored by the discoveries that hypomorphic mutation in the U4atac snRNA causes the
developmental disorders microcephalic osteodysplastic primordial dwarfism type 1 (MOPD1),
Roifman syndrome, and Lowry Wood syndrome (144, 157, 164). All of these disorders, despite
being caused by systemic loss of minor splicing, are primarily characterized by microcephaly and
dwarfism, which suggests a tissue-specific requirement for the minor spliceosome in development
(144, 157, 164). Therefore, to understand the mechanism of disease pathogenesis in these
syndromes, it is important to understand the regulation of minor intron-containing genes (MIGs)
in cortical development.
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Proper cortical development requires a balance between amplification of the neural
progenitor cells (NPCs) and neurogenesis. Overproduction of neurons at the expense of selfamplifying NPC divisions can deplete the NPC pool early in cortical development, resulting in
microcephaly (444). The presence of different NPC types can regulate neurogenesis. In the
mammalian cortex, there are two types of NPCs: radial glial cells (RGCs) and intermediate
progenitor cells (IPCs). RGCs can undergo symmetric proliferative divisions, which produce two
RGCs, or asymmetric differentiative divisions, to produce one RGC and either one IPC or one
neuron. In contrast, most IPCs undergo symmetric neurogenic divisions, to produce two neurons
(240). A small fraction undergoes symmetric proliferative division, producing two IPCs, prior to
symmetric neurogenic division (247). Ultimately, RGCs are required to maintain the NPC
population, while IPCs primarily contribute to neuron production (246). In short, microcephaly can
be caused by (1) death of the NPC or neuronal populations; (2) increased neuron production,
resulting in depletion of the NPC pool; and/or (3) decreased IPC production, resulting in fewer
neurons. It is unclear how these processes are affected by loss of minor splicing in MOPD1,
Roifman syndrome, and Lowry Wood syndrome. Here, we report the role of minor splicing in
mammalian cortical development. For this, we leveraged a novel conditional knockout (cKO)
mouse for the gene encoding the U11 snRNA, a crucial component of the minor spliceosome (9).
5.2 Results
5.2.1

Constitutive loss of U11 is embryonically lethal.

We generated the Rnu11 cKO mouse by engineering loxP sites 1090 bp upstream and 1159 bp
downstream of the Rnu11 gene (Figure 5.1A and 5.2). Successful targeting of the loxP sites was
confirmed by long-range nested PCR in targeted embryonic stem cells (Figure 5.2B-C) and further
validated by the loss of the wild-type (WT) allele in Rnu11Flx/Flx mice (Figure 5.1A). EIIa-Cremediated germline recombination generated Rnu11WT/KO mice, which showed the presence of the
KO allele that was absent in Rnu11WT/WT genomic DNA (Figure 5.1A). Quantitative PCR (qPCR)
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for the WT allele showed 50% reduction in Rnu11WT/KO mice compared to Rnu11WT/WT mice (Figure
5.1B). Intercrossing Rnu11WT/KO mice did not yield Rnu11KO/KO mice (Figure 5.1C), indicating
embryonic lethality.
5.2.2

Ablation of U11 in the pallium causes microcephaly.

We employed Emx1-Cre mice to specifically ablate Rnu11 in the pallium (445). Emx1-Cre
expression begins at E9.5 in the neuroepithelium of the pallium, prior to the production of RGCs,
IPCs, or neurons at E10-E11 (Gorski et al., 2002). Ablation of U11 in the pallium resulted in
profound microcephaly at birth in Rnu11Flx/Flx::Emx1-Cre+/- mutant mice, due to collapse of the
cortex and absence of the hippocampus (Figure 5.1D). To understand how this microcephaly
precipitated, we sought to determine the kinetics of U11 snRNA loss after Emx1-Cre-mediated
Rnu11 ablation. In situ hybridization (ISH) for U11 snRNA revealed a reduction in U11 signal
(purple) in the E10 mutant pallium, relative to the control (Rnu11WT/Flx::Emx1-Cre+/-) (Figure 5.1E).
This U11-null domain was expanded in the E11 mutant pallium, and by E12, the majority of cells
in the Emx1-Cre domain lacked U11 expression (Figure 5.1F&G). We observed scattered U11+
cells at this point (Figure 5.1G), which may represent either inefficient Emx1-Cre recombination
or migrating interneurons produced in the ventral telencephalon, where Emx1-Cre is not active
(445, 446). There was no observable morphological difference between mutant and littermate
control pallia at E10, E11, and E12 (Figure 5.1E-G). At E13, we observed persistence of the U11null domain alongside collapse of the lateral ventricle in the mutant telencephalon, without a
significant change in pallial thickness (Figure 5.1H&J). At E14, the thickness of the mutant pallium
was significantly reduced relative to the control (Figure 5.1I-J).
5.2.3

Cell death causes microcephaly in the U11 cKO mice.

We first performed fluorescent ISH (FISH) for U11 to identify the U11-null domain, followed by
terminal dUTP nick-end labeling (TUNEL) to detect apoptotic cells. Results showed sporadic loss
of U11 snRNA in the E11 mutant pallium without a significant increase in TUNEL + cells (Figure
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5.3A). Onset of cell death was observed at E12, with a statistically significant increase in TUNEL +
cells in the mutant compared to littermate controls (Figure 5.3B), and death continued at E13 and
E14 (Figure 5.3C-D). Since TUNEL marks cells in late stages of apoptosis, we sought to verify
the timing of cell death in the mutant pallium using a marker of early apoptosis (447). For this, we
employed immunofluorescence (IF) for cleaved caspase 3 (CC3) (448) at E11 and E12, which
confirmed that the onset of cell death was occurring at E12 (Figure 5.3E-F).
5.2.4

Microcephaly is predominantly caused by loss of NPCs.

To identify the cell type being lost in the mutant pallium, we investigated the numbers of
proliferating NPCs (Ki67+) versus neurons (NeuN+) by IF (449, 450). We found no change in the
number of proliferating NPCs in the E12 mutant pallium compared to the control (Figure 5.4A&D).
However, at E13 and E14, the number of Ki67 + NPCs was significantly reduced in the mutant
pallium compared to the control (Figure 5.4B-D). Unlike NPCs, we did not observe significant
difference in the number of neurons between the control and mutant at E12 or E13 (Figure 5.4AB&D). To confirm that the neurons present in the E12 and E13 mutant pallium were in fact U11null, we performed U11 FISH in conjunction with IF for Ki67 and NeuN, which showed the
presence of both U11-null NPCs and U11-null neurons (Figure 5.5A). Finally, at E14, there were
significantly fewer neurons in the mutant compared to the control, which was consistent with the
depletion of the NPC population at E13 (Figure 5.4B-D). Together, these data suggested that the
U11-null NPCs dividing to produce more NPCs were most likely dying, while both U11-null NPCs
undergoing neurogenic cell division and U11-null neurons managed to escape this fate.
5.2.5

Self-amplifying RGCs require the minor spliceosome for survival.

We next sought to identify the type of NPC being lost in the U11-null pallium. Using the nuclear
RGC marker Pax6, we did not observe a significant difference in the number of RGCs between
the control and mutant at E12 (Figure 5.4E&H) (243). At E13, there was a significant reduction in
the number of RGCs with nuclear Pax6 signal in the mutant compared to the control (Figure
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5.4F&H). However, widespread cytoplasmic Pax6 expression, which was rarely seen in control
sections, was observed in the mutant (Figure 5.4F). This cytoplasmic staining was primarily
observed around condensed nuclei, suggesting that the cytoplasmic Pax6 expression was
occurring in dying cells. This was confirmed by colocalization of the cytoplasmic Pax6 expression
with CC3 (Figure 5.5B-B’’’). Therefore, only cells with nuclear Pax6 expression were quantified.
At E14, there were few RGCs in the mutant, which was consistent with the small number of Ki67 +
cells at this time-point (Figure 5.4D&G-H). Next, we investigated the number of IPCs in the U11null pallium using the marker Tbr2 (249), which revealed no significant difference in the E12
mutant compared to the control (Figure 5.4I&L). At E13, we observed a significant reduction in
the IPC population in the mutant relative to the control (Figure 5.4J&L), which continued at E14
(Figure 5.4K-L).
Both the RGC and IPC populations were significantly reduced in the mutant pallium at
E13, but not at E12, relative to the control (Figure 5.4D&H). However, the trends of RGC and IPC
loss across mutant pallium development were not similar: While comparison of the E12 mutant
and E13 mutant pallium revealed a significant decline in the number of RGCs, there was no
significant change in the number of IPCs between these time-points in the mutant (Figure 5.5CD). A significant decline in IPC number was only observed between E13 and E14 (Figure 5.5D).
Therefore, the decline in RGC number occurred earlier in the mutant pallium than the decline in
IPCs, suggesting that IPCs were being produced in the U11-null pallium. Moreover, the
observation that the E13 control and mutant pallia both contained similar numbers of neurons
suggested that neuron production was also occurring in the E12 mutant pallium (Figure 5.4B&D).
To study neuron production in the mutant pallium, we pulsed pregnant dames carrying E12
embryos with the thymidine analog 5-bromo-2’-deoxyruidine (BrdU), to mark S-phase NPCs,
followed by harvest at E13 (451). IF for BrdU and NeuN showed that 31.3±1.0% of NeuN + neurons
in the mutant pallium were BrdU+, which was significantly lower than observed in the control
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(47.7±3.7%, Figure 5.5E). The presence of BrdU+ neurons in the mutant indicated that U11-null
NPCs produced neurons between E12 and E13, albeit at a lower rate than the control. Together,
these findings suggested that the majority of cells dying between E12 and E13 were selfamplifying RGCs.
5.2.6

DNA damage and p53 upregulation occur in U11-null RGCs.

To understand the molecular defects underlying the loss of self-amplifying RGCs, we performed
RNAseq on control (N=5) and mutant (N=5) pallia from E12 embryos (Figure 5.6A inset). At this
time-point, U11 loss occurs throughout the entire Emx1-Cre domain without major histological
changes, such as shifts in NPC number (Figure 5.1G and 5.4D). Confirmation of the pallial
dissection was reflected by the expression of Emx1 in the control (19.1 fragments per kilobase
per million mapped reads [FPKM]) and mutant (20.3 FPKM). Expression of Dbx1, which marks
the pallial-subpallial boundary, and Lhx6, which is expressed in the medial ganglionic eminence
(452), were expressed below 1 FPKM in both the control and mutant samples. Together, these
results confirm the integrity of our dissection. Expression of Rnu11 was reduced by 2.95 fold in
the mutant compared to the control, which was further confirmed by quantitative reverse
transcriptase-PCR (qRT-PCR) (Figure 5.6B). The incomplete loss of U11 expression in the
mutant likely reflects (1) contamination of non-Emx1-lineage cells of the meninges and blood
vessels (Figure 1G) (453); (2) contamination from non-Emx1-lineage cells migrating into the
pallium (Figure 1G) (446); and/or (3) incomplete recombination by Emx1-Cre. Regardless, the
mutant samples showed a clear reduction in U11 expression compared to the control, which was
in agreement with the ISH analysis (Figure 5.1G). Next, we interrogated the expression of all
protein-coding genes with ≥1 FPKM in the control or mutant. Overall, there was an increase in
the number of genes upregulated (74; ≥2-fold change [FC], P≤0.01) relative to those
downregulated (11; ≥2-FC, P≤0.01) in the mutant (Figure 5.6A). DAVID analysis (454) performed
on the downregulated protein-coding genes revealed no significant enrichments by Benjamini
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score. However, the upregulated protein-coding genes significantly enriched for the GO-term
“intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator” (Table
5.1), implicating this pathway in the cell death observed at this time-point (Figure 5.3).
To test whether DNA damage and p53 activation were occurring in the E12 mutant, we
employed IF with the DNA damage marker ɣH2AX (455), along with antibody against p53. We
observed that the majority of ɣH2AX + cells were pyknotic (54.1±3.5%), suggesting that they were
dying cells (Figure 5.6D). To verify this, we employed the early-apoptotic marker CC3, which
revealed that 93.2±3.5% of ɣH2AX+ cells were CC3+ (Figure 5.6D). Because most cells
undergoing the final stages of apoptosis do not express nuclear markers, we removed all pyknotic
ɣH2AX+ cells from the quantification strategy. Using this approach, we observed significantly more
non-pyknotic ɣH2AX+ cells scattered throughout the E12 U11-null pallium relative to the control
(Figure 5.6E). Similarly, we observed significantly more cells upregulating p53 throughout the E12
U11-null pallium compared to the control (Figure 5.6E). Given the GO-term enriched for by the
upregulated protein-coding genes, and reports that p53 stabilization occurs in response to DNA
damage (456), we expected that most ɣH2AX+ cells would also upregulate p53. Indeed,
74.7±11.9% of ɣH2AX+ cells were also upregulating p53 (Figure 5.6E, left inset). In contrast, only
6.7±2.0% of p53-upregulating cells were also ɣH2AX + (Figure 5.6E, right inset). Finally, at E11,
we observed no significant difference in the number of ɣH2AX + and p53-upregulating cells in the
control and mutant, suggesting that the precipitation of cell death occurs at E12 (Figure 5.6E).
Since the majority of the cells dying between E12 and E13 were self-amplifying RGCs, we
next investigated whether RGCs were the cell type accumulating DNA damage and upregulating
p53. We found that 46.3±3.2% of ɣH2AX + cells were Pax6+ RGCs, while virtually none were
NeuN+ neurons (5.1±5.1%) or Tbr2 + IPCs (0%, Figure 5.6F). To test whether RGCs were the
primary cell type upregulating p53, we also performed IF for p53 and Pax6. This revealed that the
vast majority of p53-upregulating cells were Pax6 + RGCs (98.1±0.85%), a significant enrichment
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compared to the percentage of Pax6 + RGCs found in the mutant pallium (93.61±0.56%; Figure
5.6G). In all, we found that U11-null RGCs are the primary cell type both accumulating DNA
damage and upregulating p53, which most likely contribute to their widespread death between
E12 and E13.
5.2.7

U11 loss results in elevated minor intron retention in MIGs that regulate cell cycle.

Since U11 is an essential component of the minor spliceosome, the expected result of U11 loss
is disruption of minor intron splicing. However, none of the genes upregulated in the E12 mutant
pallium that enriched for p53-mediated apoptosis contain minor introns, indicating that their
upregulation is a secondary effect of U11 loss. Therefore, we next investigated the expression of
the minor spliceosome targets, i.e., the MIGs, and the splicing of their minor introns. Overall, the
vast majority of MIGs were not differentially expressed (Figure 5.6A). Only one MIG, Spc24,
showed >2-fold downregulation in the mutant (Figure 5.6A, arrow), which was independently
confirmed by qRT-PCR (Figure 5.6C). To assess minor intron splicing, we employed the strategy
previously described by (140), which utilizes a mis-splicing index (MSI) to reflect intron retention.
Using this strategy, we identified 299 (out of 545) minor introns and 11,187 (out of 54,500
randomized major introns) that passed the filtering criteria, indicating that they show some level
of intron retention. We then calculated the difference in MSI for each intron between the mutant
and the control (mutant MSI – control MSI; ∆MSI) and generated frequency plots (Figure 5.7A).
These revealed a rightward ∆MSI shift for the 299 minor introns, while the 11,187 randomized
major introns followed a normal distribution. This indicated that loss of U11 inactivates the minor
spliceosome, resulting in elevated retention of minor, but not of major, introns.
To identify the specific minor introns with elevated retention in the mutant, we employed
student’s t-tests to compare the MSI of each minor intron between the control and mutant
samples. Of the 299 minor introns, we identified 186 minor introns, found in 178 MIGs, with
significantly elevated minor intron retention in the mutant. For three of these MIGs (Coa3, Parp1,
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and Pten), this was confirmed by qRT-PCR (Figure 5.8). Minor intron retention has been predicted
to result in the introduction of premature stop codons, subsequently targeting MIG transcripts for
degradation by the nonsense mediated decay (NMD) pathway {Patel, 2002 #262}. To test whether
retention of these 186 minor introns would indeed introduce a premature stop codon, we curated
a list of all annotated isoforms of these 178 MIGs, and extracted all the isoforms that would require
minor intron splicing for their production, resulting in a list of 330 isoforms. Bioinformatics analysis
showed that minor intron retention in 99.1% of these isoforms would introduce a stop codon prior
to the annotated stop codon (Figure 5.7B). Since stop codons found >50 nt upstream of an exonexon junction are predicted to trigger the NMD pathway (408), we also interrogated the location
of the premature stop codons in these 330 MIG transcripts in relation to their exon-exon junctions.
Again, we found that the majority (83.8%) of the premature stop codons would be predicted to
activate NMD, resulting in transcript degradation (Figure 5.7B). For the remaining 53 MIG
transcripts, minor intron retention would introduce a stop codon in the 3’ end of the transcript,
potentially allowing these transcripts to escape NMD and be translated, resulting in the production
of truncated proteins (Figure 5.7B inset).
Regardless of whether a MIG transcript would be degraded via NMD or would produce an
aberrant protein, the functions executed by these MIGs would likely be compromised. To identify
which biological processes would be affected in the mutant, we submitted the 178 MIGs with
elevated minor intron retention to DAVID (454). Functions significantly enriched for by these MIGs
included cell cycle and centrosome, indicating that aberrant minor intron splicing might result in
cell cycle defects (Figure S3B, Table S5). Moreover, the only downregulated MIG in the mutant
pallium, Spc24, is involved in kinetochore assembly (Figure 5.6A&C) (457). In all, disruption of
minor intron splicing most likely affected cell cycle in the E12 mutant pallium.
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5.2.8

U11-null RGCs experience S-phase, prometaphase/metaphase, and cytokinesis
defects.

Among the 21 cell cycle-regulating MIGs with significantly elevated minor intron retention, there
were two noteworthy enrichments: nine MIGs that regulate mitosis and cytokinesis, and six MIGs
that regulate S-phase and DNA replication (Table S5). Therefore, we expected that
mitosis/cytokinesis and S-phase would likely be affected in the mutant pallium.
To study mitosis in the U11-null pallium, we performed IF for Ki67 and PH3, a marker of
mitosis (458), and quantified PH3+ mitotic cells as a percentage of the entire Ki67 + cycling cell
population, to identify the mitotic fraction of the NPC population (Figure 5.7C). This quantification
revealed a significantly larger mitotic fraction in the E12 mutant pallium relative to the control
(Figure 5.7C). To investigate whether a specific stage within mitosis was affected in the U11-null
E12 pallium, we employed the mitotic marker Aurora B. The staining pattern of Aurora B
corresponds to specific phases within mitosis (459) (Figure 5.9A); by quantifying cells within these
specific phases of mitosis, we were able to identify the fraction of mitotic cells in prophase,
prometaphase+metaphase, anaphase, and telophase. Aurora B staining was combined with IF
for either Pax6 or Tbr2, to assess cell type-specific defects. This staining paradigm revealed a
significantly higher percentage of mitotic Aurora B +/Pax6+ RGCs in prometaphase+metaphase in
the E12 mutant pallium than the control, while prophase, anaphase, and telophase were not
significantly different (Figure 5.7D-E). In mitotic Tbr2+ IPCs, we did not observe any significant
differences in the fractions in prophase, prometaphase+metaphase, anaphase, or telophase
(Figure 5.9B-C). To investigate cytokinesis in the E12 mutant pallium, we performed IF for citron
kinase (Citk), which marks the cytokinetic midbody (460). At E12, there was a significant reduction
in Citk+ cytokinetic midbodies lining the ventricular edge in the U11-null pallium (Figure 5.7F). This
reduction was not observed at E11, when the number of Citk+ cytokinetic midbodies across the
U11-null pallium was similar to the control (Figure 5.7F and 5.9D). These data suggest that U11
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loss causes both prolonged prometaphase/metaphase, specifically in RGCs, and cytokinesis
defects.
Next, we explored how minor intron retention in the S phase-regulating MIGs impacted S
phase kinetics in the mutant pallium. For this, we pulsed pregnant females with the thymidine
analog EdU (461), followed by harvest one hour later. EdU detection revealed a significantly lower
percentage of EdU+/Pax6+ RGCs in the mutant compared to the control at E12 (Figure 5.7G),
while there was no significant difference in the percentage of EdU+/Tbr2+ IPCs between the E12
control and mutant pallium (Figure 5.7H). In addition, we observed no change in the percentage
of EdU+/Pax6+ RGCs in the E11 mutant pallium compared to the control (Figure 5.9E). Thus, U11
loss in RGCs causes S-phase defects at E12, while U11-null IPCs are spared.
Together, these findings indicate that U11 loss disrupts the splicing of MIGs that are
involved in mitosis, cytokinesis, and S-phase, resulting in defects in these cell cycle phases. To
determine whether other cell cycle phases were affected in the U11-null pallium, we employed
the markers cyclin B1, which is cytoplasmic in G2 phase, and Aurora B, which is localized to
condensing chromosomes in cells in G2 (462, 463) (Figure 5.9A). Neither quantification of cyclin
B1+ G2 cells, nor quantification of the percentage of G2 Aurora B + RGCs or IPCs revealed a
significant difference between the E12 mutant and control pallium (Figure 5.9B&F-G), further
underscoring that U11 loss causes three significant and specific cell cycle defects, affecting (1)
prometaphase/metaphase, (2) cytokinesis, and (3) S-phase.
5.2.9

P53 upregulation occurs predominantly in RGCs in G1 phase.

Since the MIGs with significantly elevated minor intron retention enriched for cell cycle functions,
we expected that the observed cell cycle defects were the primary cause of RGC death, while the
observed DNA damage and p53 upregulation were secondary effects. To determine whether DNA
damage and p53 upregulation were occurring in NPCs in S-phase and mitosis/cytokinesis, we
combined IF for either ɣH2AX or p53 with different cell cycle markers. To determine whether cells
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accruing DNA damage were in S-phase, we employed the aforementioned EdU pulse strategy.
IF for ɣH2AX combined with EdU detection revealed that 38.5±9.3% of ɣH2AX+ cells were also
EdU+, similar to the total percentage of EdU+ cells in the mutant pallium (37.8±1.0%, Figure
5.10A). We did not observe any ɣH2AX +/PH3+ cells in the E12 mutant pallium, indicating that cells
with DNA damage were not in mitosis (Figure 5.11).
To investigate convergence between p53 upregulation and cell cycle phase, we employed
the aforementioned EdU pulse paradigm along with IF for Aurora B. In the E12 mutant pallium,
approximately one third (32.5±4.4%) of p53-upregulating cells were also EdU+ (Figure 5.10B).
However, this enrichment was not statistically significant, when compared to the total percentage
of EdU+ cells in the E12 mutant pallium (42.3±1.2%, Figure 5.10B). We then leveraged Aurora B
to interrogate p53 upregulation in G2 and mitosis. Quantification of cells with G2-specific Aurora
B staining in the E12 mutant pallium revealed that 14.4±2.1% of p53-upregulating cells were in
G2 phase, a significantly lower percentage than would be expected based on the total percentage
of G2 cells in the mutant pallium (26.5±1.4%, Figure 5.10C). Similar quantification of mitotic
Aurora B+ cells showed that 2.4±0.3% of p53-upregulating cells were mitotic, which was
significantly lower than expected from the total percentage of mitotic cells in the mutant pallium
(8.5±0.5%, Figure 5.10C). Thus, approximately half of p53-upregulating cells were not labeled by
these S-, G2-, and M-phase markers, suggesting that these p53-upregulating cells were in G1
phase.
Given that we observed a relationship between p53 upregulation and cell cycle phase, we
sought to determine whether apoptosis in U11-null cells was also linked to cell cycle phase. Since
pyknotic cells in later stages of apoptosis would not express cell cycle markers, we employed
both IF for CC3, to mark cells in early-to-late apoptosis, with TUNEL, to mark cells in late stages
of apoptosis. For our analysis, we excluded pyknotic TUNEL + cells, so that we only considered
cells in early stages of apoptosis. First, to investigate S-phase cells, we employed the
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aforementioned EdU pulse paradigm. Of the CC3+ cells of the E12 mutant pallium, 38.0±19.1%
were also EdU+, which was expected based on the total percentage of EdU + cells in the mutant
pallium (42.2±1.2%, Figure 5.10D). To assess G2 and mitotic cells, we employed IF for Aurora B.
In the E12 mutant pallium, we observed virtually no CC3 +/Aurora B+ cells (2.1±2.1%, Figure
5.10E), indicative of minimal death of cells in G2 and M phases. Together, these findings indicate
a relationship between apoptosis and cell cycle that mirrors that of p53 upregulation and cell cycle:
few dying cells are in G2 or M phase, and less than half are in S phase. Therefore, the majority
of dying cells in the E12 mutant pallium are most likely in G1 phase.
5.3 Discussion
Here, we explored the role of minor splicing in mouse development by Cre-mediated U11
snRNA ablation. The developmental disorders linked to minor spliceosome dysfunction—
MOPD1, Roifman syndrome, and Lowry Wood syndrome—are caused by impairment, but not
complete inactivation, of minor spliceosome activity. Specifically, MOPD1 is associated with 90%
loss of minor spliceosome activity, while the mutations underlying Lowry Wood syndrome and
Roifman syndrome result in less severe minor spliceosome impairment, and therefore less severe
symptoms (144, 157, 164). It is thought that partial (≥10%) minor spliceosome activity allows early
stem cells to survive, while 100% minor spliceosome inactivation would result in embryonic
lethality. However, the microcephaly and skeletal abnormalities observed in all three disorders
indicate that reduced minor spliceosome activity impairs the survival and/or behavior of brain and
limb progenitor cells (144, 157, 164). Even within the brain, progenitor cells of the cortex are the
most sensitive to inhibited minor splicing, as evidenced by the consistent set of cortical
abnormalities observed in MOPD1 patients (157). Moreover, the development of other tissues in
these patients is comparatively unaffected, further underscoring the cell type-specific requirement
of minor intron splicing in cortical and skeletal progenitor cells. However, investigation into the
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requirement of minor splicing for cortical development, and whether this requirement is cell typespecific within the cortex has, until now, been unexplored.
As predicted, germline ablation of the U11 snRNA, and therefore 100% inactivation of the
minor spliceosome, resulted in embryonic lethality (Figure 5.1C), which is consistent with findings
in Drosophila and zebrafish (129, 137). To circumvent embryonic lethality and to investigate the
role of minor splicing in cortical development, we specifically removed U11 in the developing
mouse cortex. These mutant mice were born with profound microcephaly, bolstering the link
between minor spliceosome inactivation and impaired brain development (Figure 5.1D).
Moreover, this mouse is the first mammalian model of microcephaly caused by minor spliceosome
inactivation, allowing us to study the pathogenesis of microcephaly in disorders caused by minor
spliceosome disruption. From these disorders and the observed microcephaly in the U11 cKO
mouse, it is evident that the developing cortex is highly sensitive to minor spliceosome activity
levels (144, 157, 164). Unexpectedly, we found that even within the developing cortex, different
cells showed drastically different sensitivities to U11 loss. Specifically, RGCs were highly sensitive
to minor spliceosome inactivation, while IPCs and neurons were less affected (Figure 5.4, 5.5CD, & 5.12A). Even within the RGC population, we observed differential sensitivity to minor
spliceosome inactivation, linked to RGC division type: U11-null RGCs were successfully dividing
to produce IPCs and neurons (Figure 5.5D-E & 5.12A). This is further corroborated by the
observation that we do not observe a reduction in the total number of neurons in the E13 mutant
pallium, after cell death is observed at E12 (Figure 5.3B & 5.4D). To test whether neurons were
being produced at E12, we pulsed BrdU at E12 followed by harvest at E13, which revealed that
that the percentage of neurons that were BrdU + (i.e., born post-BrdU pulse) was significantly
reduced in the mutant compared to the control (Figure 5.5E). This is consistent with the presence
of fewer RGCs in S-phase at E12 in the mutant (Figure 5.7G). However, the reduced contribution
of neurons produced between E12 and E13 is discordant with the similar numbers of neurons
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observed in the control and mutant at E13 (Figure 5.4D). Thus, these findings suggest that there
was a compensatory production of neurons prior to the BrdU pulse, to achieve the normal neuron
population size. Together, our findings show that minor spliceosome inactivation in the developing
mouse cortex predominantly affects the survival of self-amplifying RGCs, resulting in depletion of
the RGC pool (Figure 5.4H & 5.12A) and thus microcephaly (Figure 5.1D).
In the developing mouse cortex, the U11-null RGCs experience a host of cell cycle defects
that most likely contribute to their death. For example, fewer U11-null RGCs were in S-phase
(Figure 5.7G), suggesting either faster S-phase progression or death in late G1/early S-phase.
U11-null RGCs also displayed prolonged prometaphase/metaphase (Figure 5.7C-E), indicative
of spindle assembly defects. The observed reduction in Citk + cytokinetic midbodies along the
ventricular edge where RGCs divide, without a change in the fraction of mitotic RGCs in telophase
(Figure 5.7E-F), pointed to either RGC death prior to cytokinesis or improper Citk localization to
the midbody. Since proper Citk localization is required for cytokinesis, mislocalization would cause
aberrant cytokinesis, resulting in RGC death post-division (464). In addition to these cell cycle
defects, we observed RGC-specific accumulation of DNA damage and p53 upregulation (Figure
5.6E-G). The majority of RGCs with DNA damage also upregulated p53 (Figure 5.6E). Thus,
activation of the DNA damage response pathway in these cells likely results in the stabilization of
p53 protein, as has been reported (465). However, the vast majority of p53-upregulating RGCs
did not have DNA damage (Figure 5.6E). For these RGCs, we expect that p53 upregulation is
triggered by prometaphase/metaphase prolongation and cytokinesis defects, as has been
proposed (Figure 5.7C-E) (466, 467). This is consistent with the observation that most p53upregulating cells were in G1 phase (Figure 5.10B-C). RNAseq of the pallium, followed by DAVID
analysis of genes upregulated in the U11-null pallium, revealed significant enrichment for genes
involved in “intrinsic apoptotic signaling pathway in response to DNA damage by p53 class
mediator,” which is consistent with the observed p53 upregulation in RGCs (Figure 5.6G & Table
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5.1). Two of the genes enriching for this functional category were the well-known p53-mediated
apoptosis effectors Puma and Noxa (Table 5.1). Upregulation of these p53-mediated apoptosis
effectors is likely RGC-specific, since (1) p53 upregulation was observed specifically in RGCs
(Figure 4G), and (2) the E12 pallium, which was used for RNAseq, is comprised primarily of RGCs
at this time-point (Figure 3E). Activation of these apoptosis effectors likely drives the observed
RGC-specific death at this time-point, which is supported by the observation that most dying cells
were in G1 phase (Figure 5.10D-E).
In essence, all of these RGC-specific cellular defects are caused by minor spliceosome
inactivation—i.e., missplicing of MIGs. In the U11-null pallium, 62% of minor introns were
significantly retained compared to the control; DAVID analysis of the MIGs containing these minor
introns revealed significant enrichment for cell cycle regulation (Figure 5.8B & Table S5). Notably,
four of these cell cycle-regulating MIGs—Cdc45, Dna2, Prim1, and Rfc5—regulate DNA
replication and S-phase progression (Table S5); therefore, disruption of their function likely results
in DNA damage and cell death in S-phase, which is consistent with the observed cellular defects
(Figure 5.6D-E, 5.7G, & 5.12B). Ineffective DNA damage repair, due to minor intron retention in
the 13 MIGs regulating this process (Table S6), would further contribute to DNA damage
accumulation and the subsequent p53 upregulation. Disrupted function of many of the remaining
cell cycle-regulating MIGs, such as Ahctf1, Dctn3, Dync1li1, Gak, Mau2, and Zfp207, is reported
to cause spindle assembly defects, chromosome mis-segregation, and aberrant cytokinesis
(Table S5). Thus, minor intron retention in these genes likely contributes to the prolonged
prometaphase/metaphase and cytokinesis defects observed in U11-null RGCs (Figure 5.12B).
The identification of this subset of MIGs, which show significantly elevated minor intron retention
and whose functions track with the observed cellular defects in the U11-null pallium, opens new
avenues of research for scientists investigating the pathogenesis of the developmental disorders
linked to minor spliceosome inactivation.

124

Out of the total 186 minor introns that showed significantly elevated retention in the U11null pallium, we predicted that the majority would result in nonsense-mediated decay (Figure
5.6B). However, none of the 147 MIGs containing these retained minor introns were
downregulated in the E12 U11-null pallium. This is in agreement with the finding that mutation in
an essential minor spliceosome protein (rnpc3) in zebrafish did not affect expression levels of
90% of MIGs, while still resulting in elevated minor intron retention (137). These findings suggest
that inactivation of the minor spliceosome, while disrupting minor intron splicing, does not
necessarily result in downstream changes in overall gene expression. This could be a result of a
transcriptional feedback loop, driving compensatory upregulation of MIG transcription in response
to impaired function of these MIGs (157). If these transcripts are used for protein production, this
could flood the cell with aberrant proteins. While these abnormal proteins could be non-functional,
some could gain novel, potentially toxic functions, contributing to the RGC-specific cellular defects
and death.
Together, our findings reveal that even within a progenitor pool in the developing cortex,
there are vastly different outcomes of minor spliceosome inactivation, which are dependent on
both progenitor cell type (RGC vs IPC) and the type of cell division (proliferative vs differentiative)
(Figure 5.12A). One feature that tracks with sensitivity to U11 loss is cell cycle speed: selfamplifying RGCs, the cell type most sensitive to U11 loss, divide the most rapidly in the developing
cortex (468). Therefore, cell cycle speed may underlie the observed cell type-specific sensitivity
to U11 loss. In this scenario, rapidly dividing, self-amplifying RGCs would accumulate the
observed S-phase and mitosis/cytokinesis defects earlier than NPCs that cycle more slowly,
resulting in DNA damage, p53 upregulation, and cell death in these self-amplifying RGCs (Figure
5.6E-G, 5.7C-E, 5.5C). It is curious, however, that rapidly dividing early stem cells of MOPD1
patients can survive/divide with partial (≥10%) minor splicing activity, while the survival/division of
cortical and skeletal progenitors is impaired. This may be informed by differences in their MIG
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expression, where higher MIG expression is correlated with increased sensitivity to minor
spliceosome inactivation. Furthermore, if minor introns themselves display differential sensitivity
to minor spliceosome inactivation, as our data suggest, then the identity of MIGs expressed in
specific cell types could inform that cell type’s susceptibility to minor spliceosome inactivation. In
all, our findings establish how minor spliceosome inactivation in the developing mammalian cortex
leads to microcephaly. Moreover, we are the first to identify cell type-specific requirements for
minor spliceosome activity within the developing cortex, raising new questions about the
mechanisms underlying cell type-specific sensitivity to minor spliceosome activity in mammalian
development and disease.
5.4 Materials and Methods
Animal Procedures and Generation of the Rnu11 cKO Mouse
All mouse procedures were performed according to the protocols approved by the University of
Connecticut Institutional Animal Care and Use Committee. The Rnu11 conditional knockout (cKO)
mouse was generated by the University of Connecticut Health Center. A single targeting construct
was utilized to introduce both loxP sites into the Rnu11 locus in mouse embryonic stem (ES) cells
(Figure S1A). This construct contained a 5’ loxP site 1090 bp from the Rnu11 gene. Immediately
upstream of the 3’ loxP site was a phosphoglycerine kinase (PGK)-Neomycin (Neo) cassette
flanked by Frt sites. Additionally, this construct contained a PGK-dTA (diphtheria toxin A) negative
selection cassette downstream of the 3’ arm of homology. This construct was electroporated into
129X1/SvJ mouse embryonic stem (ES) cells. Successful targeting was verified by G418mediated positive selection. Subsequently, nested long-range PCR was employed to confirm
successful homologous recombination at both the 5’ and 3’ loxP sites (Figure S1C). Two ES-cell
clones, F4 and H8, were then used for morula aggregation using C57BL/6 embryos to generate
a chimera. Germline transmission and ablation of the Neo cassette was verified by introducing
germline Flp recombinase. Proper loxP site placement in the resulting mouse line was confirmed
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by PCR (Figure 1A; Table S7) to identify loss of the wild-type allele in the homozygous floxed line
and by breeding in the germline EIIa-Cre (469) (Figure 1A). Emx1-Cre was bred into the Rnu11
conditional knockout line to target Rnu11 for removal in the developing forebrain (445). The
primers used for Rnu11, Cre, and Emx1-Cre zygosity genotyping PCRs are listed in Table S7. All
experiments were performed using male and female Rnu11WT/Flx and Rnu11Flx/Flx mice that were
Emx1-Cre+/-. For matings intended for embryonic harvests, the plug date was considered E0; on
the harvest date, the embryonic time-point was further verified by Theiler staging of the embryos.
Quantitative PCR
Quantitative PCR (qPCR) using Genomic DNA
To determine Rnu11 heterozygosity and loss of the WT allele, 25 ng of gDNA from Rnu11WT/KO
and Rnu11WT/WT mice was used for qPCR with Rnu11 cKO, 5’ loxP primers (Table S7). Equal
gDNA input was controlled with amplification for Hist1h1a, an intronless gene, which was then
used to normalize amplification for Rnu11.
Quantitative Reverse-Transcriptase PCR (qRT-PCR)
Loss of U11 expression was confirmed by qRT-PCR with U11 primers (Table S7) on cDNA
prepared from total RNA extracted from the pallium of control (N=3) and mutant (N=4) E12
embryos. In this case, Neat1, a non-coding RNA that did not show change in expression between
the control and mutant samples by RNAseq, was used to normalize expression of U11 by qRTPCR (470). The same cDNA was used to determine expression of Spc24, using primers designed
in the 3’ UTR of the gene (Table S7). The Cq values obtained for Sfrs10 (Table S7) were used to
normalize expression of Spc24 (471). For minor intron retention in Coa3, Parp1, and Pten,
expression values of exon-intron (unspliced) product were normalized using Cq values generated
using intergenic primers (Table S7) to offset any gDNA contamination (Banday et al. 2014).
Expression values of exon-exon (spliced) product were normalized using Sfrs10 Cq values (471).
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Minor intron retention for each of these MIGs was calculated by dividing the normalized fold
expression values of the unspliced product by the normalized fold expression values of the spliced
product. Statistical significance was determined by two-tailed student’s t-tests.
Hematoxylin and Eosin Staining
Frozen 16 µm coronal sections of P0 mouse brains were cured at room temperature for 15
minutes, followed by incubation in PBS for 15 minutes. The tissue was then dehydrated using an
ethanol gradient (25%, 50%, and 75%). Slides were washed twice in 100% ethanol for 30 seconds
each, with agitation, then washed twice in 95% ethanol for 30 seconds each, with agitation.
Following a rinse in running tap water, the sections were incubated in Harris hematoxylin (Fisher
Scientific, #6765001) for 7 minutes. Excess hematoxylin was removed by washing in running
water for 30 seconds. The slides were briefly agitated in 1% acid alcohol (1% HCl in ethanol),
then briefly rinsed in running water. Sections were then incubated for 2-3 minutes in saturated
lithium carbonate (1.54% in dH2O), followed by a 5-minute incubation in tap water. After a 30
second wash in 80% ethanol with agitation, slides were incubated in an eosin Y-phloxine B
solution (0.1% eosin Y, 0.01% phloxine B, 0.45% glacial acetic acid, 82.9% ethanol) for 1 minute.
The sections were then washed in 95% ethanol for 30 seconds with agitation, followed by two 30second washes in 100% ethanol with agitation and incubation in 100% ethanol for 1 minute. After
washing in xylene for 30 seconds with agitation, the slides were washed in xylene for 1 minute,
then mounted using PermountTM mounting medium (Fisher Scientific, #SP15-100).
In Situ Hybridization
16 µm cryosections of mouse heads (for E10–E12 and P0), telencephalons (E13–E14), and whole
brains (for P21), N=3 for each time-point and genotype, were used for section in situ hybridization
(SISH). SISH was performed using antisense, digoxigenin-labeled U11 RNA probe, which was
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detected using either alkaline phosphatase (AP) or fluorescent labeling (FISH), as described in
(141). The U11 probe was generated using the U11 expression primers in Table S7.
TUNEL Assay
16 µm cryosections of either embryonic mouse heads (for E10 – E12) or telencephalons (E13 –
E14) were used for terminal deoxynucleotidyl transferase dUTP nick ending labeling (TUNEL)
analysis. The in situ cell death detection kit, TMR red (Roche, #12156792910), was used,
according to the manufacturer’s instructions.
Immunofluorescence
Immunofluorescence was performed using one of three protocols. Staining for Tbr2 was
performed as described by (472). For staining with anti-NeuN antibody, heat-mediated antigen
retrieval was performed using citrate buffer, per the manufacturer’s instructions (Vector
Laboratories, #H-3300), followed by 10 minute PBS washes (3x). After three 10 minute washes
in 0.5% Triton® X-100 in PBS (PBT), sections were incubated in 10% FBS in PBS for one hour
at room temperature. Sections were then incubated in a PBS solution containing 1% FBS, 0.1%
Triton® X-100, and the primary antibody overnight at 4°C. Following five-minute washes in PBT
(10x), incubation with the secondary antibody (1:500) was performed similarly to the primary
antibody incubation, except for two hours at room temperature. The slides were then washed five
times with PBT, followed by three PBS washes and mounting with ProLong® Gold Antifade
Mountant (ThermoFisher Scientific, #P36930). For all other antibodies, staining was performed
as described in (473). Primary antibodies were diluted to 1:50 (mouse anti-CRIK/CITK, BD
Biosciences, #611376; rabbit anti-cyclin B1, Cell Signaling, #4138; MoBu-1 clone mouse antiBrdU, Santa Cruz, #sc-51514), 1:100 (mouse anti-Aurora-B/AIM1, BD Biosciences, #611082;
mouse anti-Pax6, Developmental Studies Hybridoma Bank, #PAX6-b), 1:200 (mouse antiγH2AX, MilliporeSigma, #05-636; rabbit anti-NeuN, abcam, #ab17787), 1:300 (rabbit anti-cleaved
caspase 3, Cell Signaling, #9665S; mouse anti-KI67, BD Biosciences, #556003; rabbit anti-p53,
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Leica Microsystems, #p53-CM5p; rabbit anti-Pax6, MilliporeSigma, #AB2237), or 1:500 (rabbit
anti-PH3, Bethyl Laboratories, Inc., #IHC-00061; rabbit anti-TBR2, abcam, #ab23345).
5-bromo-2’-deoxyuridine (BrdU) and 5-ethynyl-2’deoxyuridine (EdU) Pulse Experiments
Timed-pregnant Rnu11WT/Flx::Emx1-Cre+/+ females were first weighed and peritoneally injected
with 0.2 µL 25 mM BrdU or EdU in PBS per 100 mg body weight, one hour prior to embryonic
harvest. BrdU incorporation was detected using the BrdU-specific MoBu-1 clone anti-BrdU
antibody (Santa Cruz, #sc-51514) (474). EdU detection was then performed on sections of the
pallium, using the Click-iTTM EdU Alexa FluorTM 647 imaging kit (ThermoFisher Scientific,
#C10340) in accordance with the manufacturer’s instructions.
Image Acquisition and Quantification
Processed slides were imaged with a Leica SP2 confocal microscope, where settings for laser
intensity, excitation-emission windows, gain, and offset conditions were identical between control
and mutant sections on a given slide. For every slide that was processed for ISH, FISH, or IF, the
slide contained at least one control and one mutant section. Sections serial to those that revealed
loss of U11 by ISH analysis were used for IF staining, and images were collected in regions of
the pallium that showed U11 loss in the mutant by ISH (Figure 1E). For each channel for every
experimental condition, confocal imaging settings were optimized for fluorescence in the control
section on a given slide, and maintained for all other sections on that slide. For TUNEL, CC3,
γH2AX, and p53 imaging, collection settings were adjusted using the control section. These
settings were maintained when imaging the mutant section(s) on the same slide. Further
processing was performed on IMARIS v8.3.1 (Bitplane Inc.) and Adobe Photoshop CS4 (Adobe
Systems Inc.). All image processing in IMARIS and Photoshop was identical between images of
control and mutant sections from the same slide. Manual quantification was performed using the
spot tool in the IMARIS software, on 240 µm-wide columns of the pallium; statistical significance
was calculated using two-tailed student’s t-tests. For quantification of mitotic phases, as identified
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by Aurora B staining (Figure S4A), prometaphase and metaphase cells were summed together
into a single category (prometaphase/metaphase). For analysis of Pax6+ and Tbr2+ cell
quantification across mutant cortical development, statistical significance was determined by oneway ANOVA, followed by the post hoc Tukey test. For comparisons between the ɣH2AX +, p53+,
or CC3+ subpopulation and all DAPI+ cells in the E12 mutant pallium, statistical significance was
determined by Fisher exact test. Specifically, for each N, a separate Fisher exact test was
performed on quantification data from a 240 µm-wide column of the mutant pallium. The P values
from these Fisher exact tests were then combined using Fisher’s method.
Bioinformatics Analysis
RNAseq
The pallium was dissected from E12 (N=5 Rnu11WT/Flx Emx1-Cre+/-, N=5 Rnu11Flx/Flx::Emx1-Cre+/) embryos, followed by RNA extraction using TRIzol (Thermo Fisher Scientific, #15596018), per
the manufacturer’s instructions. Sample preparation and sequencing were performed by the
University of Connecticut Center for Genome Innovation. Total RNA library was prepared by
Illumina TruSeq Stranded Total RNA Library Sample Prep Kit (RS-122-2201) with Ribozero to
remove ribosomal RNA, and were then sequenced using Illumina NextSeq 500. Each sample was
barcoded so that the sequencing could be multiplexed. In total, we obtained 189,989,434 pairedend 151 bp reads for the control (N=5) and 219,849,711 paired-end 151 bp reads for the mutant
samples (N=5).
Gene expression
First, reads of individual replicates were merges and mapped to the mm10 genome (UCSC
genome browser) using Hisat2 (options –no-discordant and –no-mixed), with an overall alignment
rate of 85% (414). Reads that mapped to multiple locations in the genome were removed. Since
the samples were obtained from C57BL/6-129X1/SvJ mice, SNVQ was run to call single
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nucleotide variations (SNVs) (475), which were used to create a new reference genome. Reads
from all replicates were then mapped separately to the newly generated reference genome using
Hisat2. Isoform expression was determined by IsoEM2, an expectation-maximization algorithm
that bootstraps samples in order to determine an expression value in fragments per kilobase per
million mapped reads (FPKM) unit (415). Gene expression was then calculated by taking the sum
of the FPKM values of a given gene’s constituent isoforms. Finally, differential gene expression
(≥2 fold change, P≤0.01) was determined by IsoDE2 (415). Briefly, this tool utilizes the 200
bootstrapping iterations to compute a confident log2FC, which is the maximum log2FC that can
be computed within the specified P-value. A log2FC of 100 is reported when the FPKM value for
one of the conditions was 0 in one of the bootstrapping iterations.
Splicing efficiency
To assess minor intron splicing, sequences of the 555 minor introns were curated from the U12DB
(14) and blasted using Ensembl83 to obtain the minor intron coordinates in the canonical
transcript. Sequences of eight minor introns (found in Arpc5l, Cacna1c, Exosc2, Golga7, Ift80,
Mlst8, Tmem161b, and Morc4) that did not have 100% identity with any annotated intron in the
Ensembl database were removed from our analysis. All gene and exon coordinates from the
mm10 genome were obtained from a Biomart file (Ensembl v84). Major intron coordinates were
downloaded from the UCSC genome browser (Ensembl v84) and randomized after removal of
introns smaller than 4 nt.
Reads from each of the biological replicates were separately mapped with Hisat2 to the
previously described post-SNVQ generated reference genome. Reads that mapped to multiple
locations were then filtered out. To determine splicing efficiency of minor introns, we employed
the strategy described by (140). Briefly, all reads mapping to an exon-intron boundary were
extracted and quantified using BEDTools (417). The mis-splicing index (MSI) was then calculated
for each intron by dividing the number of exon-intron junction reads by the number of reads
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mapping to the canonical exon-exon splice-junctions. Only introns with >4 exon-intron boundary
reads, ≥1 read aligning to either the 5’ or 3’ splice site, and >95% intron coverage in at least one
sample were used for this analysis (140). As a control for the 545 minor introns subjected to these
criteria, we also generated 100 lists of 545 randomized major introns (54,500 randomized major
introns in total), to which we applied the same criteria. For each intron that passed the filtering
criteria, we calculated the difference between the mutant and the control (mutant MSI – control
MSI; ∆MSI). To determine which minor introns were retained significantly more in the mutant, we
compared the average MSI of each minor intron between the control and mutant samples using
two-tailed student’s t-tests.
ORF analysis
To analyze the effect of minor intron retention on the ORF, we curated all annotated isoforms of
the 178 MIGs containing minor introns with significantly elevated retention in the mutant from
Ensembl (v84). From this list of isoforms, we extracted only isoforms that would require minor
intron splicing for their production, i.e. the blasted minor intron coordinates match one of the
annotated intron coordinates 100%, resulting in 330 isoforms. Comparison of the annotated open
reading frame (ORF) sequence, with the sequence of the isoform containing a retained minor
intron, was performed to determine whether minor intron retention would result in introduction of
a premature stop codon in these isoforms. Isoforms were then binned into one of four categories:
(1) truncation of the ORF, due to a premature stop codon; (2) elongation of the ORF, with usage
of a premature stop codon; (3) elongation of the ORF, with usage of the isoform’s annotated stop
codon; and (4) no change in ORF size, with usage of a premature stop codon. For the 273
isoforms binned in category (1), we identified the location of the stop codon relative to the
downstream exon-exon junction. Based on this information, we further subdivided isoforms from
category (1) into (a) isoforms with premature stop codons >50 nt upstream of an exon-exon
junction, which would be predicted to activate nonsense mediated decay (NMD) of the transcript
133

(408); and (b) isoforms with premature stop codons >50 nt upstream of an exon-exon junction,
which might escape NMD and be used for protein production.
RNA Extraction and cDNA Preparation.
Palliums were dissected from E12 Rnu11 control (N=3) and mutant (N=4) mice, and the tissue
collected from each embryo was individually used for total RNA isolation. Tissue from each
embryo was separately triturated in 100 µL of TRIzol (Invitrogen, #15596026). RNA was extracted
using the DirectZOLTM RNA MiniPrep kit (Zymo Research, #R2050), per the manufacturer’s
instructions. For total RNA samples, 500 ng of RNA was used for cDNA synthesis, which was
performed as previously described in (141).
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5.5 Figures and tables

Figure 5.1. U11 loss in the developing mouse neocortex causes severe microcephaly.
(A) Schematic of the Rnu11 floxed (Flx) allele with positions of the loxP sites (blue triangles), with
agarose gel image showing PCR results detecting the upstream (left) and downstream (right) loxP
sites. Below is a schematic of the Rnu11 knockout (KO) allele, confirmed by PCR. (B) Results of
quantitative PCR (qPCR) detecting the WT allele. (C) Table showing genotype frequency of pups
produced from crosses of Rnu11WT/KO mice. (D) Images of P0 Rnu11WT/Flx::Emx1-Cre+/- (control,
ctrl) and Rnu11Flx/Flx::Emx1-Cre+/- (mutant, ctrl) pups, with lateral view of P0 ctrl and mut brains.
Scale bar=5 mm. At right are coronal sections of P0 ctrl and mut brains stained with hematoxylin
and eosin. Arrowheads indicate the choroid plexis. Scale bar=500 µm. (E-I) In situ hybridization
(ISH) for U11 expression (purple signal) in sagittal sections of the telencephalon from ctrl (top
row) and mut (bottom row) (E) E10, (F) E11, (G) E12, (H) E13, and (I) E14 embryos. Scale
bars=500 µm. Insets show higher magnification of the boxed regions; scale bars=200 µm. (J) Bar
graphs showing the average thickness of the E12, E13, and E14 ctrl and mut pallium.
Quantification data are represented as mean±SEM. n.s.=not significant; *=P<0.05; ***=P<0.001
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Figure 5.2. Generation and confirmation of the Rnu11 cKO mice.
(A) Schematic of the Rnu11 locus. The gray box represents the predicted gene Gm28874. Below
the Rnu11 locus schematic is the targeting construct used to introduce the loxP sites by
homologous recombination (dashed lines). (B) Schematic representing the targeted allele,
showing the primers used to interrogate the 5’ loxP site (black and green arrows, left) and the 3’
loxP site (black and purple arrows, right). For the 5’ loxP site primer set, the outermost forward
primer (black arrow, left) was designed outside the 5’ arm of homology, with the outermost reverse
primer (black arrow, left) positioned downstream of the 5’ loxP site. The inner set of nested primers
(green arrows) were designed in the 5’ arm of homology and within the 5’ loxP site, respectively.
For the 3’ loxP site primer set, the outermost forward primer (black arrow, right) was designed in
the Frt site located upstream of the 3’ loxP site, with the outermost reverse primer (black arrow,
right) positioned downstream of the 3’ arm of homology. The inner set of nested primers (purple
arrows) were designed in the 3’ loxP site and the 3’ arm of homology, respectively. (C) Agarose
gel images of long-range nested PCRs, performed on genomic DNA (gDNA) from targeted ES
cells, using the 5’ loxP site primer set (black and green arrows, left) and the 3’ loxP site primer
set (black and purple arrows, right). The number at the right of each gel image represents the
expected product size produced from this strategy.
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Figure 5.3. Cell death contributes to microcephaly in the U11 cKO.
(A-E) Fluorescent ISH (FISH) signal for U11 (white) combined with TUNEL (red) on control (ctrl,
left) and mutant (mut, middle) pallium sections from (A) E11, (B) E12, (C) E13, and (D) E14
embryos, with quantification of TUNEL + cells (right). Ap=apical; ba=basal. (E-F)
Immunofluorescence (IF) for cleaved caspase 3 (CC3) in ctrl (left) and mut (middle) pallium
sections from (E) E11 and (F) E12 embryos, with quantification of CC3 + cells (right). Scale
bars=30 µm. Data are represented as mean±SEM. n.s.=not significant; *=P<0.05; **=P<0.01;
***=P<0.001.
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Figure 5.4. U11 loss results in depletion of RGCs.
(A-C) IF for Ki67 (green) and NeuN (magenta) on sagittal sections of the control (left) and mutant
(right) pallium across (A) E12, (B) E13, and (C) E14, with (D) quantification. (E-G) IF for Pax6
(green) on sagittal sections of the control (left) and mutant (right) pallium across (E) E12, (F) E13,
and (G) E14, with (H) quantification. (I-K) IF for Tbr2 (green) on sagittal sections of the control
(left) and mutant (right) pallium across (I) E12, (J) E13, and (K) E14, with (L) quantification. Scale
bars=30 µm. Data are represented as mean±SEM. Subp.=subpallium; n.s.=not significant;
*=P<0.05; **=P<0.01; ***=P<0.001.
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Figure 5.5. U11 loss and death of self-amplifying RGCs in the mutant pallium.
(A) Separated channels for sagittal section U11 FISH (middle row) and immunofluorescence (IF)
for Ki67 (green) and NeuN (magenta) (top row), with overlay (bottom row), from the E12 and E13
control (ctrl) and mutant (mut) pallium. Scale bars=30 µm. (B) IF for Pax6 (green) and cleaved
caspase 3 (CC3, magenta) on sagittal section of E13 mutant pallium. White line marks the
boundary between the subpallium and the pallium. Scale bar=30 µm. (B’-B’’’) Magnified images
of the dashed box in (B), showing overlay of all channels (B’), Pax6 and DAPI (B’’), and CC3 and
DAPI (B’’’). Scale bars=7 µm. (C) IF for CC3 (magenta) and Tuj1 (green) in sagittal section of the
E12 ctrl and mut pallium, with bar graphs showing the percentage of CC3+ cells that were pyknotic
(left) and the percentage of non-pyknotic CC3+ cells that were Tuj1+ (right). Scale bars=30 µm.
(D-E) Bar graphs showing quantification of cells with nuclear Pax6 staining (D) or cells with
nuclear Tbr2 staining (E) across development in the mutant pallium, from E12 and E14. Statistical
significance across the three tested time-points was determined by one-way ANOVA, followed by
Tukey’s multiple comparison test to determine specific P values. (F) IF for BrdU (magenta) and
NeuN (green) in the E13 ctrl and mut pallium, which had been pulsed with BrdU at E12. Scale
bars=30 µm. At right are bar graphs showing the percentage of NeuN + cells that were BrdU+ in
the E13 pallium, or the percentage of non-pyknotic BrdU+ cells that were NeuN+ in the E13 pallium.
Statistical significance was determined by two-tailed student’s t-tests. Quantification data are
represented as mean±SEM from N=3 for each condition per time-point; individual data points are
superimposed on bar graphs. Non-pyk.=non-pyknotic. n.s.=not significant; *=P<0.05; **=P<0.01.
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Figure 5.6. U11 loss triggers DNA damage and p53 upregulation in RGCs.
(A) Scatterplot depicting the expression of protein-coding genes ≥1 FPKM in the control (x-axis)
and mutant (y-axis) E12 pallium. Inset shows the E12 mutant pallium, with dashed lines marking
the dissected region. (B-C) Normalized expression, determined by qRT-PCR on E12 control and
mutant pallium, for (B) Rnu11 and (C) Spc24. (D) IF for CC3 (green) and ɣH2AX (magenta) in the
E12 control (ctrl) and mutant (mut) pallium, with quantification. (E) IF for ɣH2AX (magenta) and
p53 (green) in E11 and E12 ctrl and mut sagittal pallial sections, with quantification. Inset pie
charts show the percentage of ɣH2AX+ cells that upregulated p53 (p53 +) (left) and the percentage
of p53+ cells that were ɣH2AX+ (right). (F) IF for ɣH2AX (magenta) and Pax6 (green), Tbr2 (green),
or NeuN (green), on sagittal sections of the E12 mut pallium, with quantification. (G) IF for p53
(magenta) and Pax6 (green) in the E12 mut pallium, with pie charts showing the percentage of
Pax6+ cells of the p53+ population (left) and of all DAPI + cells (right). Scale bars=30 µm.
Quantification data are represented as mean±SEM. n.s.=not significant; *=P<0.05; **=P<0.01;
***=P<0.001.
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Figure 5.7. U11-null RGCs exhibit S-phase, metaphase, and cytokinesis defects.
(A) Frequency plot of the change in mis-splicing index (∆MSI, x-axis) of major (blue) and minor
(red) introns. (B) Pie chart showing the effect of minor intron retention on the open reading frame
(ORF), for the 186 minor introns with significantly elevated retention, across all annotated MIG
transcripts requiring minor intron splicing. The truncation category is further broken down into the
percentage of transcripts predicted to be degraded by nonsense-mediated decay (NMD) or to
produce protein (prot.). (C) IF for Ki67 (green) and PH3 (magenta) in sagittal sections of the E12
control and mutant pallium, with quantification. (D) IF for Aurora B (green, AurB) and Pax6
(magenta) in sagittal sections from E12 ctrl and mut pallium, with quantification of mitosis-specific
Aurora B staining (M). (E) Quantification of the percentage of Aurora B+ cells in different mitotic
phases for E12 ctrl and mut pallium. (F) IF for Citk (green) in sagittal sections of ctrl and mut E12
pallium, quantification of Citk+ cytokinetic midbodies along the ventricular edge in the E11 and
E12 control and mutant pallium. (G) IF for Pax6 (green) and EdU (magenta) on E12 ctrl and mut
sagittal pallial sections, with quantification. (H) IF for Tbr2 (green) and EdU (magenta) on sagittal
sections of E12 ctrl and mut pallium, with quantification. Scale bars=30 µm. Data are represented
as mean±SEM. n.s.=not significant, *=P<0.05, **=P<0.01, ***=P<0.001.
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Figure 5.8. Validation of expression and minor intron retention changes in the E12 mutant
pallium.
(A) Minor intron retention of Coa3 (left), Parp1 (middle), and Pten (right) in the E12 ctrl and mut
pallium, as determined by qRT-PCR. The value plotted is the average ratio of normalized
unspliced expression/normalized spliced expression ± SEM from N=3 for each condition.
Individual data points are superimposed on the bar graphs. Statistical significance was
determined by two-tailed student’s t-tests. *=P<0.05, **=P<0.01, ***=P<0.001. (B) GO Terms
enriched for by DAVID analysis of MIGs with statistically significant elevated minor intron retention
in the E12 mutant pallium, with cell cycle-related terms highlighted in yellow.
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Figure 5.9. Cell cycle defects are not observed in the E11 mutant pallium, in IPCs of the
E12 mutant pallium, or in G2 phase.
(A) IF for Aurora B (green, AurB) showing phase-specific Aurora B staining patterns in cells in
G2, prophase (pro.), prometaphase (prometa.), metaphase (meta.), anaphase (ana.), and
telophase (telo.) in the E12 pallium. Scale bars=4 µm. (B) IF for Aurora B (green) and Tbr2
(magenta) in sagittal sections of control (ctrl) and mutant (mut) E12 pallium, with bar graph
showing the percentage of Tbr2 + cells with mitosis- and G2-specific (N=4) Aurora B staining
patterns. (C) Bar graph showing the percentage of Aurora B+/Tbr2+ mitotic cells in prophase,
prometaphase/metaphase (prometa./meta.), anaphase, and telophase (N=4). (D) IF for Citk
(green) in sagittal sections of E11 control and mutant pallium. (E) IF for Pax6 (green) and EdU
detection (magenta) in sagittal sections from E11 control (ctrl, left) and mutant (mut, right) pallium,
with bar graph showing the percentage of Pax6 + cells that were EdU+ in the E11 ctrl and mut
pallium. (F) IF for cyclin B1 (green) in sagittal sections of the E12 ctrl and mut pallium, with bar
graph showing the number of cell with cytoplasmic (cytopl.) cyclin B1. (G) Bar graph showing the
percentage of Pax6+ cells with G2-specific Aurora B+ staining in the E12 ctrl and mut pallium.
Scale bars=30 µm, unless otherwise specified. Quantification data are represented as
mean±SEM from N=3 for each condition per time-point, unless otherwise specified. Statistical
significance was determined by two-tailed student’s t-test (Table S8). n.s.=not significant.
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Figure 5.10. P53 upregulation and apoptosis predominantly occur in either cells in G1 or
post-mitotic cells.
(A) IF for ɣH2AX (green) and EdU (magenta) in sagittal sections of E12 mutant (mut) pallium, with
pie charts showing the percentage of EdU+ cells of the non-pyknotic (non-pyk.) ɣH2AX+ and DAPI+
populations. See also Figure S5. (B) IF for p53 (green) and EdU (magenta) in sagittal sections of
E12 mut pallium, with pie charts showing the percentage of EdU+ cells of the p53+ and DAPI+
populations. (C) IF for Aurora B (green, AurB) and p53 (magenta) in sagittal section of the E12
mut pallium, with pie charts showing the percentage of G2 Aurora B + cells of the p53+ and DAPI+
populations (left), and the percentage of mitotic (M) Aurora B + cells of the p53+ and DAPI+
populations (right). (D) IF for CC3 (green), EdU (magenta), and TUNEL (yellow) in sagittal section
of E12 mut pallium, with pie charts showing the percentage of EdU + cells of the non-pyknotic
CC3+ cell population. (E) IF for CC3 (green), Aurora B (magenta), and TUNEL (yellow) in sagittal
sections of the E12 mut pallium, with quantification. Scale bars=30 µm. Quantification data are
represented as mean±SEM. n.s.=not significant, ***=P<0.001.
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Figure 5.11. Cells with DNA damage are not in mitosis.
IF for PH3 (green) and ɣH2AX (magenta) in a sagittal section of the E12 mutant pallium. Scale
bar=30 µm.
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Figure 5.12. Model of cortical development in U11 cKO mice.
(A) Schematic representing cortical development in wild-type and mutant embryos, from E12 to
E14. Black arrows show type of cell division; arrow thickness denotes relative frequency of that
division. Question marks and dashed lines indicate events that remain to be explored. (B)
Schematic of proliferating RGCs progressing through the cell cycle in the late E11/early E12
pallium. Arrow color denotes presence (blue) or absence (black) of U11. MIGs with significantly
elevated minor intron retention, and with known functions at specific cell cycle phases, are listed
in boxes. Pro.=prophase; met.=metaphase; ana.=anaphase; tel.=telophase; cyt.=cytokinesis.
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Table 5.1. Mammalian functions of the 4 genes upregulated in the mutant pallium that
enriched for “intrinsic apoptotic signaling pathway in response to DNA damage by p53
mediator” by DAVID.
FC=expression fold-change between control and mutant. Ave=average.
Gene

Bbc3

Eda2r

Perp

Pmaip1

Synonyms

Puma,
Jfy1,
Jfy-1

Xedar

Kcp1,
Krtcap1,
Pigpc1,
Thw

Noxa, Apr

Ave
FPKM
Ctrl

0.720

1.670

0.467

0.721

Ave
FPKM
Mut

1.806

10.58

1.028

2.323

FC

Function Description

2.44

p53 upregulated modulator of apoptosis, a
BH3 domain-containing gene (PMID:
11572983); alongside Pmaip1 (below),
important activator of genotoxic stressinduced apoptosis in NPCs (PMID:
16822983); required for apoptosis driven by
increased p53 expression (PMID: 12574499)

6.86

both EDA2R and its ligand, EDA, are
transcriptionally activated by p53 (PMID:
19543321, 20501644); regulator of p53mediated apoptosis via interaction with the
death receptor FAS, and increased
expression of EDA2R results in
upregulation/stabilization of FAS protein
levels (PMID: 19543321)

2.24

p53 apoptosis factor related to PMP-22;
transcriptionally activated by p53 during
p53-mediated apoptosis, but not during p53mediated G1 arrest (PMID: 10733530,
14707288); induces p53 upregulation, posttranslational p53 modifications that disrupt
MDM2-p53 binding, and p53 nuclear
translocation (PMID: 21451571); important
positive regulator of p53-mediated
apoptosis in the embryonic mouse brain
(PMID: 14614825); DNA damage
upregulates Perp expression (PMID:
14614825)

2.56

pro-apoptotic, BH3 domain-containing gene
whose transcription is activated by p53
(PMID: 10807576, 14500851); alongside
Bbc3 (above), important activator of
genotoxic stress-induced apoptosis in NPCs
(PMID: 16822983)
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Chapter 6 Exon definition in minor intron-containing genes
Loss of U11 resulted in the retention of many minor introns, but not all. This led me to interrogate
other forms of alternative splicing that might occur around minor introns. I found that inhibition of
not only U11, but all minor spliceosome snRNAs, resulted in upregulation of alternative splicing
around minor introns. Notably, we identified the aberrant expression of these alternatively spliced
MIG transcripts in individuals with minor spliceosome-related diseases. These findings also
provided insight into the normal regulation of minor introns: alternative splicing is usually
repressed by interactions between the major and minor spliceosome. In this Chapter, I will discuss
how these two machineries may interact to regulate the expression of MIGs.
6.1 Introduction
Proper gene expression in eukaryotes relies on the splicing of introns to produce mRNA
transcripts capable of encoding a full-length protein. This involves the precise identification of the
5’ and 3’ end of introns, which is accomplished by the spliceosome through the recognition of
consensus sequences at the 5’ and 3’ splice site (SS), respectively (41). The high frequency of
these sequences in transcripts can complicate the pairing of the appropriate 5’ and 3’ SS (15,
476). While the use of many non-canonical or cryptic SSs can yield alternatively spliced isoforms,
the aberrant use of these SSs can result in the introduction of pseudo-exons and/or cause
frameshifts and disease (477). Thus, the pairing of the correct 5’SS and 3’SS during splicing is
crucial for the expression of most genes.
Since vertebrate genes generally consist of short exons and long introns, this pairing is
thought to occur via the exon-definition model (91, 478). It postulates that after transcription of
the intron, U1 small nuclear ribonucleoprotein (snRNP) binds to the 5’SS to mark the exon/intron
boundary, whereas the U2AF complex binds to the polypyrimidine tract (PPT) (92). Then, once
the 5’SS of the downstream intron is transcribed, another U1 snRNP will bind to it and interact
with the U2AF complex of the upstream intron through serine/arginine-rich (SR) proteins (204).
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These exon-definition interactions then facilitate the recruitment of U2 snRNP to the appropriate
branch point sequence (BPS), after which the spliceosome splices the major, or U2-type, intron
(41, 62). Thus, U1 snRNP not only identifies the 5’SS of an intron, it also facilitates the
identification of the 3’ end through the recruitment of U2 snRNP.
This model applies to all major introns, which make up ~99.5% of all introns in the human
genome. However, the remaining 0.5% of introns have been classified as minor, or U12-type,
introns. These minor introns have divergent 5’SS, BPS and 3’SS consensus sequences (120).
Therefore, the major spliceosomal snRNAs cannot base pair to these sequences and execute
splicing. Instead, there is a parallel, highly conserved machinery called the minor spliceosome,
which consists of U11, U12, U4atac, and U6atac snRNA, that splices these minor introns (98, 99).
The minor spliceosome shares the U5 snRNP and many proteins of the major spliceosome, but
it also contains seven unique proteins (ZMAT5, snRNP25, ZCRB1, snRNP35, snRNP48, PDCD7
and RNPC3) (101).
Importantly, the significance of understanding the minor spliceosome function and minor
intron splicing is underscored by several diseases that have been linked to mutations in minor
spliceosome components. For example, a mutation in U12 snRNA has been linked to early-onset
cerebellar ataxia (EOCA) and disparate mutations in U4atac snRNA have been associated with
microcephalic osteodysplastic primordial dwarfism (MOPD1), Roifman syndrome (RS), and
Lowry-Wood syndrome (LWS) (144, 145, 157, 164, 165). In these patients, the inhibition of the
minor spliceosome results in the retention of minor introns in a subset of minor intron-containing
genes (MIGs), but the effect of minor spliceosome defects on the splicing of the flanking major
introns remains unexplored (144, 145, 157, 164, 165). Extending the exon-definition model to
MIGs would suggest that the co-transcriptional splicing of minor introns and the flanking major
introns requires interactions between the major and minor spliceosome (479). Previously, we
have shown that alternative splicing (AS) around minor introns occurs in wild-type tissues,
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supporting the presence of these interactions (120). Moreover, it has been shown that binding of
U1 snRNP to a major-type 5’SS downstream of a minor intron greatly enhances the splicing
efficiency of the minor intron, suggesting that exon-definition complexes may be formed between
major and minor-type splice sites (121). Given that U11 snRNP is analogous to U1 snRNP, it is
likely that it is involved in exon-definition interactions in MIGs (400). However, the exact
components involved in these interactions remain unknown, as well as the consequences of
disrupted exon-definition interactions on development and disease.
Here we wanted to test whether the exon-definition model extends to MIGs, by
determining the effect of U11 loss at the 5’SS of the minor intron on identification of the 3’SS of
the upstream major intron. Our results show that disrupted minor intron splicing results in the
elevated retention and AS of the upstream major intron, which strongly supports the exon-bridging
interactions between the major and the minor spliceosome. We found that these exon-bridging
interactions are mediated by PDCD7 (U11-59K), which we show here interacts with crucial major
spliceosome proteins involved in 3’ end recognition of the upstream major intron. The significance
of detecting elevated AS in the U11 conditional knockout (cKO) mouse is further underscored by
the identification of similar AS events in peripheral blood mononuclear cells (PBMCs) from
individuals with minor spliceosome-related diseases such as RS, LWS, and EOCA. These
findings reveal that the expression of aberrant alternatively spliced MIG isoforms might contribute
to disease pathogenesis. Indeed, expression of an aberrant isoform of the MIG Dctn3, in the
developing mouse cortex showed cell cycle defects, which is thought to underlie the microcephaly
phenotype in individuals with MOPD1, RS and LWS. In all, here we show novel interactions
between the two spliceosomes to control the splicing and expression of MIGs in development and
disease.
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6.2 Results
6.2.1

U11 is required for the efficient splicing of a subset of major introns located
upstream of minor introns.

Extending the exon-definition model to MIGs predicts that loss of U11 snRNP would not only
affect the splicing of minor introns, but also the splicing of the upstream major introns. Here we
analyzed RNAseq from the E12 dorsal telencephalon of our U11 cKO mouse, that had shown
widespread elevated minor intron retention (142). Specifically, we focused on the 437 MIGs that
were expressed ≥1 TPM and contain one or more minor introns with an upstream major intron
(major-1 intron) (Figure 6.1A). We found that loss of U11 resulted in the significantly elevated
retention of a subset (86; 18%) of these major -1 introns, but not of major introns located two
positions upstream (major-2 introns) of the minor intron, which is consistent with the exon-definition
model (Figure 6.2A). Moreover, we found that the median mis-splicing indices (%MSIRet) of the
major-1 introns was significantly elevated in the U11 cKO (2.22-fold; P<0.001). However, the
%MSIRet of major-2 introns were not significantly different (1.13-fold; P=0.1079) (Figure 6.2B).
Consistently, the %MSIRet ratio of major-1 was significantly higher than major-2 introns (P<0.001)
(Figure 6.2B). Finally, we found that major introns in non-MIGs were entirely unaffected by the
loss of U11 (Figure 6.1B). Thus, we have discovered a subset of MIGs that require U11-mediated
exon-bridging interactions to splice the major intron upstream of the minor introns.
6.2.2

Loss of U11 results in elevated alternative splicing executed by the major
spliceosome.

Disruption of exon-bridging interactions could also result in the utilization of an alternative 3’SS in
the major-1 intron (90). Investigation of AS around these major-1 introns in the U11 cKO revealed
no significant increase in cryptic 3’SS usage, but we did observe increased skipping of the exon
in between the major-1 intron and the minor intron (Figure 6.2D). This type of AS event was
detected in six MIGs in the control dorsal telencephalon, but observed in 40 MIGs in the U11 cKO
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(Figure 6.2D). Skipping of this exon was sometimes combined with the use of a cryptic 3’SS in
the minor intron, which would obviate the need for the minor spliceosome. This result led us to
interrogate other AS events around the minor intron that could bypass minor intron splicing (Figure
6.2E). We found that U11 loss also resulted in skipping of both exons flanking 30 minor introns
(CAT2), while this was never observed in the control (Figure 6.2E-F). In total, 116 AS events were
observed in the U11 cKO, of which 50% were exclusive to the mutant and many were validated
by RT-PCR and Sanger sequencing (Figure 6.2F-G, Figure 6.1C). The remainder 58 AS events
were detected in both samples (Figure 6.2E). Of these, only three AS events, found in the MIGs
Mapk9, Spc24, and Ccdc43, were significantly upregulated in the U11 cKO. Sanger sequencing
revealed multiple AS events in the same MIG transcripts and analysis of the consensus
sequences resulting from the new splice sites showed known major-type consensus sequences
(Figure 6.2F-I). Thus, minor spliceosome disruption results in elevated AS around minor introns,
that is executed by the major spliceosome.
6.2.3

Inhibition of U12, U4atac and U6atac snRNAs all result in elevated AS around
minor introns.

The upregulation of AS in U11 cKO mice points to an essential role of U11 snRNP in maintaining
exon-definition. However, unlike U1 snRNP, U11 snRNP exists as a di-snRNP with U12 in the
minor spliceosome (106). Thus, we hypothesized that inhibition of other minor spliceosome
components might also perturb the exon-definition interactions in MIGs and result in upregulated
AS around minor introns. To test this hypothesis, we employed antisense morpholino
oligonucleotides (MO) against U12, U4atac and U6atac snRNAs in HEK293 cells, followed by
capture of the nascent RNA and RNAseq (Figure 6.3A). While this strategy would reduce the
number of MIGs for analysis, it allowed us to capture the most immediate splicing defects after
minor spliceosome inhibition. Inhibition of the minor spliceosome was confirmed through analysis
of minor intron retention levels. Compared to the control MO, we found that inhibition of U12
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snRNA led to significantly elevated retention of 22 minor introns, whereas inhibition of U4atac and
U6atac snRNA both resulted in the significant retention of 74 minor introns (Figure 6.4A-C).
Importantly, an MO against U2 snRNA did not result in elevated minor intron retention (Figure
6.3B).
Next, we analyzed the level of AS across minor introns (%MSI AS) in the aforementioned
conditions. We found 94 AS events around minor introns in the control condition (Figure 6.4D).
Moreover, we detected 147, 119 and 152 AS events upon inhibition of U12 snRNA, U4atac
snRNA, and U6atac snRNA, respectively (Figure 6.4D). In contrast, inhibition of U2 snRNA
resulted in a reduction of AS around minor introns (69 AS events), which is consistent with our
finding that the major spliceosome executes the AS around minor introns (Figure 6.2I; 6.4D). The
increased AS levels upon inhibition of the minor spliceosome components was primarily due to
an increase in exon skipping (Figure 6.4D). While also present in the control condition, the usage
of this AS event had doubled upon minor spliceosome inhibition (Figure 6.4D). Overall, 111 AS
events were uniquely present when one or more minor spliceosomal components were inhibited.
In addition, 12 AS events were present in the control condition, but significantly upregulated upon
inhibition of the minor spliceosome. Together, 65% of these events involved the skipping of one
or both exons flanking the minor intron (Figure 6.3C). To determine whether the individual minor
spliceosome snRNAs regulated AS across different minor introns, we next performed an
intersection analysis of all AS events that were upregulated upon inhibition of the minor
spliceosome. This revealed that only 18% of the 123 upregulated AS events was observed in the
U12, U4atac and U6atac MO condition, thereby affecting the splicing of 18 minor introns (Figure
6.4E). Instead, AS across the majority of minor introns was upregulated in just one or two MO
conditions (Figure 6.4E). Using RT-PCR analysis, we detected these events in all conditions, but
at different levels (Figure 6.4F). For example, AS around the minor intron of TGS1 was most
highly upregulated upon inhibition of U4atac snRNA, whereas AS around the minor intron of E2F3
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was most responsive to inhibition of U12 snRNA (Figure 6.4F). Thus, AS across minor introns is
differentially affected by U12, U4atac and U6atac snRNA in a gene-specific manner.
6.2.4

U11-59K (PDCD7) mediates exon-definition interactions between the major and
minor spliceosome.

We found that the major spliceosome executes AS across minor introns, which implies cross-talk
between the two machineries. Therefore, we sought to identify splicing and/or AS factors that
might be involved in the exon-bridging interactions between the major and the minor spliceosome.
For this, we designed an AS mini-gene construct with a minor intron and the flanking major introns
of the MIG Mlst8, such that disruption of exon-definition interactions would result in the elevated
production of an alternatively spliced transcript consisting of exons 1 and 4 (Figure 6.5A; 6.6A’).
We then leveraged this readout to perform a siRNA screen against 55 known splicing and AS
factors, followed by RT-PCR analysis for the Mlst8 construct. Quantification of the alternatively
spliced product as a ratio of the canonically spliced transcript (%MSIAS), showed the largest
increase resulted from siRNAs against PDCD7 (U11-59K), RNPC3 (U11/U12-65K) and ZRSR2
(Urp) (Figure 6.6A; 6.5B). After successful confirmation of downregulation of these genes, we
repeated the screen with siRNAs against PDCD7, RNPC3 and ZRSR2 in triplicate (Figure 6.6BE). This revealed that AS across the minor intron of Mlst8 was indeed significantly >2-fold
upregulated upon inhibition of these splicing factors, compared to the scrambled siRNA (Figure
6.6D-E). Thus, the crosstalk between the major and minor spliceosome might be through protein
components of the minor spliceosome.
For major intron splicing, it is known that U1-70K is crucial for the maintenance of the
exon-bridging interactions (93). Since PDCD7 (U11-59K) is the only U11 snRNP component that
showed increased AS (Figure 6.6E), we hypothesized that it could perform an analogous role to
U1-70K in the maintenance of exon-definition interactions involving the minor spliceosome. To
test this hypothesis, we sought to identify Pdcd7-interacting proteins by mass spectrometry
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(Figure 6.6F). To determine the most robust interacting partners, we curated proteins with >2-fold
higher spectrum counts in the Pdcd7-Myc condition compared to a negative control (Figure 6.5D;
6.6F). Since we wanted to study exon-bridging interactions, we then focused on proteins with a
known role in splicing. This resulted in a list of 25 proteins, of which many were core components
of the major spliceosome (Figure 6.6F). Specifically, we detected several proteins that have been
identified in the major spliceosome E complex, such as SF1, SRSF1, SRSF2, SRSF3, SF3B1,
U2AF1 and U2AF2 (480). Moreover, the U5 snRNP components SNRNP40 and PRPF8 coimmunoprecipitated with Pdcd7. These interactions with the major spliceosome E complex
proteins were then confirmed using western blot (Figure 6.6G). Next, we wanted to determine
whether these were direct protein-protein interactions, or whether Pdcd7 engaged with the major
spliceosome through RNA-mediated interactions. Therefore, we treated the transfected samples
with RNase A, followed by IP and western blot for several proteins. This revealed that Pdcd7
directly interacts with SRSF1, SF3B1, U2AF1 and U2AF2, and that these interactions are not
RNA-dependent (Figure 6.6H). Thus, U11 snRNP directly interacts with the major spliceosome E
complex through PDCD7 to regulate the production of alternatively spliced MIG transcripts.
6.2.5

Alternatively spliced MIG transcripts are exported to the cytoplasm and bound to
polysomes.

RNA transcripts are normally under heavy surveillance by quality control mechanisms, such as
exosome-mediated nuclear degradation and non-sense mediated decay (NMD), resulting in the
degradation of aberrant transcripts (481). To test whether alternatively spliced MIG transcripts
would evade nuclear degradation, we fractionated the dorsal telencephalons from control and
U11 cKO E12 embryos into a nuclear (NE) and cytoplasmic (CE) fraction (Figure 6.7A). We found
that all of the AS events detected in whole-cell extract were also detected in the CE of U11 cKO
embryos (Figure 6.2G, 6.7A). The successful export of these alternatively spliced MIG transcripts
led us to investigate the effect of the AS on the open-reading frame (ORF), as frameshifts and
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premature stop codons are predicted to activate non-sense mediated decay (NMD) (482). We
found that ~50% of the AS events were in frame, whereas the other half resulted in a frameshift
(Figure 6.7B). The majority of the AS events that caused a frameshift also introduced a premature
stop codon that was predicted to activate NMD (Figure 6.7C). In five MIGs, the minor intron was
positioned close enough to the 3’ end of the transcript that the premature stop codon was not
predicted to trigger the NMD pathway (Figure 6.7C).
Next, to explore whether a subset of the alternatively spliced MIG transcripts was indeed
translated, we crossed our U11 cKO mice to Ribotag mice (483). RT-PCR analysis on RNA
extracted from immunoprecipitated (IP) polysomes of E14 control and U11 cKO dorsal
telencephalons showed the presence of all interrogated alternatively spliced MIG transcripts
(Figure 6.7D-E). Even MIG transcripts that were predicted to undergo NMD by bioinformatics
analyses were bound to polysomes (Figure 6.7E). Thus, we hypothesized that the alternatively
spliced MIG transcripts might produce novel protein isoforms. Therefore, we next determined the
effect of the AS on protein structure, by translating the ORF in silico, which revealed that the
majority of AS events would result in a truncation of the protein (Figure 6.7F-G). Notably, 50% of
the AS events would result in a truncation of protein domains, whereas 29% of the AS events
would result in the removal of one or more entire protein domains (Figure 6.7F-G). These results
strongly suggested that alternatively spliced protein products of MIGs might perform adverse
functions and have contributed to the microcephaly in our U11 cKO mice (142).
6.2.6

Alternatively spliced MIG transcripts in the U11 cKO mice affect cell cycle.

To determine the biological processes affected by the production of aberrant MIG proteins, we
performed functional annotation analysis, which showed a significant enrichment of the GO-term
condensed chromosome kinetochore, suggesting that cell cycle may be affected (Figure 6.8A).
Indeed, Ahctf1, Spc24, Nup107 and Dctn3, the four alternatively spliced MIGs that enriched for
this function, play known roles during mitosis (Figure 6.7G; 6.8A-B) (484-487). Previously, we
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have shown a prolonged pro-metaphase to metaphase transition of U11-null radial glial cells
(RGCs) (142). Therefore, we hypothesized that the aberrant expression of alternatively spliced
MIG transcripts contributed to the cell cycle defects observed in the U11 cKO. To test this, we
employed in utero electroporation (IUE) to express the full-length alternatively spliced Dctn3
transcript (Dctn3-AS-Myc) and GFP in E14.5 wild-type embryos (Figure 6.8C; 6.9A). At this
timepoint, the dorsal telencephalon predominantly consists of neurons in the cortical plate and
intermediate zone, but also contains two types of neural progenitor cells: RGCs and intermediate
progenitor cells (IPCs) (240). While IPCs are mostly found in the sub-ventricular zone (SVZ),
RGCs are located in the ventricular zone (VZ) and consequently take up the electroporated
plasmids (488). We found that overexpression of Dctn3-AS-Myc resulted in a significantly larger
percentage of GFP+ cells in the VZ/SVZ, as well as significantly fewer GFP + cells in the IZ (Figure
6.8D). To determine the identity of these cells, we performed immunofluorescence with antibodies
against Pax6 and Tbr2, to mark RGCs and IPCs, respectively. We found that overexpression of
Dctn3-AS-Myc resulted in a significantly higher number of Pax6 +/GFP+ RGCs in the VZ/SVZ as a
percentage of all GFP+ cells in these layers compared to the control (Figure 6.8E). In contrast,
there was no change in the number of Tbr2 +/GFP+ IPCs in the VZ/SVZ between control and Dctn3AS-Myc (Figure 6.9B-C). Thus, aberrant MIG isoform expression could contribute to the
microcephaly phenotype we observed in the U11 cKO.
6.2.7

Minor intron retention is not only a hallmark of Roifman syndrome, but also
Lowry-Wood syndrome.

Microcephaly is a common symptom in individuals with minor spliceosome-related diseases such
as, MOPD1, RS and LWS. To determine whether AS around minor introns also plays a significant
role in the pathogenesis of these diseases, we performed RNAseq on peripheral blood
mononuclear cells (PBMCs) from an individual with RS and an individual with LWS, as well as
their unaffected heterozygous parents and unrelated healthy controls. The individual with LWS
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was a 28 year old male and a compound heterozygote for the RNU4ATAC variant n.120T>G and
n.114G>C, whereas the individual with RS was 6 months old with two mutations in trans at
n.17G>A and n.116A>G (Figure 6.10A) (158, 489). Since transcriptomic analysis of individuals
with LWS have not been reported so far, we first analyzed minor intron retention levels. We
detected retention of ~170 minor introns in the healthy controls, RS carriers and LWS carrier. This
number was drastically upregulated in the individuals with RS (319 minor introns) and LWS (249
minor introns) (Figure 6.11A). Moreover, the median %MSI Ret was significantly elevated in
individuals with RS (57%) and LWS (65%) compared to the carriers (25%, 20%, 33%) and
unrelated healthy controls (22%, 20%, 22%) (P<0.0001) (Figure 6.11B). Importantly, this
upregulation of minor intron retention was validated for individual MIGs by RT-PCR (Figure
6.11C). Finally, principal component analysis (PCA) of the %MSI Ret values partitioned the patient
samples from the healthy samples (PC1: 68% of the variance) (Figure 6.11D). Thus, minor intron
splicing is affected in both individuals with RS and LWS. Moreover, this data revealed that one
mutant RNU4ATAC allele is not sufficient to affect the splicing of minor introns.
Comparison of the retained minor introns in the individuals with RS and LWS revealed
great overlap. Specifically, 92% of all retained minor introns in the individual with LWS were also
retained in the individual with RS (72% reciprocal) (Figure 6.11E). These 231 minor introns were
found in 220 MIGs that were used for functional annotation analysis, which revealed significant
enrichments such as, snRNA transcription from RNA polymerase II promoter, mRNA splicing and
nucleotide-excision repair (Figure 6.11F). Given the widespread nature of minor intron retention
in the individuals with RS and LWS, we next examined the effect of minor intron retention on the
ORF. We found that retention of 61% of the minor introns resulted in a frameshift, which was
predicted to introduce a premature stop codon (Figure 6.10B). Notably, the minor intron retention
events that were in frame (39%), were also predicted to introduce a premature stop codon in 96%
of the cases. Thus, ~98% of all minor intron retention events would result in a premature stop
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codon, which is predicted to downregulate the majority of MIGs through NMD. Despite the
retention of 319 minor introns in the individual with RS, only 8 MIGs were significantly
downregulated, which is consistent with previous reports on minor spliceosome inhibition (Figure
6.10C, 6.11A) (137, 142, 146, 157). In contrast, 83 MIGs were significantly downregulated in the
individual with LWS compared to the healthy controls, although only 17 of these MIGs had
evidence of minor intron retention (Figure 6.10C). Finally, PCA analysis on MIG expression did
not separate the patients from the control on the first axis (Figure 6.10D). While the second
principal component did partition the two groups, it only explained 21% of the variance (Figure
6.10D). Thus, minor intron retention is a better predictor of minor spliceosome disease than MIG
expression.
6.2.8

Alternatively splicing of MIGs is elevated in individuals with minor spliceosomerelated diseases.

Next, we interrogated AS around minor introns, which showed 66, 73 and 75 AS events around
in healthy controls, and unaffected RS and LWS carriers, respectively. This number was elevated
in the individual with RS (137 AS events), but not in the individual with LWS (78 AS events) (Figure
6.12A). In total, we identified 188 AS events around minor introns in one or more samples, of
which 79 were exclusively detected in the disease state. Specifically, 13 AS events were identified
in both the individuals with RS and LWS, whereas 14 and 52 AS events were exclusively found
in the individual with LWS and the individual with RS, respectively (Figure 6.13A). Together, these
79 AS events affected the splicing of 59 minor introns through exon skipping (CAT2; 30%) or
other AS types (Figure 6.12B). We then confirmed by RT-PCR many AS events common to both
patients, as well as those exclusively found in the individual with RS and not in the individual with
LWS (Figure 6.12C). Finally, PCA analysis on the %MSIAS levels for all 188 detected AS events
separated the individuals with RS and LWS from the controls on the first principal component
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(PC1: 45% of variance; Figure 6.13B). Thus, the specific mutations in the U4atac snRNA may
affect the amount of AS around minor introns.
Finally, we wanted to determine whether minor spliceosome-related diseases caused by
mutations in other minor spliceosome components than U4atac snRNA would also result in
upregulated AS in MIGs. An autosomal recessive n.84C>T mutation in the U12 snRNA has been
linked to EOCA, and has been shown to lead to elevated minor intron retention in PBMCs of these
patients (Figure 6.13C) (165). However, the effect of mutation in RNU12 on AS around minor
introns had not yet been explored. Moreover, given that inhibition of different minor spliceosome
snRNAs resulted in varying levels of AS in different MIGs (Figure 6.4E), we also wanted to
compare the effects of mutation in RNU12 and RNU4ATAC on AS around the same minor introns.
To this end, we performed RT-PCR for several minor introns that had been shown to be
alternatively spliced in the RNU4ATAC RNAseq data (Figure 6.12A, 6.13A). We found that all of
the AS events detected in the RS patient, were also identified in EOCA patients (Figure 6.12CD). However, the %MSIAS values for the events around the minor introns of PFDN5, VPS35,
NCBP2, and TCP1 were generally higher in individuals with EOCA than the individuals with RS
and LWS. In all, our data suggests that AS across minor intron significantly contributes to the
pathogenesis of minor spliceosome-related diseases.
6.3 Discussion
Intron evolution expanded regulatory control over gene expression, such as AS to produce a vast
and diverse proteome (490). At the same time, it imposed the need for precise pairing of the 5’SS
and 3’SS during co-transcriptional splicing. The exon-definition model elegantly explains the
recognition of correct 5’SS and 3’SS of major introns, but it cannot explain the splicing of a major
intron that is followed by a minor intron. In this case, U1 snRNP cannot bind to the downstream
minor-type 5’SS, and exon-definition interactions would predictably be lost and result in failed
splicing. However, major introns upstream of minor introns are spliced properly, which suggests
160

that U11 snRNP must somehow also be able to establish exon-bridging interaction. Indeed, the
identification of the minor spliceosome snRNAs and the associated proteins showed that the
minor spliceosome, for the most part, mimics the major spliceosome (98, 99, 101). In fact, the
minor spliceosome shares the U5 snRNA and many major spliceosome proteins, and only
contains seven unique proteins (99, 101). Thus, it is not surprising that there is cross-talk between
the major and minor spliceosome. Already in 1996, Wu and Krainer discovered that binding of U1
snRNP to a 5’SS would enhance the splicing of an upstream minor intron in the SCN4A splicing
construct (121). This data was the first evidence that exon-definition interactions could exist
between minor intron splice sites and the downstream major intron, which was later confirmed in
plants as well (491). It is thought that these interactions are mediated by SR proteins, but the
exact mechanism remained unknown (114, 492).
Fortuitously, our U11 cKO mouse allowed us to test whether the exon-definition model
extended to MIGs. We found that U11 loss indeed led to failed major intron splicing as evidenced
by elevated retention levels (Figure 6.2A-C). In some MIGs, the stalled splicing of the upstream
major intron was resolved by the use of an alternative major-type 3’SS further downstream, which
resulted in exon skipping. (Figure 6.2A-D). These data suggest that U11 snRNA is indeed a key
player in mediating exon-definition interactions for a subset of MIGs. Similarly, binding of U11
snRNP to U11 snRNP splicing enhancer (USSE) sequences in introns of SNRNP48 and RNPC3
has been shown to activate the usage of an upstream major-type 3’SS (115). In addition to U11,
we showed that inhibition of U12, U4atac, and U6atac snRNAs also results in elevated AS across
minor introns (Figure 6.4D). Together, these findings suggest that while U11 might be crucial for
exon-bridging interactions, the successful assembly and activity of the minor spliceosome as a
whole might regulate the major spliceosome.
Major spliceosome uses U1-70K to mediate the exon-bridging interactions, which
suggests that similar splicing and/or AS factors might play the same role in the minor spliceosome.
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Based on previous reports that SNRNP35 (U11-35K) might be the functional analog of U1-70K,
we expected that its knockdown would result in increased AS of the Mlst8 minigene construct. As
predicted, AS levels were upregulated >2-fold upon downregulation of snRNP35, but we saw the
largest increase in AS upon downregulation of PDCD7 (U11-59K), RNPC3 (U11/U12-65K) and
ZRSR2 (Urp) (Figure 6.6A) (101, 114). ZRSR2 is a component of both the major and minor
spliceosome, and is thought to play a role in 3’SS selection of both intron types (101, 122). In
contrast, both PDCD7 and RNPC3 are part of the seven unique minor spliceosome proteins (101).
Since PDCD7 is part of the U11 snRNP and has a highly specific antibody, which gave us
confidence in the efficacy of the siRNA, we focused on this protein. Immunoprecipitation of
PDCD7 followed by LC-MS/MS resulted in the detection of many interacting proteins that included
both RNA splicing factors and non-splicing factors (Figure 6.5D). This finding suggests that
PDCD7 plays additional roles besides minor intron splicing, which is also evidenced by findings
that PDCD7 transactivates E-cadherin expression and is involved in apoptosis of T-cells (170,
493). Our focus here was the role of PDCD7 as part of the minor spliceosome, and therefore we
curated those interacting proteins known to play a role in RNA splicing. This revealed that PDCD7
interacts with proteins of the SR-protein family, but also SF1, SF3B1, U2AF1 and U2AF2 (Figure
6.6G). These proteins have all been shown to be crucial components of the exon-bridging
complex between major introns and thus we have now shown that they also participate in exondefinition interactions between minor introns and upstream major introns (88). Together, these
findings for the first time reveal a potential reciprocal regulation of the two spliceosomes to
regulate MIG expression.
The appearance of the novel MIG isoforms when the exon-definition interactions between
the major and the minor spliceosome were disrupted led us to study the consequence of AS in
the U11 cKO mice. Bioinformatics analysis showed that many of the AS events were predicted to
result in a premature stop codon, which was confirmed by Sanger sequencing (Figure 6.7B-C).
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Unexpectedly, these alternatively spliced MIG transcripts were bound to the polysomes, which
revealed that they escaped both nuclear degradation as well as the NMD pathway (Figure 6.7A,
6.7E). While it is unclear how these transcripts escaped surveillance, we postulate that minor
spliceosome inhibition alters the splicing of MIGs such as Upf1, Ncbp1, Ncbp2, Ice1, which are
crucial components of the NMD pathway. Similarly, several MIGs are involved in nuclear
degradation pathways, such as Exosc1, Exosc2, Exosc5, and Exosc9 (494-496). This might
explain why we, and others, have shown the presence of aberrant MIG transcripts without their
concomitant downregulation (Figure 6.10C; 6.11B) (137, 142, 157). The presence of MIG
transcripts in polysomes suggested they are translated, thereby resulting in the production of
aberrant proteins (Figure 6.7E). These can either be non-functional and lead to proteasomal
degradation, or be toxic and result in a gain-of-function. Evidence for the latter possibility comes
from our experiments where we expressed the alternatively spliced transcript of Dctn3 in the
developing cortex of wild-type embryos (Figure, 6.8C-E). Dctn3 has been shown to play a crucial
role in mitosis and here we have shown that overexpression of the alternatively spliced isoform
affects cell divisions of neural progenitor cells (Figure 6.8D-E) (487). This is in agreement with
our previous results where we found that cell cycle defects in U11-null RGCs resulted in
microcephaly (142). Thus, these findings suggest that AS around minor introns can result in the
production of toxic proteins, thereby shedding light on the potential mechanism of disease
pathogenesis in case of compromised minor spliceosome function.
Even though our results provide strong evidence for a correlation between AS around
minor introns and disease, previous reports describing RNAseq of PBMCs from individuals with
minor spliceosome-related diseases such as MOPD1 and RS, did not find elevated exon skipping
(146, 157). Given that most AS events around minor introns are solely detected upon minor
spliceosome inhibition, they have not previously been identified and may therefore have been
missed by bioinformatics pipelines that focus on annotated AS events. Indeed, when we perfomed
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splicing analysis on PBMCs from a RS and LWS patient using our bioinformatics pipeline that is
specifically designed to identify de novo AS around minor introns, we detected many of the AS
events we had previously observed in our U11 cKO and morpholino experiments (Figure 6.1F;
6.2G; 6.4E; 6.12A-C) (120). While we found a significant overlap in the number of MIGs that
showed minor intron retention in both RS and LWS, there were much fewer overlapping AS events
(Figure 6.11E; 6.13A). This is in agreement with a recent report that found a great degree of
overlap in minor intron retention events between MOPD1 and RS patients (146). Even though all
these diseases are caused by mutations in the same gene RNU4ATAC, which reduce the
functionality of the minor spliceosome, the location of these mutations commonly differs. The RS
patient described here contains one variant in the stem II loop, which is important for base-pairing
with U6atac snRNA, and the other variant is located in the Sm binding domain (Figure 6.10A). In
contrast, both mutations in the LWS patient are located in or near the Sm binding domain (Figure
6.10A). This suggests that disruption of the Sm binding domain can result in minor intron retention,
but that base-pairing with U6atac snRNA is necessary for maintenance of exon-definition
interactions, as mutations result in elevated AS. The MIGs that showed minor intron retention in
the RS and LWS patient enriched for functions involving general RNA metabolism, such as mRNA
splicing and mRNA export (Figure 6.11F). Thus, while minor intron retention affects the function
of MIGs in these patients, the symptoms might also be due to a much larger footprint of
misregulated non-MIGs. Moreover, the severity of the symptoms might be linked to the levels of
toxic protein isoforms, which we show was elevated in clinically more severe RS compared to
LWS. Interestingly, RT-PCR analysis for several MIGs revealed that mutations in RNU12, that
are linked to EOCA, often result in elevated AS around minor introns, but leads to less minor
intron retention than mutations in RNU4ATAC (Figure 6.12C).
Overall, our work is revealing the complex regulation of splicing and AS of MIGs through
coordinated action of the major and the minor spliceosome, which is in line with the exon-definition
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model. Given that minor introns and the minor spliceosome evolved very soon after major introns,
and are highly conserved across species, the regulated cross-talk is consistent with the idea of
co-evolution of the exon-definition interactions (497). Inherent to these interactions is the means
to regulate the splicing and AS of many MIGs that are essential for survival, cell cycle and other
functions (174). As the involvement of the minor spliceosome in diseases such as amyotrophic
lateral sclerosis, myelodysplastic syndrome, and others are being discovered, understanding the
regulation of MIG expression will prove to be invaluable (140, 498, 499).
6.4 Materials and Methods
Animal husbandry
All mouse procedures were performed according to the protocols approved by the University of
Connecticut Institutional Animal Care and Use Committee (IACUC), which ensures adherence to
the U.S. Public Health Service Policy on the treatment of laboratory animals. The generation of
the U11 cKO mouse has been described previously (142). To ablate U11 snRNA in the developing
cortex, we crossed the Rnu11 cKO mouse to Emx1-Cre+ mice (445). These crosses resulted in
E12 control embryos (Rnu11WT/Flx::Emx1-Cre+/-) and U11 cKO embryos (Rnu11Flx/Flx::Emx1-Cre+/). To isolate RNA bound to polysomes, we crossed our U11 cKO mice with Rpl22-HA+ mice, and
harvested E14 embryos (483). IUE procedures were performed on E14.5 timed pregnant CD1
female mice obtained from Charles River.
Human subjects
Informed consent was obtained from individuals with mutations in RNU4ATAC (N=2), their
unaffected carrier parents (N=3), and unrelated healthy controls (N=3) using a protocol approved
by the Institutional Review Board committee at the CHU Sainte-Justine. The phenotypic
description of the LWS patient described in this manuscript had previously been published (158,
489). In contrast, the RS patient described in this manuscript had not previously been reported.
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The RS patient experienced asymmetric intra-uterine growth retardation during pregnancy along
with other ultrasound anomalies (including a suspected aortic coarctation, which was later not
confirmed). Prenatal investigations revealed a normal array CGH (Comparative Genome
Hybridization) and a customized Noonan syndrome panel revealed an inherited KMT2D variant
of uncertain significance. Given that this variant was inherited, it was deemed non-pathogenic.
The patient was born at term with a weight (2320g) and length (42cm) both below the third
percentile. Moreover, the head circumference was at the 50 th percentile. He had micromelia and
brachydactyly, and a skeletal survey showed platyspondyly, irregular metaphyses and delayed
epiphyseal ossification (i.e. a clinical presentation of spondyloepimetaphyseal dysplasia (SEMD)).
A SEMD panel then revealed two RNU4ATAC mutations in trans (Figure 6.10A), which have
previously been reported in an individual with RS (159). The patient was then evaluated by
additional clinicians who determined the presence of low titers of antibodies against tetanus
following immunization. Therefore, he is now, at nine months of age, supplemented with
immunoglobins. He has not had a serious infection to date and is doing well.
The individuals with mutation in RNU12 (N=5) and their unaffected carrier parents (N=3)
mentioned in this manuscript have been described previously (165). Informed consent from these
families was obtained using protocols approved by Institutional Review Board committee at Weill
Cornell Medicine-Qatar and Hamad Medical Corporation.
Cell culture
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented
with 10% fetal bovine serum (FBS), 5% sodium pyruvate and penicillin (100 IU/mL) and
streptomycin (100ug/mL). Cells were maintained at 37 °C and 5% CO 2.
In utero electroporation (IUE) and immunofluorescence
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In utero electroporation was performed as described previously (500). Briefly, timed pregnant
(E14.5) CD1 females were anesthetized by intraperitoneal (i.p.) injection of a mixture of 90mg/kg
bodyweight ketamine and 10mg/kg xylazine. After exposure of the uterine horns, ~1 ul of plasmid
DNA (1.5ug/ul) mixed with Fast Green was injected into the lateral ventricles of the embryos using
a glass micropipette. For the control condition this included a pCAG-GFP plasmid, whereas the
experimental condition consisted of an equal mixture pCAG-GFP and pCAG-Dctn3AS-Myc. Using
a square-pulse electroporator and electrode paddles placed on each side of the embryo’s head,
we then applied five 50ms pulses of 35V at 0.1 second intervals. After the electroporations, the
uterus was placed back in the abdominal cavity and the wound was surgically sutured. The mice
were closely monitored following the surgery and Metacam analgesics was injected
subcutaneously once a day for two days. After 72 hours, embryos were harvested and the heads
were used to generate 30um coronal cryosections. These were used for immunofluorescence as
described in (501). Primary antibodies were diluted to 1:300 (chicken anti-GFP; rabbit anti-Tbr2;
rabbit anti-Pax6) or 1:500 (mouse anti-Tubb3 and all secondary antibodies).
Image acquisition and quantification
Processed slides were imaged with a Leica SP2 confocal microscope, where settings for laser
intensity, excitation-emission windows, gain and offset conditions were identical between the two
conditions on a given slide. Further processing was performed on IMARIS v.8.3.1 (Bitplane) and
Adobe Photoshop CS4 (Adobe Systems). All image processing in IMARIS and Photoshop was
done using identical settings between the two conditions. Manual quantification was performed
using the spot tool in IMARIS and statistical significance was calculated using two-tailed Student’s
t-test.
To determine MSI values based on RT-PCR analysis, we employed ImageJ. Band
intensity of canonically spliced and alternatively spliced products was calculated and used to
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determine the MSI value as is done for RNAseq (i.e. intensity AS product / (intensity AS product
+ intensity canonical product).
Immunoprecipitation
Polysomes
Ribosomal-bound RNA was extracted from the dorsal telencephalons of E14 Rnu11WT/Flx::Emx1Cre+/-::Rpl22-HA+/- and Rnu11Flx/Flx::Emx1-Cre+/-::Rpl22-HA+/- embryos as described previously
(483). Briefly, for each litter, the dorsal telencephalons of all embryos of each genotype (~N=4)
were pooled and used for dounce homogenization in 1mL polysome buffer (50mM Tris pH7.5,
100mM KCl, 12mM MgCl2, 1% Igepal, 1mM DTT, 200U/ml RNAse Inhibitor, 1mg/mL heparin,
100ug/mL cycloheximide, 1X protease inhibitor). 50uL of the dounce homogenized sample was
labelled as “input” and added to 350uL RLT buffer with 1% 2-mercaptoethanol (Qiagen), followed
by RNA extraction. The remainder sample was centrifuged and the supernatant was extracted.
This was then added to HA-coupled protein G Dynabeads (ThermoFisher Scientific, #10004D)
and rotated overnight at 4C. Afterwards, beads were washed three times in high salt buffer (50mM
Tris pH7.5, 300mM KCl, 12mM MgCl2, 1% Igepal, 1mM DTT, 100ug/mL cycloheximide) and
350uL RLT buffer with 1% 2-mercaptoethanol was added to the beads. After vigorous vortexing,
the beads were immobilized and supernatant was labelled as “IP”. Figure 4E contains
representative images of results that have been repeated at least four times.
Pdcd7-Myc
To identify which proteins Pdcd7 interacts with, we overexpressed a pCMV6-Pdcd7-Myc plasmid
(OriGene, #MR214517) in HEK293T cells using GenJet II (SignaGen, #SL100489), as per the
manufacturer’s guidelines. As a control, an empty vector was utilized. After 48hrs, cells were
washed three times in 1X PBS and crosslinked with UV (365nm) using the Stratalinker 2400.
Settings were set to 4000J/cm 2, followed by 2000J/cm 2. Cells were dislodged and resuspended
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in 400ul modified RIPA buffer (50mM Tris-HCl pH8.0, 150mM NaCl, 0.5% SDS and 1X protease
inhibitor). The lysate was then pre-cleared for 1 hour by mixing 400uL sample with protein G
Dynabeads (ThermoFisher Scientific, #10004D). Afterwards, the pre-cleared lysate was
incubated with a primary antibody (goat anti-Myc #ab9132 or goat anti-mouse IgG (H+L) #115005-003) overnight at 4C. Protein G Dynabeads were then added to the samples, followed by a
3-hour incubation, and washing with 1X PBS. Finally, proteins were extracted by adding 30uL
modified RIPA buffer and boiling of the sample at 95C for 3 minutes.
Mass spectrometry
Protein samples (N=6 per condition) were submitted to the Proteomics and Metabolics
Core facility at the University of Connecticut for a slightly modified filter-aided sample preparation
(FASP) method in a microcon YM-10 10kD molecular weight cutoff (MWCO) filter (Thermo Fisher
Scientific) (502). Briefly, all IP elutions were diluted to 250 µL final volume using UA buffer (8 M
urea in 0.1 M Tris HCl, pH 8.5) and reduced using 25 mM dithiothreitol for 1.5 hr at 37°C. The
samples were added to the MWCO filter and spun at 14,000 x g for 40 min, washed with 200 µL
UA buffer and spun again using Spin Condition 1 (14,000 x g for 40 min). Cys residues were
carbamidomethylated using 50 mM iodoacetamide in UA buffer for 15 min in the dark at 37°C and
then centrifuged at Spin Condition A. Proteins were washed using two cycles of resuspension in
100 µL UB buffer (8 M urea in 0.1 M Tris HCl, pH 8.0) and centrifuged using Spin Condition 1
(14,000 x g for 30 min). Proteins were resuspended in 50 µL UB buffer, removed from the MWCO
filter and placed into a new 1.7 mL Eppendorf safe-lock tube. The MWCO filter was washed with
two aliquots of 50 µL 0.1 M ammonium bicarbonate and pooled to result in a final urea
concentration <1 M. The first stage of proteolysis was initiated by adding Endoproteinase LysC
(Pierce) at a 1:50 protein:protein (w/w) ratio for 16 hr at 37°C on a thermo shaker (Thermo
Scientific). Sequencing Grade Modified Trypsin (Promega) was then added at a 1:50
protein:protein (w/w) ratio and allowed to proceed for an additional 8 hr at 37°C. Enzymatic
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digestions were quenched using concentrated formic acid to result in a final pH of 2.5 and desalted
using C18 Peptide Desalting Spin Columns (Pierce) following manufacturer’s instructions.
Peptide samples were subject to mass analysis using a Thermo Scientific Ultimate 3000
RSLCnano ultra-high performance liquid chromatography (UPLC) system coupled directly to a
high resolution Thermo Scientific Q Exactive HF mass spectrometer. An aliquot of each peptide
preparation was injected onto a PepMap RSLC C18 analytical column (2 µm, 100 Å, 75 µm x 25
cm, Thermo Scientific) and subject to a 90 min, 300 nL/min reversed-phase UPLC method.
Peptides were eluted directly into the Q Exactive HF using positive mode nanoflow electrospray
ionization. A data-dependent Top 15 tandem mass spectrometry (MS/MS) acquisition method
was used that implemented the following parameters for MS scan acquisition: 60,000 resolution,
1e6 AGC target, maximum ion time of 60 ms, and a 300 to 1800 m/z mass range of. MS/MS scan
acquisition included the following parameters: 15,000 resolution, maximum ion time of 40 ms,
isolation window of 2.0 m/z, 30 s dynamic exclusion window, normalized collision energy of 27, a
200 to 2,000 m/z scan range, and charge exclusion “on” for all unassigned, +1, and >+8 charged
species.
Peptides were identified and quantified via label-free quantification using MaxQuant
(v1.6.0.1) and the embedded Andromeda search engine (503). The raw data was then searched
against an in-house generated protein database consisting of the myc-tagged Pdcd7 primary
sequence and the entire Uniprot Homo sapiens proteome database (identifier UP000005640,
accessed 20170422). The following parameters were used for the search: variable modifications
oxidation of Met, acetylation of Protein N-termini, and Gln to pyro-Glu conversion, fixed
carbamidomethylation of Cys, trypsin enzyme specificity with up to 2 missed cleavages, LFQ
quantitation “on”, and a minimum of 5 amino acids per peptide. All results were filtered to a 1%
false discovery rate at the peptide and protein levels; all other parameters were kept at default
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values. MaxQuant-derived output was uploaded into Scaffold Q+S (v 4.0, Proteome Software) for
visualization and further analysis.
Only proteins for which exclusive unique spectrum counts were detected in five out of the six
Pdcd7 IPs were included for further analysis. Interacting proteins were defined as having a fold
change in the sum of exclusive unique spectrum counts between the Pdcd7-Myc and control
condition greater than 2. To identify interacting proteins that could play a role in exon-definition,
all interacting proteins were submitted to DAVID for functional annotation analysis, and proteins
that significantly enriched for the function mRNA splicing were extracted.
siRNA screen
To knockdown splicing factors in HEK293T cells, we obtained a customized library containing
ON-TARGET plus SMARTpool siRNAs from Dharmacon Inc. siRNAs were resuspended in UP
H2O to a concentration of 2uM. 50pmol of siRNA against each gene, combined with 500ng pCAGMlst8 splicing reporter were co-transfected in 24-well plates using DharmaFECT DUO, as per the
manufacturer’s guidelines (Dharmacon Inc, #T-2010-01). After 48 hours, cells were harvested in
100uL TRIzol or 100uL modified RIPA buffer (50mM Tris-HCl pH8.0, 150mM NaCl, 0.5% SDS
and 1X protease inhibitor). To repeat the experiments with N-value, we obtained siGenome
SMARTpool siRNAs for PDCD7 (#M-012096-00-0005), RNPC3 (#M-021646-01-0005), and
ZRSR2 (#M-006596-01-0005) and followed the same experimental paradigm as described
before.
Plasmids and splicing constructs
The pCAG-GFP plasmid (Addgene, #11150) was obtained from Addgene and utilized for the
design of the pCAG-Mlst8 splicing reporter and the pCAG-Dctn3-AS-Myc plasmid. First, the
pCAG-GFP plasmid was cut with EcoRI and NotI to remove the GFP cassette. The four exons
and three introns of Mlst8 were PCR amplified with primers listed in Table S8 and then cloned
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into the pCAG backbone using the Gibson Assembly Master Mix (NEB, #E2611S). Similarly, the
alternatively spliced isoform of Dctn3 was amplified using primers listed in Table S8, followed by
cloning into the pCAG backbone using the Gibson Assembly Master Mix (NEB, #E2611S). The
pCMV6-Pdcd7-Myc plasmid was obtained from Origene (OriGene, #MR214517).
Morpholino electroporation
Electroporations were performed as described previously (504). Briefly, control (5′CCTCTTACCTCAGTTACAATTTATA-3’) (128), U12 (5’-TCGTTATTTTCCTTACTCATAAGTT-3’)
(504),

U4atac

(5’-CAGGCGTTAGCAGTACTGCCCTCAC-3’),

AACCTTCTCTCCTTTCATACAACAC-3′)

(128)

and

U6atac

(5′-

U2

(5’-

TGATAAGAACAGATACTACACTTGA-3’) (504) antisense morpholino oligonucleotide were
obtained from GeneTools, Inc and dissolved in water to a final concentration of 0.5 nmol/uL.
Approximately 1-2*104 cells were used for each separate electroporation (N=3 per electroporation
condition). Cells were washed with PBS, followed by mixing with 15nmol of morpholino in a 1.5mL
Eppendorf tube. After a 10min incubation at room temperature, cells were transferred to a 4-mmgap electroporation cuvette and electroporated using a Bio-Rad Gene Pulser at 200V for 50ms.
Cells were then plated in 10mL growth medium for 6 hours. Afterwards, cells were washed once
in PBS and plated in new growth medium supplemented with 200uM 5’-ethynyl uridine (EU)
(ThermoFisher Scientific, #C10365). Two hours later cells were harvested and homogenized in 1
mL TRIzol (ThermoFisher Scientific, #15596018), followed by extraction of total RNA. For
isolation of nascently transcribed, EU-pulsed RNA, 5ug of total RNA was biotinylated using the
Click-IT kit (ThermoFisher Scientific, #C10365), per the manufacturer’s instructions. Then, 50ng
of biotinylated RNA was pulled down on Dynabeads (ThermoFisher Scientifc, #C10365) and
resuspended in 5uL buffer. The nascently transcribed RNA was then immediately used for library
preparation as described below.
RNA extraction, cDNA preparation and PCR analysis
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U11-null dorsal telencephalon
Dorsal telencephalons were dissected from E12

Rnu11WT/Flx::Emx1-Cre+/- (N=3) and

Rnu11Flx/Flx::Emx1-Cre+/- (N=3) embryos and individually used for RNA extraction. The tissue was
triturated in 100uL TRIzol (ThermoFisher Scientific, #15596018) and RNA was extracted using
the DirectZOL RNA Miniprep Plus Kit (Zymo Research, #R2072), per the manufacturer’s
instructions. 500ng of total RNA was then used for cDNA synthesis, as described previously (419)
and 25ng of cDNA was used for reverse transcriptase PCR (RT-PCR) analyses.
HEK293T cells
For the experiments described in Figure 2, HEK293T cells were resuspended in 1mL TRIzol
(ThermoFisher Scientific, #15596018) and RNA was extracted using phenol:chloroform, as per
manufacturer’s instructions. For RT-PCR analyses, 1ug of total RNA was used for cDNA
synthesis. For the siRNA screen, HEK293T cells were resuspended in 100uL TRIzol and RNA
was extracted using the DirectZOL RNA Microprep kit (Zymo Research, #R2062). 100ng of total
RNA was then used for cDNA synthesis and 25ng of cDNA was used for RT-PCR analysis. To
confirm downregulation of PDCD7, RNPC3 and ZRSR2, we performed quantitative RT-PCR
(qRT-PCR) analysis on 25ng cDNA. The Cq values were then normalized to the expression of
GAPDH.
PBMCs from individuals
PBMCs from individuals were pelleted and washed three times with 1X PBS. Afterwards, the
pellet was resuspended in 100uL TRIzol and the RNA was extracted using the DirectZOL RNA
Microprep kit (Zymo Research, #R2062). 100ng of total RNA was then used for cDNA synthesis
and 20ng of cDNA was used for RT-PCR analysis.
Bioinformatics analysis
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Library preparation
Total RNA was depleted from rRNA using the RiboZero kit (#MRZH116) by the Center for
Genome Innovation at the University of Connecticut. mRNA library was then prepared using the
Illumina TruSeq Stranded Total RNA Library Sample Prep Kit (#RS-122-2201) and sequenced on
the Illumina NextSeq 500. This resulted in 60-100 million paired-end 151 bp reads per sample.
Gene expression analysis
Reads from each sample were aligned to the hg38 genome (UCSC genome browser) using
Hisat2 as described previously (Table S9) (142, 414). Gene expression was then determined by
IsoEM2, followed by differential gene expression by IsoDE2, as described previously (142, 415,
505).
Intron retention and alternative splicing analysis
Minor intron coordinates were downloaded from the Minor Intron DataBase (MIDB) (120).
Coordinates of the flanking major introns were then extracted for the canonical MIG transcripts
(as defined by Ensembl). These were then used to determine retention and alternative splicing
levels as described previously (120).
Functional enrichment analysis
Genes were submitted for functional enrichment analysis to DAVID (399). Only significant GOTerms (Benjamini-Hochberg adjusted P-value<0.05) were reported.
Consensus sequence analysis
Novel junction coordinates were extracted for each upregulated AS event in the U11 cKO dorsal
telencephalon using BEDTools (417). These were then utilized to extract the novel intronic
sequences generated by AS events with the BEDTools getfasta tool. Finally, frequency plots of
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the annotated and novel splice sites were made using WebLogo (506). If not a single novel exonexon junction was supported by more than 10 reads, this MIG was excluded from the analysis.
ORF analysis
To determine the effect of AS events across minor introns on the ORF, known exon-exon junctions
for the canonical MIG transcripts were adjusted to contain the novel junction coordinates using
BEDTools (417). These were then used to generate the full coding sequence as well as for in
silico translation. To predict whether an alternatively spliced transcript with premature stop codon
would be targeted for NMD, the location of the stop codon was compared to the annotated last
exon-exon junction of each gene. If this was >50nt upstream of the last exon-exon junction, it was
predicted to be targeted to NMD, otherwise it was considered to be translated into protein. The
effect of AS on protein domains was determined using the pfam database (507). Alternatively
spliced MIGs that did not have a single novel exon-exon junction supported by more than 10
reads were excluded.
Principal component analysis
Principal component analysis was performed based on MIG expression (TPM values), retention
levels (%MSIRet) and alternative splicing levels (%MSI AS) using the default settings in ClustVis
(508).
Quantification and statistical analysis
Statistical details of the experiments can be found in the figures and figure legends, as well as
the results section. To determine whether the retention and AS levels of individual introns were
significantly different in the U11 cKO, we performed a Student’s t-test. For the morpholino
experiments, a one-way ANOVA followed by post-hoc Tukey test was performed. To determine
whether major intron retention levels were generally significantly different between control and
U11 cKO, we performed a Mann-Whitney U-test. Moreover, statistical differences in expression
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levels of PDCD7, RNPC3 and ZRSR2 was determined by Student’s t-test. Furthermore,
significant differences in cell numbers in the IUE experiments were also determined by Student’s
t-test. P<0.05 was considered as significant in all analyses.
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6.5 Figures and Tables

Figure 6.1. Major and minor intron retention in the U11 cKO.
(A) Piechart representing the location of minor introns within the canonical MIG transcripts. (B)
Scatterplot with ratio of MSIRet values (U11 cKO vs. control) of individually retained introns. Line
represents median value. (C-E) Scatterplots with comparisons of the distribution of flanking minor
intron length (C), bridged exon length (D), and minor intron 5’SS strength (E) for upstream major
introns that are either retained or spliced. Line represents median value. n.s.=not significant. (F)
Agarose gel images of RT-PCR products resulting from AS around minor introns. Molecular
weight is shown on the left; product schematics are shown on the right. The %MSIAS was
calculated using ImageJ.
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Figure 6.2. Loss of U11 results in elevated AS and retention of minor introns and flanking
major introns.
(A) Bargraph showing the number of major introns located directly (major-1) and two positions
(major-2) upstream of the minor intron with significantly elevated retention in the U11 cKO
compared to control. Statistical significance was determined by Student’s t-test. (B) Scatterplot
with %MSIRet values of upstream major introns in the control and U11 cKO. Line represents
median value. Significance was determined by Mann-Whitney U test. (C) Scatterplot with ratio of
MSIRet values (U11 cKO vs. control) of individually retained introns. Line represents median value.
Significance was determined by Mann-Whitney U test (D-E) Bargraph with number of AS events
around the upstream major intron (D) and minor intron (E). (F) Heatmap of MSIAS values for AS
events uniquely detected in the U11 cKO. (G) Acrylamide gel images of RT-PCR products
resulting from AS around minor introns. Molecular weight of Sanger-sequenced products is shown
on the left; product schematics are shown on the right. (H) Sashimi plots showing combined AS
usage around minor introns. (I) Frequency logos of the 5’ and 3’ SS of alternatively spliced minor
introns.
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Figure 6.3. Inhibition of U2 snRNA does not affect minor intron splicing.
(A) Schematic of experimental design for morpholino (MO) electroporations. (B) Volcano plot
showing the delta MSIRet for minor introns upon inhibition of U2 snRNA.
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Figure 6.4 Inhibition of U12, U4atac and U6atac snRNAs all result in elevated AS around
minor introns.
(A-C) Volcano plots showing the delta MSI Ret for retained minor introns upon inhibition of U12
snRNA (A), U4atac snRNA (B), and U6atac snRNA (C). Significance was determined by one-way
ANOVA, followed by post-hoc Tukey test. (D) Bargraph with number of AS events around the
minor introns. AS categories are the same as in Fig. 1E. (E) Venn diagram showing the overlap
of minor introns with significant upregulation of AS upon inhibition of the minor spliceosome. (F)
Agarose gel images of RT-PCR products resulting from AS around minor introns. Molecular
weight of Sanger-sequenced products is shown on the left; product schematics are shown on the
right. The %MSIAS was calculated using ImageJ.
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Figure 6.5. Identification of proteins interacting with U11-59K
(A) Example of agarose gel image of the Mlst8 splicing reporter RT-PCR products resulting from
downregulation of proteins in the siRNA screen. (B) Equation used to determine the normalized
%MSIAS in the siRNA screen. (C) Western blot for Myc and Pdcd7 on samples transfected with a
control or pCMV6-Pdcd7-Myc plasmid and immunoprecipitated with IgG or Myc antibodies. (D)
Heatmap of exclusive unique spectrum counts of all proteins >2-fold enriched in the Pdcd7-Myc
IP samples. Zoomed in subset shown on the right. Proteins involved in splicing are shown in bold.
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Figure 6.6. U11-59K (PDCD7) mediates exon-definition interactions between the major
and minor spliceosome.
(A) Bargraph showing the %MSIAS of the Mlst8 splicing reporter, in response to siRNA against
splicing factors. Inset shows schematic of the Mlst8 splicing reporter and the resulting products.
(B) qRT-PCR results with expression levels of PDCD7, RNPC3 and ZRSR2, normalized to
GAPDH. Significance was determined by Student’s t-test. (C) Immunoblot for PDCD7 and Actin.
(D-E) Agarose gel image of the Mlst8 splicing reporter RT-PCR products resulting from
downregulation of minor spliceosome proteins (D) and quantification of the %MSIAS using ImageJ
(E). Significance was determined using one-way ANOVA, followed by post-hoc Tukey test. (F)
Heatmap of the exclusive unique spectrum count of the most robust Pdcd7-interacting proteins
involved in splicing. (G-H) Western blot for different proteins on (RNase A-treated) samples
transfected with a control or pCMV6-Pdcd7-Myc plasmid and immunoprecipitated with IgG or Myc
antibodies.
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Figure 6.7. Alternatively spliced MIG transcripts are exported to the cytoplasm and bound
to polysomes.
(A) Agarose gel images showing the nuclear lncRNA Xist s a fractionation control; shown below
are alternatively spliced RT-PCR products in the cytoplasmic fraction of the E12 dorsal
telencephalon (B) Bargraph with the predicted effects of upregulated AS around minor introns in
the U11 cKO on the ORF. (C) Piechart with the number of AS events resulting in a premature
stop codon that triggers NMD. (D) Schematic of experimental design to isolate RNA bound to
polysomes in the U11 cKO. (E) Agarose gel images of alternatively spliced RT-PCR products in
whole extract (In, Input) and bound to polysomes (IP) of E14 control and U11-cKO dorsal
telencephalon. (F) Piechart with the effect of AS on protein domains of affected MIGs. PD=protein
domain; AA=amino acid (G) Schematics showing altered protein domains due to AS around minor
introns. Numbers above indicate amino acids that encode for each protein domain.
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Figure 6.8. Alternatively spliced MIG transcripts in the U11 cKO mice affect cell cycle.
(A) Bargraph with functional annotation of MIGs with elevated AS around minor introns in the U11
cKO. (B) Schematic of layers in developing cortex and the location of radial glial cells (RGCs).
On the right is a schematic of and RGC in metaphase and the MIGs enriching for the kinetochore
function in (A). (C) Experimental design for in utero electroporations (IUE). Shown below is a
schematic of the protein domains of the two isoforms of Dctn3. (D-E) Immunofluorescence for
GFP (D) and Pax6 (E) on E17.5 cortices electroporated with GFP and Dctn3-AS-Myc. Higher
magnification image of the insets is shown next to each panel, with the quantification on the right.
DAPI marks all nuclei. Scale bars=30um. Statistical significance was determined by two-tailed
Student’s t-test. CP=cortical plate; IZ=intermediate zone; VZ=ventricular zone;
SVZ=subventricular zone.
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Figure 6.9. Overexpression of alternatively spliced Dctn3 isoform does not affect IPC
numbers.
(A) Western blot for Myc on HEK293T cells transfected with pCAG-GFP, pCAG-Dctn3-WT-Myc
and pCAG-Dctn3-AS-Myc. (B-C) Immunofluorescence for GFP and Tbr2 on E17.5 cortices
electroporated with pCAG-GFP (left) or a combination of pCAG-GFP and pCAG-Dctn3-AS-Myc
(right) (B), with quantification in (C). DAPI marks all nuclei. Scale bars=30um. Statistical
significance was determined by two-tailed Student’s t-test. CP=cortical plate; IZ=intermediate
zone; VZ=ventricular zone; SVZ=subventricular zone.
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Figure 6.10. The effect of RNU4ATAC mutations on MIG expression.
(A) Schematic of the secondary structure of U4atac snRNA and the locations of the mutations in
the RS and LWS patient. (B) Piechart with the effect of minor intron retention in the RS and LWS
patient on the ORF. (C) Bargraph with number of differentially expressed MIGs in the RS patient
and LWS patient compared to healthy control. (D) Principal component analysis (PCA) on TPM
values of MIGs in patients and controls. Prediction ellipse is drawn such that the probability is
95% that a new observation from the same condition falls inside the ellipse.
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Figure 6.11. Minor intron retention is not only a hallmark of Roifman syndrome, but also
Lowry-Wood syndrome.
(A) Bargraph with the number of retained minor introns in each individual. (B) Violin plots of the
%MSIRet for all retained minor introns in each individual. Solid line denotes median; dotted lines
depict Q1 and Q3. (C) Agarose gel images of RT-PCR products resulting from minor intron
retention in PBMCs. Molecular weight of products is shown on the left; product schematics are
shown on the right. The %MSIRet was calculated using ImageJ. (D) Principal component analysis
(PCA) on %MSIRet values in patients and controls. Prediction ellipse is drawn such that the
probability is 95% that a new observation from the same condition falls inside the ellipse. (E) Venn
diagram of the number of retained minor introns in the RS and LWS patient. (F) Bargraph with
functional annotation of MIGs with minor intron retention in disease state. (1)=preincision complex
stabilization; (2)=DNA incision, 3’-to lesion; (3)=preincision complex assembly; (*)=exonucleolytic
nuclear-transcribed mRNA catabolic process involved in.
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Figure 6.12. Alternatively splicing of MIGs is elevated in individuals with minor
spliceosome-related diseases.
(A) Bargraph with number of AS events around the minor intron. (B) Piechart with the distribution
of different AS events that are uniquely detected in the RS and/or LWS patient. (C) Agarose gel
images of RT-PCR products resulting from AS around minor introns in PBMCs of individuals with
mutation in RNU4ATAC (left) and RNU12 (right). Molecular weight of products is shown on the
left; product schematics are shown on the right. The %MSI AS was calculated using ImageJ.
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Figure 6.13. AS around minor introns is upregulated in Roifman Syndrome.
(A) Venn diagram of the number of AS events that are unique to the RS and LWS patient. (B)
Principal component analysis (PCA) on %MSI AS in patients and controls. Prediction ellipse is
drawn such that the probability is 95% that a new observation from the same condition falls inside
the ellipse. (C) Schematic of the secondary structure of U12 snRNA and the locations of the
mutations in the EOCA patients.
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Chapter 7 The role of the minor spliceosome in ALS pathogenesis
During my thesis work, an increasing number of diseases were associated with minor
spliceosome inhibition. One of these was amyotrophic lateral sclerosis, a neurodegenerative
disease with many underlying pathogenesis mechanisms. In 2016, it was proposed that mutations
in FUS, which result in its cytoplasmic aggregation, also result in the sequestration of the minor
spliceosome snRNAs U11 and U12 to the cytoplasm. It was hypothesized that this toxic gain-offunction resulting in disrupted minor intron splicing would underlie the disease pathogenesis in a
subset of patients. To test whether minor spliceosome inhibition could indeed contribute to the
disease, we ubiquitously ablated U11 snRNA in juvenile mice. We found that these mice exhibit
many of the pathological hallmarks observed in other ALS mouse models, which is described in
this chapter.
7.1 Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that is often fatal
within 2-5 years from symptom onset (352). While the majority of ALS cases are sporadic,
approximately 10% of all cases are familial (371). Of these, 5% have been linked to mutations in
the ubiquitously expressed RNA-binding protein fused in sarcoma (FUS) (509). Wild-type FUS is
found in the early spliceosomal complex E and therefore is thought to act as a splicing factor
(480). Indeed, interactomes of FUS revealed strong binding to U1 snRNP and U11/U12 diSNRNP, which are components of the major and minor spliceosome, respectively (498, 510).
ALS-associated mutations in FUS are found throughout the entire gene, but they are
especially clustered in the nuclear localization signal (NLS) (511). These mutations result in the
mislocalization of FUS to the cytoplasm, where it forms aggregates (512-514). As a result, nuclear
levels of FUS are reduced in ALS patients (513, 515). Therefore, both gain-of-function and lossof-function mechanisms have been proposed to describe how mutations in FUS can lead to ALS
(516). However, conditional knockout of Fus did not result in ALS-like phenotypes, pointing to a
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gain-of-function mechanism (376). Indeed, transgenic mice with overexpressed human FUSP525L
or FUSR521C, but normal levels of mouse Fus, experienced motor neuron loss in the lumbar spinal
cord (382). Thus, mutations in the NLS of FUS are thought to result in motor neuron degeneration
through a gain-of-function mechanism (382, 517, 518).
One such mechanism that could underlie the toxicity of the cytoplasmic mutant FUS
aggregates is the aberrant interactions with proteins and RNAs that are normally only transiently
interacting with FUS. Indeed, cytoplasmic aggregates of FUSP525L, which has been associated
with an aggressive, juvenile-onset form of ALS, has been shown to sequester U11 and U12
snRNAs to the cytoplasm (498). These snRNAs are components of the minor spliceosome, which
is responsible for the splicing of ~700 minor introns in the human genome (14, 99, 120). As such,
their sequestration to the cytoplasm by FUS aggregates results in a reduction of their nuclear
levels and elevated minor intron retention (Figure 7.10) (498). It has been hypothesized that this
inhibition of the minor spliceosome, which can affect the expression and function of approximately
700 minor intron-containing genes (MIGs), might be the toxic gain-of-function that mutant FUS
has acquired (498). As such, disrupted minor intron splicing might be the underlying cause for the
motor neuron degeneration observed in ALS patients.
To test whether inhibition of the minor spliceosome indeed underlies a subset of ALS
cases characterized by FUS+ cytoplasmic aggregates, we ubiquitously ablated U11 snRNA in
mice in a wild-type Fus background. We found that ubiquitous, postnatal loss of U11 resulted in
early mortality at around one year of age. Moreover, loss of U11 snRNA resulted in motor deficits
as reflected by tail-suspension tests and gain analysis. These behavioural phenotypes were
accompanied by neuronal loss in the motor cortex, as well as motor neuron loss in the lumbar
segment of the spinal cord. Finally, U11-null mice experienced muscle atrophy and had kyphosis.
Thus, U11-null mice recapitulate many of the cardinal phenotypes in ALS mouse models.
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Therefore, these findings suggest that minor spliceosome inhibition contributes to the
pathogenesis of ALS caused by mutant FUS.
7.2 Results
7.2.1

Postnatal CAG-Cre-mediated ablation of U11 snRNA partially reduces U11 levels.

We sought to test whether inhibition of the minor spliceosome caused by sequestration of U11
and U12 snRNA by FUS aggregates underlies the pathogenesis of some ALS cases. Since FUS
is ubiquitously expressed, we also wanted to remove Rnu11 ubiquitously (519). Given that
germline ablation of U11 snRNA is embryonically lethal (see section 5.2.1), we crossed our U11
cKO mice to tamoxifen-inducible CAG-CreERT2+ mice (520). Moreover, both wild-type (Rnu11Flx/Flx)
and mutant (Rnu11Flx/Flx::CAG-CreERT2+) mice were crossed with an Ai9-tdTomato reporter line,
where tdTomato is expressed upon Cre-mediated recombination (521). We then induced mice
with tamoxifen once daily at P15 and P16, which resulted in tdTomato + signal in the paws and
snout of mutant mice at P21 (Figure 7.1A-B). In agreement with the presence of tdTomato signal,
we detected the KO allele in genomic DNA from retina, brain and skeletal muscle of 2-month old
mutant mice (Figure 7.1C). However, this PCR analysis also revealed the presence of the floxed
allele, suggesting that not all U11 had recombined (Figure 7.1C). This was confirmed by qPCR
analysis, which showed that U11 snRNA was reduced by approximately ~20% in the cerebral
cortex and gastrocnemius of 2-month old mutant mice, compared to their wild-type littermates
(Figure 7.1D). Moreover, U11 levels were reduced by ~35% in the mutant spinal cord compared
to the wild-type (Figure 7.1D). Since sequestration of U11 snRNA by FUS P525L also does not result
in a complete loss of U11 snRNA in the nucleus, but merely a reduction, we believed that partial
loss of U11 snRNA was appropriate to test whether minor spliceosome inhibition could contribute
to ALS pathogenesis (498).
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7.2.2

U11 cKO mice die early.

The first overt phenotype we observed in the U11 cKO mice was greying of their fur coat. While
wild-type and mutant littermates were indistinguishable three weeks after tamoxifen injections,
after four weeks, we started to observe grey hairs in mutant mice (Figure 7.2A). This greying
progressed over time, resulting in a fully grey fur coat by the time these mice reached P100
(Figure 7.2A). Notably, this phenotype was observed regardless of whether their original coat
color was black or agouti.
Because ALS mouse models for FUS commonly die prematurely, we next wanted to
establish the death kinetics of U11 cKO mice (383). We found that loss of U11 resulted in an early
death. Specifically, 50% of all mutant mice had died at one year of age, while all control mice
were still alive at this time (Figure 7.2B). A log rank test then confirmed that the Kaplan-Meier
survival rate of the mutants was significantly different than that of wild-type mice (Figure 7.2B).
7.2.3

U11 cKO mice are hyperactive and fail to gain weight.

Monitoring of weight kinetics in the wild-type and mutant mice, revealed that U11 loss resulted in
a failure to gain weight. Already one-week post-tamoxifen injections, mutant mice were
significantly lighter than their wild-type counterparts (Figure 7.3A). Regardless, the mutant mice
continued to gain weight, until approximately 8 weeks after tamoxifen injections, when their weight
stabilized and they hardly gained any more weight (Figure 7.3A). Weight gain is normally
regulated by a balance between energy intake and energy expenditure (522). Therefore, to
determine whether a reduced food intake was the underlying cause for the failure to thrive
phenotype in mutant mice, we placed them on a liquid food diet after weaning (2 weeks post
induction), that allowed us to measure their food intake. This revealed no significant difference in
the amount of food consumed by wild-type and mutant mice for six weeks, suggesting this did not
cause the failure to gain weight (Figure 7.3B). Therefore, we next monitored their activity using
the Noldus Ethovision equipment after a 48-hour habituation period. Heatmaps of the time spent
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in specific locations within a two-hour window (one hour light and one hour dark) revealed that
wild-type mice predominately spent time in their nestlet and near the food, whereas mutant mice
were much more active exploring the home cage (Figure 7.3C). This was confirmed by traces of
their movement, which revealed that mutant mice on average travelled approximately twice as
much as wild-type mice (Figure 7.3C-D). Notably, 24-hour monitoring of these mice revealed that
this hyperactivity was restricted to the dark cycle, suggesting that U11 loss did not affect their
circadian rhythm (Figure 7.4). Thus, the hyperactivity of mutant mice might underlie the failure to
gain weight, although a metabolic contribution cannot yet be excluded.
While the mutant mice hardly gained any weight throughout their lives, we did observe a
significant loss in weight just before their deaths (Figure 7.3E). Specifically, we found that mutant
mice lost approximately 10% of their total body weight a week before their death (Figure 7.3E).
As such, we used body weight as a means to determine the end-stage of mutant mice, which was
the time point used to perform histological analysis.
7.2.4

U11 cKO mice experience motor deficits.

Motor neuron degeneration in ALS results in motor impairment, which is frequently assessed in
ALS mouse models through tail suspension tests and gait analysis. Tail suspension tests,
whereby mice are suspended by their tail for 30 seconds, can be used to assess fore- and
hindlimb clasping. Specifically, we scored the clasping phenotype on a scale from 0 (no clasping)
to 4 (both fore- and hindlimbs clasped) (Figure 7.5A). This clasping phenotype with a score of 3
or 4 is frequently observed in mouse models with pathologies in the spinal cord, cerebellum, or
basal ganglia and can therefore be used to infer motor deficits (523). We found that mutant mice
had an equal or higher clasping score than wild-type mice, which was significantly higher as the
mice grew older (Figure 7.5B).
While the tail suspension tests are informative and widely used, they do not provide insight
in the specific motor deficits. Therefore, we next assessed the walking gait of 10-month old mice
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on a motor-driven treadmill and focused on the knee and ankle joints (Figure 7.5C). Compared to
wild-type mice, this gait analysis revealed that mutant mice experienced a more restrictive
hindlimb gait, that occurred in a crouched position (Figure 7.5D). We found that the total peak
knee and ankle joint angles, as well as the total joint excursions (max-min joint angle), were
statistically significantly reduced in the mutant mice compared to the wild-type (Figure 7.5E-F).
Additionally, this analysis revealed temporal shifts in the percentage of the step cycle: the timing
of mutant gait events generally occurred earlier in the stance phase than that of wild-type mice
(Figure 7.5D). Thus, these data suggest that U11 cKO mice experience motor deficits, resulting
in widespread sagittal plane gait adaptations. In extreme cases this even resulted in full hindlimb
paralysis in end-stage mutant mice.
7.2.5

Neuronal loss in U11 cKO mice.

To understand whether the motor impairments observed through gait analysis and tail suspension
tests were the result of upper or lower motor neuron degeneration, we next performed Nissl
staining on brain sections of end-stage mice that contained the motor cortex (Bregma 2.46mm to
-1.34mm) (Figure 7.6A). Stereo Investigator was then used to determine the volume of the motor
cortex, which revealed no significant difference (Figure 7.6B). Moreover, we found no significant
difference in the total number of cells within the motor cortex (Figure 7.6C). However, Nissl marks
both neurons and small glia, thus to specifically determine neuronal numbers within the motor
cortex, we next performed immunofluorescence for NeuN (Figure 7.6D) (524). This approach did
revealed a significant neuronal reduction of approximately 15% in the end-stage mutant motor
cortex compared to the control mice (Figure 7.6E). Since upper motor neurons have the largest
cell bodies in the motor cortex (~100um), we next used ImageJ to specifically quantify the number
of large (≥100um) Nissl+ cells in the motor cortex (525). This showed that the end-stage mutant
mice had approximately 25% fewer upper motor neurons compared to wild-type mice, which was
a significant difference (Figure 7.6G). Importantly, there was no significant difference in the
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number of upper motor neurons between wild-type and mutant mice at 8 weeks of age (Figure
7.6F). Thus, this suggests that loss of U11 results in the degeneration of upper motor neurons.
Additionally, we found that the lamination of the motor cortex was severely disrupted in end-stage
mutant mice (Figure 7.6H). Comparison of the cortical layer sized showed that layer I was
significantly increased in the mutant mice (Figure 7.6I). Moreover, a clear distinction between
layers II and II was lacking in the mutant, which was in agreement with the reduction in NeuN +
signal we had observed in these layers (Figure 7.6D, H). Since neurons in layer II/III of the motor
cortex heavily project to the upper motor neurons in layer V, the disrupted lamination may also
affect the function of the remaining upper motor neurons in the mutant mice (526).
The gait defects observed in 10-month old mice suggested a defect in the alpha motor
neurons found in the ventral horn of the lumbar segment of the spinal cord, as these neurons
regulate voluntary hindlimb muscle contraction (527). To test whether U11 loss had indeed
resulted in a loss of lower motor neurons, we next performed immunofluorescence for ChAT and
NeuN on spinal cord sections from 10-month old wild-type and mutant mice (Figure 7.7). This
revealed a significant reduction in ChAT +/NeuN+ alpha-motor neurons at L1-L2, but not at L3-L4
and L5-L6, suggesting that a subset of lower motor neurons is also affected in the U11 cKO
(Figure 7.7).
7.2.6

Muscle atrophy in the U11 cKO mice.

Motor neuron degeneration will result in denervation of neuromuscular junctions (NMJ) and
consequently lead to muscle atrophy (528). To determine the level of innervation to NMJs in
mutant hind-limb muscles, we performed immunofluorescence with SV2 and 2H3 to mark the presynapse, and alpha-bungarotoxin (aBTX) to mark the post-synapse on the gastrocnemius of twomonth old wild-type and mutant mice (Figure 7.8A) (529). This analysis suggested that
denervation of NMJs might already start in U11 cKO mice at 2 months of age (Figure 7.8B). In
agreement with this, we found that the gastrocnemius of 10-month old mutant male mice was
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significantly smaller than that of wild-type mice (Figure 7.8C). Investigation of the ultrastructure of
the quadriceps muscles using transmission electron microscopy (TEM) showed clearly defined Ibands and A-bands, as well as M- and Z-lines in the wild-type (Figure 7.8D). In contrast, the Iband was less defined in the mutant, which also appeared to lack M-lines (Figure 7.8D). Moreover,
the mutant quadriceps contained many swollen mitochondria (Figure 7.8D). This abnormal
mitochondrial morphology is considered an early step in the degeneration of mitochondria, a
phenotype commonly observed in ALS patients and ALS mouse models (530-533). Later stages
in the apoptotic process of mitochondria involve leaking of the outer membrane, which we also
observed in the U11 cKO mice (Figure 7.8E) (534). Finally, we observed vacuolization of
mitochondria in the mutant, but never in the wild-type quadriceps (Figure 7.8E).
While atrophy of hind-limb muscles would affect the gait of mice, atrophy of paraspinal
muscles can result in kyphosis (535). Indeed, kyphosis is commonly observed in ALS mouse
models (536-538). To test whether kyphosis was also present in U11 cKO mice, we performed
microCT scans of anesthetized 10-month old mice (Figure 7.9). We then determined Cobb’s angle
from sagittal images of these mice and found that the mutant spinal curvature (58°) was
significantly higher than that of the wild-type mice (36.7°) (Figure 7.9). Thus, these results suggest
that U11 loss can result in muscle atrophy.
7.3 Discussion
ALS is a devastating neurodegenerative disease without any current cures (539). In part, this is
due to the complex genetics that underlie this disease. Even though only 10% of all ALS cases
are familial and thus provide limited insight into the underlying genetic causes, already up to 50
different genes have been linked to ALS (539). Pathogenic variants in each of these genes are
commonly inherited in an autosomal dominant manner, suggesting a toxic gain-of-function
mechanism (539). However, since each of the genes associated with ALS participate in different
biological functions, many different mechanisms have been proposed to underlie ALS
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pathogenesis. For instance, ALS-linked mutations in SOD1 are thought to result in excitotoxicity,
oxidative stress and mitochondrial dysfunction (540). In contrast, pathogenic variants in FUS are
thought to result in ALS by affecting splicing and DNA repair mechanisms (381, 541).
Here we wanted to understand the mechanism underlying ALS caused by P525L mutation
in FUS. FUS is ubiquitously expressed and normally shuttles between the nucleus and the
cytoplasm (542). However, it has been shown that FUS is enriched in the nucleus of neurons,
and is even exclusively nuclear in glia (543). This nuclear localization is disrupted by pathogenic
variants in the NLS of FUS, such as the P525L mutation (382, 498). Mutations in the NLS have
been shown to result in the cytoplasmic aggregation of FUS, which is thought to be toxic to the
cell (512, 513). Many different RNA species and proteins are trapped in these cytoplasmic FUS
aggregates, such as SMN, U11 and U12 snRNA in the case of FUSP525L (386, 498, 544).
Sequestration of U11 and U12 snRNA to the cytoplasmic mutant FUS aggregates has been
shown to disrupt minor intron splicing, which led us to test whether disrupted minor intron splicing
could be the underlying cause of ALS (Figure 7.10) (498). As such, we ablated U11 snRNA in a
wild-type Fus background, to determine whether disrupted minor intron splicing is sufficient to
induce ALS-like phenotypes.
We found that ubiquitous ablation of Rnu11 resulted in premature death at around 1 year
of age (Figure 7.2). This is later than has been reported for some ALS mouse models with
mutation in FUS (545, 546). However, in other ALS mouse models where human FUSP525L or
FUSR521C were overexpressed, the lifespan was completely unaffected (382). Additionally, we
found that U11 cKO failed to gain weight, and actively lost weight just before their death (Figure
7.3). Individuals with ALS frequently lose weight, which is hypothesized to be due to muscle
atrophy, loss of appetite, hypermetabolism and several other causes (547, 548). While the cause
of weight loss in the U11 cKO mice has not yet be determined, measurement of food intake and
muscle mass just before their death may provide insight into whether muscle atrophy or loss of
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appetite also play a role in the weight loss observed in the U11 cKO mice. Regardless, Fus
knockout mice and transgenic mice lacking the RRM domain of FUS but harbouring the R522G
pathogenic variant, as well as transgenic mice with overexpressed human wild-type FUS all had
a reduced body weight compared to their wild-type littermates and failed to gain weight (376, 545,
549).
Perhaps the most characteristic symptom of ALS is motor impairment, commonly reflected
by difficulty writing, tripping and an altered gait (352). Different motor tests have shown similar
motor defects in ALS mouse models. We found that U11 cKO mice clasp more and have a
restricted hindlimb gait, which are signs of motor impairment (Figure 7.5). Hindlimb clasping has
been observed in several ALS mouse models and can result from defects in both upper and lower
motor neurons (381, 523, 549, 550). Moreover, transgenic mice expressing a truncated FUS
protein lacking the RRM and NLS domains had an altered gait and progressive hindlimb paralysis
(546). Moreover, overexpression of human wild-type FUS resulted in a stilted gait in a crouched
position and reduced performance on the rotarod test (549). Two different FUSR521C transgenic
mouse lines also performed poorly on rotarod tests, and had reduced grip strength compared to
the wild-type littermates (381, 550). Moreover, they had gait abnormalities, and spastic paraplegia
(381, 550). Finally, FUSP525L transgenic mice had a markedly reduced latency to fall during the
wire hang test, but gait was not assessed (382). Although the specific motor defects cannot be
compared between these mouse models due to differences in tests, this data does suggest that
loss of U11 results in motor deficits commonly observed in ALS mouse models.
The widespread sagittal plane gait adaptations observed in U11 cKO mice may have
occurred due to weakness in the knee extensor muscles, the quadriceps, or from hypertrophied
knee flexor muscles such as the biceps femoris (Figure 7.5C-F). Given the atrophy and weakness
observed in other muscles of the U11 cKO mouse, we expect that especially weakness of
quadriceps muscles contributed to the altered gait (Figure 7.8C, 7.9). This could be the result
199

from denervated NMJs, as has been observed in transgenic FUS mice expressing the human
R521G and P525L pathogenic variants (382, 550). While innervation of NMJs was not
investigated in the muscles of the quadriceps, the vastus lateralis, vastus medialis and rectus
femoris, we did observe altered mitochondrial morphology in these muscles (Figure 7.8D-E).
Moreover, we found a significant loss of alpha-motor neurons in spinal cord segments L1 and L2
(Figure 7.7). The vastus lateralis and vast medialis are predominately innervated by motor
neurons located in these segments, thus supporting the possibility that denervated NMJs and/or
weakness of these muscles underlies the gait abnormalities in the U11 cKO (527).
The presence of both upper and lower motor neurons dysfunction in the absence of any
other disease typically leads to the diagnosis of ALS in humans (551). As such, upper and lower
motor neuron loss are normally examined to establish new ALS mouse models. We found that
loss of U11 resulted in moderate, but significant loss of both upper (~28%) and lower (~18%)
motor neurons (Figure 7.6G, 7.7). This suggests that the U11 cKO indeed recapitulates ALS-like
phenotypes and not SMA-like phenotypes, which has also been linked to disruption in minor intron
splicing, but is exclusively characterized by lower motor neuron loss (369, 370, 552). While the
degeneration of lower motor neurons in the U11 cKO was less severe than observed in most FUS
ALS models, there have been descriptions of ALS mouse models without any or a an equally
modest loss of lower motor neurons as we observed (381, 382, 518, 546, 549, 550). The moderate
loss of neurons in the U11 cKO compared to other ALS models may be explained by the fact that
FUSP525L cytoplasmic aggregates do not only sequester minor spliceosome components, but also
other RNAs and proteins (386, 553, 554). Thus, while loss of minor intron splicing contributes to
ALS pathogenesis, it is not the sole cause. Regardless, our data suggest that minor spliceosome
inhibition is sufficient to result in ALS-like phenotypes.
It is unclear whether minor spliceosome inhibition in these U11 cKO mice also resulted in
disrupted minor intron splicing. Previously we have reported that loss of U11 snRNA in the E12
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dorsal telencephalon does result in widespread minor intron retention and alternative splicing
around minor introns (Chapters 5 and 6) (142). Specifically, U11 loss affected the splicing of minor
intron-containing genes (MIGs) that play a role in cell cycle regulation and DNA damage (Chapter
5) (142). Since motor neurons are post-mitotic cells, most of the MIGs that participate in cell cycle
regulation might not be expressed and consequently not contribute to the pathogenesis of the
Rnu11Flx/Flx::CAG-CreERT2+ mice. However, DNA damage has been observed in motor neurons of
ALS mouse models, providing a potential molecular pathway that might underlie the shared
phenotypes observed in ALS and the U11 cKO (555). RNAseq of the motor cortex and lumbar
spinal cord of wild-type and U11 cKO mice will be able to shed light on this hypothesis.
In all, our results recapitulate all the pathological hallmarks of ALS, suggesting that minor
spliceosome inhibition contributes to the pathogenesis of ALS caused by FUSP525L. Since wildtype FUS normally binds to U11 snRNA, it is possible that any pathogenic variant in FUS that
results in the cytoplasmic aggregation of FUS without inhibiting its RNA-binding capacity can
result in the sequestration of U11 snRNA. This would mean that minor spliceosome inhibition may
not only contribute to the pathogenesis of FUSP525L, but can play a role in all forms of ALS caused
by mutations in the NLS of FUS. Additionally, FUS+ cytoplasmic aggregates have been observed
in patients with frontotemporal dementia (FTD), a syndrome that is observed in 15% of ALS
patients and is associated with a worse prognosis (556-558). This raises the possibility that minor
spliceosome inhibition may also play a role in the pathogenesis of FTD. This hypothesis is
supported by the observation of hyperactivity in our U11 cKO (Figure 7.3C-D, 7.4). While
generally not a symptom of ALS, hyperactivity has been observed in several mouse models for
FTD (559-561). Finally, U11 and U12 snRNA were significantly downregulated in the spinal cord
and motor cortex of sporadic ALS patients with cytoplasmic inclusions containing TDP43, another
splicing factor linked to ALS (389). In addition, U11-59K was found to have reduced nuclear
expression levels and an increased cytoplasmic localization in these patients and minor intron
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retention was elevated (389). Thus, these results suggest that minor splicing defects may also
play a role in ALS characterized by TDP43+ cytoplasmic aggregates, thereby expanding the
footprint of minor splicing involvement in ALS.
7.4 Materials and Methods
Animal husbandry
All mouse procedures were performed according to the protocols approved by the University of
Connecticut Institutional Animal Care and Use Committee. Rnu11Flx/Flx mice were crossed to CAGCreERT2+ mice that were obtained from Jax Labs (#004682). Wild-type (Rnu11Flx/Flx) and mutant
(Rnu11Flx/Flx::CAG-CreERT2+) mice were then crossed to the Ai9 tdTomato Cre reporter line also
obtained from Jax Labs (#007909). Wild-type and mutant mice received intraperitoneal injections
of 0.075mg/g bodyweight of tamoxifen once a day at P15 and P16, as described previously (562).
Mice were weighed once a week and harvested at either 2 months of age, 10 months of age, or
at the end-stage. End-stage was defined by loss of ~10% of their bodyweight within one week
(see Figure 7.3E).
Behaviour analyses
Food intake
To study food consumption, wild-type and mutant 4-week old mice were provided an ad libitum
liquid food diet, AIN-76 (Bio-Serv, #F1268). This diet consisted of 180 kcal/L protein, 125 kcal/L
fat, and 695 kcal/L carbohydrates. Food was dispensed in graduated feeding tubes (Bio-Serv
#9019), and food intake was measured once a week.
Home cage activity
Wild-type and mutant male mice were singly housed in Phenotyper cages (Noldus) for 48 hours
to habituate. The cage was provided with sawdust, a cotton nestlet and a hut. Moreover, mice
had ad libitum access to water and food. After the habituation period, movements of mice were
recorded and analyzed for either two or 24 hours using the Ethovision software (Noldus).
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Tail suspension test
Mice were suspended in the air by the base of their tail for 30 seconds once a week, while their
limb movements were recorded. Scoring of the videos was done as follows: no clasping (score
0), forelimb clasping (score 1), unilateral hindlimb clasping (score 2), bilateral hindlimb clasping
(score 3), fore- and hindlimb clasping (score 4). The highest score obtained within 30 seconds
was documented for each mouse.
Gait analysis
The right hindlimb of 10-month old wild-type (N=5) and mutant male mice (N=7) were shaven
before the gait analysis. They were then placed on a level-ground, motor-driven treadmill (EXER
3/6 treadmill), which was set to 9 cm/s. The gait was recorded at 250 frames per second using
OptiTrack Motive software (version 2.1.1). Markerless pose-estimation software (DeepLabCut)
was then used to extract sagittal plane angular displacement in degrees of the shaved right
hindlimb, during six consecutive step cycles.
CT-scan
10-month old mice were anesthetized with isoflurane and placed in the IVIS SpectrumCT (Perkin
Elmer) for microCT analysis. 3D Slicer was then used to obtain sagittal plane images of the
skeleton. Cobbs angle was determined by calculating the angle of intersection between two lines
drawn perpendicular to the base of the T7 and L4 vertebrae.
Transcardial perfusion
Wild-type and mutant mice were anesthetized with isoflurane, followed by transcardial perfusion
with 0.125M NaCl as described in Chapter 3. Tissues were then harvested and placed in 200uL
Trizol for RNA extraction. For histological analyses, mice were perfused with 4%
paraformaldehyde (PFA). Tissues were then harvested and incubated overnight at 4°C in 4%
PFA. Brains were then sectioned into 50um sections on the vibratome, Spinal cord and skeletal
muscles were washed in PBS, followed by cryoprotection in 30% sucrose in PBS at 4°C for two
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nights. Afterwards, they were incubated in half 30% sucrose/half OCT compound (Fisher
Scientific, #23-730-571) overnight at 4°C, and embedded in OCT compound for sectioning on a
cryostat.
Immunofluorescence
All immunofluorescence analysis performed in this chapter used the same protocol. Briefly, after
hydration, sections were washed 3x in 1X PBTS, followed by an hour blocking in 1X PBTS.
Primary antibody was then diluted in 1X PBTS and added to the tissue for overnight incubation at
4°C. This was followed by 10x 1 PBTS washes, a 3-hour incubation of the tissue with secondary
antibodies at room temperature, and five more 1X PBTS washes. After a few 1X PBS washes,
the slides were then mounted with Prolong Antifade Gold (ThermoFisher #P36930). 50um coronal
brain sections were incubated with primary antibodies against NeuN (1:200). Moreover, 30um
transverse frozen sections of the lumbar spinal cord were incubated with primary antibodies
against NeuN (1:200) and ChAT (1:300). Finally, 30um sagittal frozen sections of skeletal muscle
were incubated with primary antibodies against SV2 (1:50) and 2H3 (1:100), as well as alphabungarotoxin (1:500).
Nissl staining
50um brain sections were collected at 200um intervals on slides coated with 0.5% gelatin/0.05%
chromium potassium sulfate. Slides were then rinsed in water, dehydrated in ethanol and
incubated twice in toluene for 2 minutes. Afterwards, slides were rehydrated and incubated in
cresyl violet for 3 minutes. Finally, slides were dehydrated again and washed three times with
toluene before cover slipping.
Transmission electron microscopy
10-month old wild-type and mutant mice were transcardially perfused with 2% PFA + 3%
glutaraldehyde in 0.1M sodium cacodylate buffer pH 7.4. Quadriceps were dissected and placed
in immersion fixative overnight at 4°C, followed by 3 rinses in 0.1M sodium cacodylate buffer
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pH7.4. The tissue was then incubated in 1% osmium tetroxide in 0.1M sodium cacodylate + 1%
ferrocyanide pH7.4 for five hours at room temperature. After a water rinse, the samples were
stained in 1% aqueous uranyl acetate for two hours and dehydrated in ethanol. Finally, the tissue
was incubated in a mixture of 50% propylene oxide/50% resin for one hour, followed by incubation
in 20% propylene oxide / 80% resin for 24 hours. Once the tissue was embedded in resin, the
block was sectioned on an ultramicrotome (Leica Ultracut UCT) with a diamond knife. Sections
were collected on a 100um copper mesh grid and then imaged using transmission electron
microscopy (FEI Tecnai 12 G2 Spirit BioTWIN) at 6300X and 11000X magnification.
RNA extraction and cDNA preparation
Total RNA was extracted from 2-month old wild-type and mutant mice and converted to cDNA as
described previously (see section 3.4).
PCR
PCR
The presence of the U11 floxed and KO allele in different tissues of wild-type and mutant mice
was determined using primers flanking the loxp sites (Figure 7.1). For each reaction, 25ng of
genomic DNA was used.
qRT-PCR
To determine U11 snRNA levels, quantitative RT-PCR was performed on 25ng cDNA from wildtype and mutant tissues. Cq values were normalized to the expression of non-coding RNA Rn7sk.
Image acquisition and quantification
Brain sections stained with Nissl or NeuN were imaged on Keyence BZ-X710 at 20X magnification
and were stitched using the Keyence software. Spinal cord and skeletal muscle sections were
imaged using a Leica SP2 confocal microscope. In all cases, the same settings were used for
wild-type and mutant sections. NeuN quantification of brain sections was performed using
ImageJ, while quantification of spinal cord and muscle sections was done using the spot tool in
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the Imaris software (Bitplane). Sections stained with Nissl were imaged with an Axio2 Zeiss
microscope. Stereo investigator (MBF Bioscience) was then used to determine the volume of the
motor cortex. Next, stereology was used to determine the total number of Nissl+ cells in the motor
cortex. To quantify the number of upper motor neurons, ImageJ was utilized.
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7.5 Figures and tables

Figure 7.1. CAG-Cre mediated ablation of Rnu11 partially reduces U11 snRNA levels.
(A) Experimental design for Cre-mediated ablation of Rnu11. (B) Image of tdTomato expression
in paws and snout of P21 mutant mice. (C) Schematic of U11 floxed and KO allele with location
of primers used to determine presence of KO allele in 2-month old wild-type (WT) and mutant
(Mut) mice. (D) qRT-PCR results for U11 snRNA expression in 2-month old WT and mutant mice.
Significance was determined by two-tailed Student’s t-test. N.s.=not significant; *=P<0.05.
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Figure 7.2. U11 cKO mice die early.
(A) Images of wild-type (WT) and mutant (Mut) mice across time. (B) Kaplan-Meier survival curve
of WT and Mutant mice. Significance was determined with a log rank test.
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Figure 7.3. U11 cKO mice are hyperactive and fail to gain weight.
(A) Weight gain kinetics of wild-type (WT) and mutant (Mut) male and female mice. (B) Line graph
with amount of liquid food consumed by WT and Mut male mice. (C) Representative heatmap and
traces reflecting movements of WT and Mut 10-week old male mice in a 2-hour time span. (D)
Line graph showing distance travelled by WT and Mut male mice in a 2-hour time span. (E) Line
graph with weight reduction of mutant mice in the weeks before their death. Significance in (A-D)
was determined by two-tailed Student’s t-test. Significance in (E) was determined by one-way
ANOVA, followed by post-hoc Tukey test. N.s.=not significant; *=P<0.05; **=P<0.01.
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Figure 7.4. U11 cKO mice are hyperactive during dark cycle.
(A) Representative traces of movements from 4-month old wild-type (WT) and mutant (Mut) male
mice during a three-hour time span. (B) Line graph with activity of WT and Mut male mice during
a 24-hour cycle. Grey box reflects the time of the dark cycle. Significance was determined by twotailed Student’s t-test. n.s.=not significant; *=P<0.05.
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Figure 7.5. U11 cKO mice experience motor defects.
(A) Representative images of clasping scores. FL=forelimb; HL=hindlimb. (B) Line graph with
clasping scores of wild-type (grey) and mutant (blue) mice over time. Significance was determined
by Student’s t-test. (C) Snapshots of wild-type (WT) and mutant (Mut) 10-month old mice walking
on motorized treadmill. K= knee angle; a=ankle angle. (D) Knee and ankle angular displacements
during the step cycle of 10-month old WT and Mut mice. Data represent mean±SEM. (E) Boxplots
representing 5th-95th percentile of peak knee and ankle flexion angles across six consecutive
steps in WT and Mut mice. (F) Boxplots representing 5th-95th percentile of angular displacement
during knee and ankle excursion in WT and Mut mice. Significance in (E) and (F) was determined
by Mann-Whitney U-test. *=P<0.05; **=P<0.01; ***=P<0.001.
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Figure 7.6. Loss of U11 results in upper motor neuron degeneration.
(A) Coronal sections of end-stage wild-type (WT) and mutant (Mut) mice stained with Nissl.
Primary (M1) and secondary (M2) motor cortex are outlined in black. (B-C) Bargraphs with motor
cortex volume (B) and number of Nissl+ cells in motor cortex (C) in end-stage WT and Mut mice.
(D-E) Immunofluorescence for NeuN on coronal sections of end-stage WT and Mut motor cortex
(D) with quantification (E). (F-G) Bargraphs with number of large (≥100um) Nissl+ cells in the
motor cortex of 2-month old (F) and end-stage (G) WT and Mut mice. (H-I) Image of Nissl-stained
motor cortex of end-stage WT and Mut mice showing lamination defects (H) with quantification of
layer thickness (I). Significance was determined by Student’s t-test. n.s.=not significant; *=P<0.05.
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Figure 7.7. U11 loss results in loss of lower motor neurons.
Immunofluorescence for ChAT and NeuN on transverse sections of lumbar spinal cord from 10month old wild-type (WT; grey) and mutant (Mut; blue) mice with quantification. White arrows
point at alpha-motor neurons. Significance was determined by Student’s t-test. n.s.=not
significant; *=P<0.05.
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Figure 7.8. Loss of U11 results in muscle atrophy and abnormal mitochondrial
morphology.
(A-B) Immunofluorescence for SV2, 2H3 and alpha-bungarotoxin (aBTX) on gastrocnemius of 2month old mutant mouse (A) with quantification of denervated neuromuscular junctions (NMJs)
(B). (C) Bargraph with gastrocnemius weight of 10-month old wild-type (WT) and mutant (Mut)
male mice. (D-E) Transmission electron micrographs of 10-month old WT and Mut quadriceps
showing abnormal mitochondrial morphology. White arrows in (D) point at mitochondria. White
arrow in (E) points at leaking outer membrane of mitochondrion. Asterisk shows mitochondrial
vacuolization. Significance was determined by Student’s t-test. *=P<0.05.
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Figure 7.9. U11 cKO mice are kyphotic.
Sagittal plane views of microCT scans of 10-month old wild-type (WT) and mutant (Mut) mice with
quantification of Cobb’s angle (α). Significance was determined by Student’s t-test. *=P<0.05.
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Figure 7.10. Model for minor intron splicing disruption in ALS caused by FUSP525L.
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Chapter 8 Conclusions
Studying minor spliceosome function requires information on its targets, the minor introns. While
a comprehensive set of minor introns was identified in 2006, no update was made since, despite
the several revisions of genome annotations that have occurred in the meantime (14, 15).
Therefore, in Chapter 3, I employed position-weight matrices to identify minor introns in the
current mouse and human genome. This analysis led to an increase of approximately 150 introns
in the number of minor introns that had been identified until then (Figure 3.1). To analyze their
splicing across different tissues, I next developed bioinformatics pipelines customized to study
minor intron splicing (Figure 3.6). This revealed that minor intron splicing is regulated at a tissuespecific level. Specifically, highly proliferative tissues, such as bone marrow, thymus and testis
showed high levels of minor intron retention, as well as alternative splicing around minor introns
(Figure 3.7, 3.9, 3.12, 3.14, 3.15). Additionally, we found that minor introns are not always retained
at a higher level than the flanking major introns at steady-state (Figure 3.11). Together, these
results suggest that minor intron splicing is not a stochastic event, but instead can be highly
regulated.
The differences in minor intron splicing efficiency and MIG expression across different
tissues, led me to interrogate what tissues would be most affected when the minor spliceosome
is inhibited. So far, five different diseases have been linked to pathogenic variants in minor
spliceosome components (144, 145, 157, 164-166). In Chapter 4, I analyzed the symptoms that
are associated with each of these minor spliceosome-related diseases. I found that common
symptoms included microcephaly, short stature and intrauterine growth retardation (Figure 4.1). I
then identified a subset of MIGs that results in similar symptoms when mutated, suggesting that
their aberrant expression might underlie the symptomology of minor spliceosome-related
diseases (Figure 4.3). Mutation in these MIGs, and specifically within the splice sites of minor
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introns, commonly affected the nervous system, thus highlighting the importance of minor
spliceosome function for the CNS (Figure 4.2, 4.4, Table 4.2).
To understand how disrupted minor intron splicing affects the CNS, we next developed a
conditional knockout mouse for U11 snRNA in Chapter 5. We found that loss of U11 resulted in
microcephaly, as is observed in individuals with pathogenic variants in other minor spliceosome
components (Figure 4.1, 5.1D). The molecular mechanisms underlying this microcephaly was the
mis-splicing of minor introns in genes that regulate cell cycle (Figure 5.7, 5.8). Consequently,
radial glial cells observed defects in S-phase and prometaphase/metaphase progression, as well
as in cytokinesis (Figure 5.7). In addition, we found elevated minor intron retention in MIGs
involved in the DNA damage response, which particularly affected radial glial cells (Figure 5.6).
In all, we found that a combination of cell cycle defects and DNA damage resulted in p53-mediated
apoptosis of self-amplifying radial glial cells (Figure 5.5, 5.6). Thus, these results further refine
the tissue-specificity that I had previously observed in Chapters 3 and 4.
The widespread minor intron retention observed in Chapter 5 proved that U11 snRNA is
an essential component of the minor spliceosome. However, not all minor introns were retained
upon U11 loss (Figure 5.7). Therefore, in Chapter 6, I analyzed the effect of U11 loss on the
alternative splicing of minor introns. I found that many exons flanking the minor intron were
skipped in the U11-null dorsal telencephalon, suggesting that the presence of U11 acts as a
splicing activator (Figure 6.2). I then observed that inhibition of other minor spliceosome
components resulted in similar upregulation of exon skipping (Figure 6.4). We detected the
resulting aberrant transcripts in polysomes, suggesting that they are translated and contribute to
disease pathogenesis (Figure 6.7). Indeed, we also detected these aberrant MIG transcripts in
individuals with minor spliceosome-related diseases (Figure 6.11, 6.12). This suggests that the
minor spliceosome normally interacts with the major spliceosome to promote the use of splice
sites flanking exons, such that the exon is included. I found that this interaction is mediated by
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U11/U12-59K, which can bind to SR proteins and the U2AF complex, as predicted by the exondefinition model (Figure 6.6). Inhibition of the minor spliceosome probably disrupts these
interactions, thereby resulting in exon skipping.
Finally, in Chapter 7, we examined the role of the minor spliceosome in another part of
the CNS. In 2016, minor spliceosome inhibition was identified as a potential mechanism
underlying amyotrophic lateral sclerosis caused by mutations in the nuclear localization signal of
FUS (Figure 7.10) (498). As a result of these mutations, FUS aggregates in the cytoplasm and
sequesters RNAs and proteins that it normally only transiently interacts with. One of these RNAs
was identified as U11 snRNA, which was therefore reduced in the nucleus (498). This toxic gainof-function of FUS was thought to contribute to the pathogenesis of ALS. To test whether the loss
of nuclear minor spliceosome components would indeed contribute to the degeneration of upper
and lower motor neurons, we therefore ablated U11 snRNA ubiquitously (Figure 7.1). We found
that most of the phenotypes observed in other ALS mouse models, such as motor impairment,
early death and motor neuron loss, were all recapitulated in the U11 cKO mice (Figure 7.2, 7.57.7). While the MIGs, whose aberrant expression results in these phenotypes, still need to be
identified, these results suggest that disrupted minor intron splicing can also contribute to ALS
pathogenesis.
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Chapter 9 Implications and future directions
Analysis of the shared symptoms in individuals with minor spliceosome-related diseases in
Chapter 4 revealed that inhibition of the minor spliceosome generally results in reduced growth
rates, skeletal defects, particularly in limbs, and neurological defects such as microcephaly and
intellectual disability (Figure 4.1). This suggests that minor intron splicing is essential for
regulating growth, and the development of limbs and the nervous system. Indeed, inhibition of the
minor spliceosome in Arabidopsis thaliana has been shown to result in a reduction of the plant’s
size (133-135). Additionally, we found in Chapter 7 that ubiquitous ablation of U11 snRNA resulted
in reduced body weight and a generally smaller mouse (Figure 7.2). Recently, the role for the
minor spliceosome in limb development was also established, when Kyle Drake from the Kanadia
lab ablated U11 snRNA in the developing limbs using Prrx1-Cre (563). Finally, I showed in
Chapter 5 that minor intron splicing is necessary for proper nervous system development.
Specifically, loss of U11 snRNA in the dorsal telencephalon resulted in microcephaly, a common
symptom observed in individuals with MOPD1, Roifman syndrome, Lowry-Wood syndrome and
IGHD (Figure 5.1D, Table S3). Thus, these data confirm the importance of minor spliceosome
function for limb development, nervous system development and general organismal growth.
However, these data also raise the question as to why other tissues are less susceptible to minor
spliceosome loss.
The minor spliceosome snRNAs and proteins are ubiquitously expressed, and pathogenic
variants in these components are therefore predicted to result in systemic inhibition of the minor
spliceosome (564). Regardless, certain tissues seem to have a higher propensity for
developmental defects than others do. In order to understand whether tissue-specific expression
of MIGs or tissue-specific splicing of minor introns might contribute to this higher propensity, I
performed RNAseq analysis of different mouse and human tissues in Chapter 3. This revealed
that minor intron splicing and expression of MIGs is indeed regulated in a tissue-specific manner
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(Figures 3.2, 3.7, 3.12). However, at steady-state, the highest level of minor intron mis-splicing
was observed in the bone marrow, spleen, testis and thymus (Figures 3.7, 3.9, 3.12, 3.15). Thus,
this does not explain the enrichment of neurological defects in minor spliceosome-related
diseases. Since most of these minor spliceosome-related disorders are congenital, analysis of
minor intron splicing in embryonic tissues might provide more insight into why the nervous system
is so susceptible to minor spliceosome inhibition.
Even within the nervous system, we found that loss of U11 snRNA had a differential effect
on different cell types. In Chapter 5 we found that disruption of minor intron splicing especially
affected the survival of self-amplifying RGCs, while IPCs and neurons were less affected (Figures
5.4-5.7). Moreover, in Chapter 7 we observed that ubiquitous loss of U11 snRNA had a
disproportionally large effect on the survival of motor neurons (Figures 7.6-7.7). To truly
understand these cell-type specific differences to minor spliceosome inhibition, minor intron
splicing should ultimately be analyzed in these cell populations at a single-cell resolution.
However, since the analysis of (alternative) splicing remains complicated at the single-cell level,
fluorescence-activated cell sorting (FACS) followed by bulk RNAseq might be an alternative. To
this end, we have crossed a Mapt-eGFP allele into our Rnu11Flx/Flx::Emx1-Cre+::tdTomato+/- mice
that will allow us to isolate GFP +/tdTomato+ neurons and GFP-/tdTomato+ NPCs from the dorsal
telencephalon (565). RNAseq of these wild-type and U11-null populations might reveal the
differences in splicing and/or expression of MIGs that make NPCs so highly susceptible to minor
spliceosome inhibition. Moreover, we have crossed our Rnu11Flx/Flx::CAG-CreERT2+ mice to a
transgenic Thy1-YFP-H mouse line, which marks the cell bodies and entire nerve terminals of
upper motor neurons in layer V and most neurons in the spinal cord (566). FACS of the YFP+
cells in wild-type and mutant mice might provide more insight into the molecular defects that cause
these motor neurons to be so susceptible to disrupted minor intron splicing.
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One surprising finding was that inhibition of the spliceosome did not affect the splicing of
all minor introns that I identified in Chapter 3, but only a subset (Figures 3.1, 5.6, 5.7, 6.2). For
instance, in Chapters 5 and 6 we found that loss of U11 in the developing cortex resulted in the
retention of 299 minor introns, the alternative splicing of 49 minor introns and the differential
expression of only one MIGs. A similar percentage of minor introns were aberrantly spliced in
PBMCs from individuals with RS and LWS (Figures 6.10, 6.12).This partial disruption of minor
intron splicing has previously been reported by other groups and may be explained in several
different ways that are not necessarily mutually exclusive (ref). First, RNAseq of the mutant dorsal
telencephalon revealed that U11 snRNA was downregulated by ~75% (Figure 5.6B). Similarly, it
is thought that pathogenic variants in RNU4ATAC, resulting in MOPD1, RS and LWS are
hypomorphs (145). Thus, it is possible that residual activity of the minor spliceosome was
sufficient to properly splice a subset of minor introns. Another option might be that the use of
consensus sequences at the 5’SS, BPS and 3’SS in Chapter 3 was not sufficient to identify a
‘true’ minor intron. Even though I have not been able to identify any characteristics that distinguish
minor introns that did and did not respond to minor spliceosome inhibition, this does not negate
the possibility that such a feature exists. Charles Schwoerer from the Kanadia lab is currently
trying to solve this conundrum through the identification of minor introns in other eukaryotic
genomes. Orthologous mapping of minor introns across species, in combination with results from
RNAseq experiments performed on these different species where the minor spliceosome is
inhibited, may provide more insight into the definition of a ‘true’ minor intron. Finally, another
possibility is that while U11 snRNA has been established as a crucial component of the minor
spliceosome, its role can be substituted by other components in its absence. For instance, SR
proteins may aid in the identification of the 5’SS of minor introns when U11 is lost, as these have
been shown to recognize the 5’SS of major introns in absence of U1 snRNA (567). This
hypothesis could be tested by incubation of the Mlst8 splicing reporter from Chapter 6 in nuclear
extract from the U11-null dorsal telencephalon. Examining the splicing patterns in response to
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supplementation of different SR proteins may elucidate which ones can substitute for U11 snRNA.
Regardless, to identify the introns that are truly regulated by the minor spliceosome, CLIPseq of
minor spliceosome proteins such as U11/U12-48K, which has been shown to contact the 5’SS of
minor introns, or U11/U12-59K, which we showed regulates AS around minor introns, will be
necessary (Figure 6.6) (113).
Similarly, it remains enigmatic that the retention and AS of minor introns, while resulting
in transcripts with premature stop codons that are predicted to undergo NMD-mediated
degradation, does not result in downregulation of MIGs (Figures 5.6, 5.7, 6.7). It is possible that
compensatory AS changes occur at other locations in the pre-mRNA transcript that allow for the
maintenance of the ORF. Since Illumina sequencing results in reads of 150bp, we have not been
able to interrogate this option at a large scale. Therefore, full-length RNA sequencing with a
platform such as PacBio must be performed to comprehensively evaluate the splicing of MIGs.
Then, to test whether these aberrant MIG transcripts are actual NMD targets, the minor
spliceosome can be inhibited in cell culture using morpholinos against snRNAs, or siRNAs against
minor spliceosome-specific proteins. If aberrant MIIG transcripts are indeed NMD targets, then
inhibition of NMD with cycloheximide should result in increased levels of these transcripts. A
similar approach has already been employed to show that aberrant MIG transcripts can be
degraded by the nuclear exosome (126). The fact that so few MIGs are downregulated raises the
possibility that exosome-mediated degradation and the NMD pathway are compromised upon
minor splicing inhibition. After all, several components that play a role in these pathways contain
minor introns and require the minor spliceosome for their proper expression (494-496).
Regardless of the mechanism by which these MIG transcripts escape degradation, their
translation into proteins may be toxic to the cell if they exert a dominant negative effect. Indeed,
this is supported by our findings in Chapter 6, where we observed that aberrant MIG transcripts
are bound in polysomes and that overexpression of the alternatively spliced Dctn3 transcript
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affects RGC divisions (Figures 6.7, 6.8). To determine whether these isoforms are indeed
translated and play a role in the pathogenesis of minor spliceosome-related diseases, LC-MS/MS
must be performed on PBMCs from individuals with RS, LWS or EOCA.
Finally, an important gap in our knowledge remains the structure of the minor spliceosome.
While the components of the minor spliceosome have been identified for over 20 years, most of
the steps of the minor splicing reaction have been extrapolated from the major splicing pathway
(98, 99, 101). This is an understandable assumption, as the minor spliceosome snRNAs share
similar secondary structures as those of the major spliceosome, and many proteins are shared
between the spliceosomes (98, 99, 101). However, U11 and U12 exist as a di-snRNP, and the
function of several of these protein components, as well as the identity of interactors remains
unexplored (106). In Chapter 6, I identified a role for U11/U12-59K in the exon-definiton
interactions between the major and minor spliceosome (Figure 6.6). However, the specific protein
domains of U11/U12-59K required for these interactions remain unknown. Moreover, cryoelectron microscopy structures of spliceosome complexes are restricted to the major
spliceosome, and thus crucial information on minor spliceosome assembly is lacking. Availability
of these structures for the minor spliceosome might also provide insight into how inhibition of
U4atac and U6atac can affect exon-definition interactions. Finally, the binding of the minor
spliceosome with other splicing factors needs to be further examined. For instance, it is currently
unknown how FUS interacts with U11 snRNP, both normally, as well as in the case of cytoplasmic
aggregation of FUS. Given the relevance of these interactions in disease pathogenesis of ALS,
insight into these structural relationships might open avenues for new therapeutics.
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Chapter 11 List of Common Abbreviations
ALS=amyotrophic lateral sclerosis
AS=alternative splicing
BPS=branch point sequence
CC3=cleaved caspase 3
CP=cortical plate
EOCA=early onset cerebellar ataxia
FPKM=fragments per kilobase per million mapped reads
IGHD=isolated growth hormone deficiency
IPC=intermediate progenitor cell
IZ=intermediate zone
LWS=Lowry-Wood syndrome
MIDB=Minor Intron DataBase
MIG=minor intron-containing gene
MO=antisense morpholino oligonucleotide
MOPD1=microcephalic osteodysplastic primordial dwarfism type I
MS=mass spectrometry
MSI=mis-splicing index
MZ=marginal zone
NLS=nuclear localization signal
NMD=non sense-mediated decay
NMJ=neuromuscular junction
NPC=neural progenitor cell
ORF=open reading frame
PBMC=peripheral blood mononuclear cell
PCA=principal component analysis
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PPT=polypyrimidine tract
PWM=position weight matrix
RGC=radial glial cell
RS=Roifman syndrome
siRNA=small interfering RNA
SMA=spinal muscular atrophy
snRNA=small nuclear ribonucleic acid
snRNP=small nuclear ribonucleic protein
SR=serine/arginine-rich
SS=splice site
SVZ=subventricular zone
TPM=transcripts per million mapped reads
VZ=ventricular zone
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Chapter 12 Supplementary Figures and Tables
Table S1. Significant functional enrichments for tissue Up- and DownSignatures.
Tissue
Signature
Bone_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Cerebrum_UpSig
Testis_UpSig
Testis_UpSig
Testis_UpSig
Liver_DownSig
Liver_DownSig
Liver_DownSig
Liver_DownSig
Liver_DownSig
Liver_DownSig

GO-Term Name
Calcium Ion Binding
Voltage-Gated Sodium Channel Complex
Phosphatidylinositol Phospholipase C Activity
Ion Channel Activity
Voltage-Gated Ion Channel Activity
Voltage-Gated Calcium Channel Activity
Voltage-Gated Sodium Channel Activity
Calcium Channel Activity
Sodium Channel Activity
Voltage-Gated Calcium Channel Complex
Ion Transport
High Voltage-Gated Calcium Channel Activity
Neuronal Action Potential
Sensory Perception Of Pain
Dendrite
Sodium Ion Binding
Sodium Channel Complex
Regulation Of Ion Transmembrane Transport
Neuronal Cell Body
Transmembrane Transport
Membrane Depolarization During Action Potential
Centriole
Cilium
Cilium Assembly
Voltage-Gated Ion Channel Activity
Voltage-Gated Calcium Channel Activity
Calcium Channel Activity
Centrosome
Voltage-Gated Calcium Channel Complex
Cilium Assembly

Benjamini
7.54E-04
4.53E-06
1.44E-02
1.93E-06
4.03E-06
9.84E-05
6.67E-06
1.47E-03
3.95E-02
2.36E-05
6.90E-04
7.33E-05
1.14E-04
1.30E-04
4.20E-03
3.37E-06
3.50E-03
8.24E-06
3.17E-04
1.98E-04
1.73E-10
1.55E-03
8.49E-05
6.25E-03
2.56E-03
2.00E-04
2.51E-02
1.58E-04
2.01E-05
1.55E-03
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Table S2. Mapping statistics for RNAseq datasets analyzed in Chapter 3.
Sample
P53_Cerebrum_WT_rep4
P53_Cerebrum_WT_rep5
P53_Cerebrum_WT_rep6
p53_Spleen_WT_rep2
p53_Spleen_WT_rep4
p53_Spleen_WT_rep5
p53_Liver_WT_rep2
P53_Liver_WT_rep6
P53_Liver_WT_rep7
p53_Thymus_WT_rep3
p53_Thymus_WT_rep4
p53_Thymus_WT_rep5
p53_Lung_WT_rep3
p53_Lung_WT_rep5
p53_Lung_WT_rep6
p53_Kidney_WT_rep2
p53_Kidney_WT_rep3
p53_Kidney_WT_rep5
p53_Heart_WT_rep2
p53_Heart_WT_rep3
p53_Heart_WT_rep6
p53_Testis_WT_rep2
p53_Testis_WT_rep3
p53_Testis_WT_rep6
p53_Muscle_WT_rep2
p53_Muscle_WT_rep5
p53_Muscle_WT_rep6
p53_Bone_WT_rep3
p53_Bone_WT_rep4
p53_Bone_WT_rep5
p53_BoneMarrow_rep4
p53_BoneMarrow_rep6
p53_BoneMarrow_rep7
Bonemarrow_1
Bonemarrow_2
Bonemarrow_3
Bonemarrow_4
cerebralcortex_1
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# read
# uniquely
% overall
% aligned
pairs
mapped read pairs alignment rate once
33107295
26138450
95.78
78.95
33164653
22928130
96.16
69.13
33019648
26014519
95.77
78.78
34457263
26853102
95.16
77.93
31827264
24916056
95.18
78.29
32481582
25294194
95.19
77.87
33170936
21945761
92.72
66.16
32029852
21209769
92.39
66.22
31601305
21709594
92.95
68.7
29384620
21268435
92.77
72.38
29500235
21241918
92.76
72.01
30180243
21680760
92.64
71.84
29172989
21078394
93.56
72.25
29154927
20937279
92.96
71.81
29068569
20642292
92.59
71.01
33052082
21364757
91.96
64.64
29616387
18725555
92.11
63.23
30674265
19870092
92.17
64.78
30818583
18327300
90.4
59.47
32613001
19236934
89.95
58.99
32396154
18721565
90.56
57.79
32876264
26499055
94.8
80.6
31712609
25411522
94.57
80.13
32280344
25883600
94.75
80.18
35563925
25074129
96.21
70.5
35992452
25521001
95.9
70.91
33503351
23994894
95.91
71.62
40319548
32649604
95.69
80.98
39576581
31889713
95.63
80.58
43450344
34970513
95.72
80.48
30112113
18477249
94.42
61.36
32624188
19637883
94.14
60.19
30268547
18366915
94.01
60.68
29688296
21251765
83.62
71.58
32812930
22288707
84.69
67.93
34645079
24944578
86.91
72
34136154
23469406
84.58
68.75
28466648
18317380
78.07
64.35

Sample
cerebralcortex_2
cerebralcortex_3
heart_1
heart_2
heart_3
heart_4
kidney_1
kidney_2
kidney_3
kidney_4
liver_1
liver_2
liver_3
lung_1
lung_2
lung_3
lung_4
lung_5
spleen_1
spleen_2
spleen_3
spleen_4
testis_1
testis_2
testis_3
testis_4
testis_5
testis_6
testis_7

# read
pairs
24323755
17585264
28894943
33292059
35113905
30478769
16450970
24572266
12164943
18261280
30478994
12225037
22811186
25354832
29340443
17543394
12668427
27245050
26648704
24108091
24473462
27044102
17690315
35915919
32054218
39007238
33605790
44085084
44436072

# uniquely
mapped read pairs
15872192
10796237
19469786
24800439
24347454
21061336
8645949
12298685
7106419
10459551
20637174
8659087
12814154
16175337
19221019
9832680
6033270
15773757
17087412
14577701
15293330
17600355
11492475
25314884
22879288
24843334
24691973
31837270
31742795

% overall
alignment rate
78.96
80.55
82.57
86.56
84.09
83.96
81.42
80.46
78.37
78.51
85.85
87.15
79.84
76.64
79.18
67.66
54.06
69.08
77.75
74.16
76.03
78.85
75.31
82.58
84.31
75.25
86.04
84.83
84.51

% aligned
once
65.25
61.39
67.38
74.49
69.34
69.1
52.56
50.05
58.42
57.28
67.71
70.83
56.17
63.8
65.51
56.05
47.62
57.9
64.12
60.47
62.49
65.08
64.96
70.48
71.38
63.69
73.48
72.22
71.43

257

Table S3. Frequency of symptoms observed in minor spliceosome-related diseases.
Number of reported cases
References

Microcephaly
Short stature
Intrauterine growth retardation
Aplasia/Hypoplasia of the corpus callosum
Abnormality of the nose
Sparse scalp hair
Proptosis
Abnormality of the pinna
Sloping forehead
Abnormal cortical gyration
Brachydactyly
Flexion contracture
Abnormal bone ossification
Dry skin
Abnormality of the mandible
Abnormal location of the ears
Global developmental delay
Short femur
Micromelia
Abnormality of the hip bone
Enlarged metaphyses
Thin eyebrow
Aplasia/Hypoplasia involving bones of the
hand
Abnormality of the cerebellar vermis
Hypoplasia of the frontal lobes
Short humerus
Abnormality of the calvaria
Abnormality of the neck
Oligohydraminos
Premature birth
Femoral bowing
Seizures
Delayed skeletal maturation
Abnormal form of the vertebral bodies
258

MOPD1
RS
49
14
(145,
(157,
148159150,
162)
154,
155,
229,
230,
568572)

LWS
5
(158,
164,
489,
573)

EOCA
6
(165)

IGHD
3
(166)

47
44
37
35
32
33
31
32
29
29
29
24
25
23
20
20
18
17
19
16
13
14
14

7
12
12
0
9
0
0
0
0
0
12
0
6
0
0
0
10
0
0
1
0
0
8

5
3
0
0
4
1
0
0
3
0
3
2
0
0
0
0
1
0
0
1
0
0
3

0
Some
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Some
0
0
0
0
0
0

2
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

11
11
10
12
11
10
8
10
7
8
7

0
0
0
0
0
0
6
0
2
6
4

0
0
0
0
0
0
2
0
0
2
1

5
0
0
0
0
0
0
0
4
0
0

0
0
0
0
0
0
0
0
0
3
0

Single transverse palmar creases
Small anterior fontanelle
Gray matter heterotopia
Cryptorchidism
Abnormal eyelash morphology
Failure to thrive
Bowed humerus
Hip dislocation
Clinodactyly of the 5th finger
Micropenis
Atrial septal defect
Functional respiratory abnormality
Spasticity
Specific learning disability
Hyperkeratosis
Abnormality of the palpebral fissures
Abnormal renal morphology
Thick vermilion border
Elbow dislocation
Jaundice
Broad distal phalanx of finger
Abnormality of the clavicle
Intellectual disability
Epiphyseal dysplasia
Irregular epiphyses
Postnatal growth retardation
Eczema
Recurrent pneumonia
Recurrent otitis media
Decreased antibody level in blood
Thin upper lip vermilion
Long philtrum
Prominent eyelashes
Hypertelorism
Retinal dystrophy
Spondyloepiphyseal dysplasia
Eosinophilia
Visceromegaly
Ventricular septal defect
Hypergonadotrophic hypogonadism
Small epiphyses
Abnormality of retinal pigmentation
Small for gestational age
Nystagmus
Muscular hypotonia
Cerebellar atrophy
Gait disturbance
Frequent falls

MOPD1
8
7
7
6
6
6
6
6
5
4
5
4
2
3
4
1
3
3
2
5
2
2
1
0
0
5
2
1
1
0
1
1
0
3
2
0
0
0
3
0
0
5
45
3
4
1
1
1

RS
4
0
0
0
0
2
0
0
5
0
0
2
0
0
0
7
0
0
0
4
1
0
5
6
6
5
7
8
5
13
9
9
6
6
9
9
3
9
2
2
0
3
5
0
10
0
0
0

LWS
0
0
0
0
0
0
0
3
3
0
1
0
0
0
0
1
0
4
1
1
0
0
4
5
0
0
1
0
0
1
0
0
0
0
2
0
0
0
0
0
2
1
3
0
0
0
0
1

EOCA
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
5
5
5
5

IGHD
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
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Dysarthria
Poor fine motor coordination
Delayed gross motor development
Intention tremor
Growth hormone deficiency
Obesity
Frontal bossing
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MOPD1
0
1
1
0
0
0
0

RS
0
2
2
0
0
0
0

LWS
0
0
0
0
0
0
0

EOCA
5
6
6
6
0
0
0

IGHD
0
0
0
0
3
3
3

Table S4. Pathogenic variants in minor intron splice sites and associated diseases.
Minor intron
chr11119090266119091412
chr153423397334235180
chr106841510868416708

chrX136033494136040075

chr92706065227062617
chr33862249038630310
chr78195935881959719
chr16340712763411145
chr117811925078121064
chr108786454987894024
chr117720321877204075
chr2166056501166058569

MIG

Pathogenic Affected
Associated disorder
variant
sequence

HMBS

-1G>A

3'SS

Acute intermittent porphyria

SLC12A6

+2T>G

5'SS

Andermann syndrome

DNA2

+6delC

5'SS

Ateleiotic dwarfism; Seckel
syndrome 8

SLC9A6

-19to-3del

3'SS

Autistic disorder of childhood onset;
Pectus excavatum; Esotropia;
Global developmental delay;
Seizures; Short stature; Failure to
thrive; Deeply set eye; Clinodactyly
of the 5th finger; Impaired use of
nonverbial behaviours; Generalized
hypotonia; Chorea; Postnatal
microcephaly; Focal white matter
lesions

IFT74

-1G>T

3'SS

Bardet-Biedl syndrome 20

SCN5A

-1C>T

3'SS

Brugada syndrome

CACNA2D1 -4-3delTT

3'SS

Cardiovascular phenotype

ALG6

-2A>G

3'SS

Congenital disorder of glycosylation
type 1C

ALG8

+1G>A

5'SS

Congenital disorder of glycosylation
type 1H

PTEN

-3C>G

3'SS

Cowden syndrome 1

MYO7A

+3A>G

5'SS

Deafness

SCN1A

+5C>G

5'SS

Early infantile epileptic
encephalopathy
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Minor intron

MIG

chr204605730446057513

SLC12A5

chr191330361413303766

CACNA1A

chrX154478412154478727
chr2227282533227283766
chr1912185011219323
chr1912185011219323
chr108786454987894024
chr108786454987894024
chr5170050398170055304
chr129598086495983910
chr129599482695994932
chr154240999642410427
chr1781746178175756
chr2166306600166306955
chr1912185011219323
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Pathogenic Affected
Associated disorder
variant
sequence
Early infantile epileptic
encephalopathy 34; Epilepsy,
-3C>A
3'SS
idiopathic generalized susceptibility
to, 14
Episodic ataxia type 2;
Spinocerebellar ataxia 6; Familial
-15C>T
BPS
hemiplegic migraine type 1; Epileptic
encephalopathy, early infantile, 42

LAGE3

+1G>A

5'SS

Galloway-Mowat syndrome 2, Xlinked

COL4A3

-1G>T

3'SS

Hematuria; Glomerulopathy

STK11

+1A>G

5'SS

Hereditary cancer predisposing
syndrome

STK11

-11T>C

BPS

Hereditary cancer predisposing
syndrome

PTEN

+3A>G

5'SS

Hereditary cancer-predisposing
syndrome

PTEN

+4T>C

5'SS

Hereditary cancer-predisposing
syndrome

DOCK2

+1G>A

5'SS

Immunodeficiency 40

HAL

+2T>C

5'SS

Increased histidine

HAL

+1G>A

5'SS

Increased histidine

CAPN3

+1G>A

5'SS

Limb-girdle muscular dystrophy type
2A

TMEM107

+1G>A

5'SS

Meckel syndrome 13

SCN9A

+5C>T

5'SS

Pain insensitivity

STK11

+2T>C

5'SS

Peutz-Jeghers syndrome

Minor intron
chr1912185011219323
chr1912185011219323
chr108786454987894024
chr108786454987894024
chr108786454987894024
chr108786454987894024
chr2166056501166058569
chr2166056501166058569
chr7100101773100101879
chrX1371609013716533
chr54180316441805566
chr117720321877204075

MIG

Pathogenic Affected
Associated disorder
variant
sequence

STK11

+3A>G

5'SS

Peutz-Jeghers syndrome

STK11

-13C>T

BPS

Peutz-Jeghers syndrome

PTEN

-1G>C

3'SS

PTEN harmartoma tumor syndrome

PTEN

+5C>G

5'SS

PTEN harmartoma tumor syndrome

PTEN

+7A>T

5'SS

PTEN

+7A>G

5'SS

SCN1A

-1C>G

3'SS

Severe, myoclonic epilepsy in
infancy

SCN1A

+1A>G

5'SS

Severe, myoclonic epilepsy in
infancy; History of
neurodevelopmental disorder

AP4M1

+2T>G

5'SS

Spastic paraplegia 50, autosomal
recessive

TRAPPC2

+4T>C

5'SS

Spondyloepiphyseal dysplasia tarda

OXCT1

-15A>G

BPS

Succinyl-CoA acetoacetate
transferase deficiency

MYO7A

-11A>G

BPS

Usher syndrome type 1

PTEN harmartoma tumor syndrome;
Hereditary cancer-predisposing
syndrome
PTEN harmartoma tumor syndrome;
Hereditary cancer-predisposing
syndrome; Cowden syndrome 1
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Table S5. Mammalian functions of the 21 MIGs regulating cell cycle with significantly elevated minor intron retention the
mutant pallium. P-values were determined by two-tailed student’s t-test. Syns=synonyms, ave=average. MSI=mis-splicing index.
MIG

Ahctf1

Syns

Elys,
Mst108,
Tmbs62

Ccnk

Cpr4,
CycK

Ccnt1

Ccnt,
Cyct1,
Hive1

Cdc45

Cep164

Ave
FPKM
Ctrl

25.97

5.34

16.7

24.4

Nphp15

5.08

Ave
FPKM
Mut

27.7

5.32

19.3

27.8

5.32

Ave
MSI
Ctrl

7.64

5.05

8.40

2.46

5.90

Ave
MSI
Mut

27.5

27.0

16.5

19.2

30.0

MSI
Pvalue

0.0018

0.0046

0.0456

0.0017

0.0004

∆MSI

Cell Cycle Function Description

19.9

in HeLa cells, localizes to nuclear pore and
kinetochores, and RNAi-mediated knockdown causes
cytokinesis defects (PMID: 17098863); required for
nuclear pore assembly (PMID: 17098863); siRNAmediated knockdown in HeLa cells results in
mislocalization of LBR, which is important for reforming
nuclear envelope post-mitosis (PMID: 22555603)

22.0

cyclin K; highly expressed in pluripotent mouse
embryonic stem cells, and knockdown results in
increased cell differentiation (PMID: 22547058);
knockdown of two Cdk partners identified in study
(Cdk12 & Cdk13), enhanced differentiation, suggesting
role in self-renewal (PMID: 22547058)

8.16

normally associates with chromosomes during mitosis,
and mislocalization caused arrest at G1 and apoptosis,
indicating necessary role in transcribing genes during
cell division (PMID: 18292778)

16.7

initiation of DNA replication (PMID: 25933514); recruits
DNA polymerase α-primase (see Prim1 below) to the
DNA replication complex (PMID: 10518787)

24.1

siRNA-mediated knockdown in HeLa cells shows
important role in G2/M checkpoint of cell cycle (PMID:
18283122); in human RPE-FUCCI cells, knockdown
causes shorter G1, G2, and M phases, but reduced
proliferation, slowed S phase, and increased apoptosis
(PMID: 25340510)
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MIG

Syns

Ave
FPKM
Ctrl

Ave
FPKM
Mut

Ave
MSI
Ctrl

Ave
MSI
Mut

MSI
Pvalue

∆MSI

Cgrrf1

Cgr19,
Rnf197

3.37

3.10

7.18

35.1

0.0015

27.9

Dna2

Dna2l

3.92

3.75

4.80

17.4

0.015

12.6

Dctn3

Dctn22,
p22, p24

49.6

41.5

1.65

12.2

0.002

10.5

Dync1li1

Lic1,
Dncli1,
Dnclic1

11.1

11.3

2.30

8.52

0.021

6.22

E2f1

Rbp3,
Rbap1,
Rbbp3

6.06

6.48

12.9

53.2

0.001

40.3

E2f6

E2f6b,
Ema

9.95

8.84

6.96

31.4

0.0006

24.5
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Cell Cycle Function Description
cell growth regulator; transcriptionally upregulated by
p53, and its overexpression suppresses cell
proliferation (PMID: 8968090)
helicase/nuclease; functions in DNA replication & S/G2
phase DNA stability (PMID: 22570476); chromosome
segregation role, based on effect of knockdown (PMID:
23604072)
dynactin necessary for mitosis progression and
chromosome
segregation
(PMID:
25645239,
21163948)
dynein, light intermediate chain 1; knockdown
alongside LIC2 results in misregulation of centriole
cohesion during mitosis (PMID: 25422374); depletion
in human cells causes metaphase delay and increased
interkinetichore distance, suggesting a role in the
spindle assembly checkpoint (PMID: 19229290)
transcription factor induced by cellular stress, including
DNA damage, resulting in apoptosis (PMID:
12717439); target of pRB and complexes with it—
depending on circumstance and cell cycle stage, can
drive either activation or repression (PMID: 20016602,
20224733); however, based on KO mouse studies
(which interrogated E2f1, E2f2, & E2f3), not required
for cell division in embryonic tissues and specific adult
tissues tested, but it is required for DNA integrity and
cell survival (PMID: 20016602); misexpression in
embryonic lens fiber cells causes cell cycle entry and
subsequent apoptosis (PMID: 11095619); AKT is a
target of E2f1 (PMID: 22298593)
Rb-independent transcription repressor that may
repress E2F-responsive genes during S phase; also
interacts with chromatin remodeling complex member
Brg1 on G1/S gene..

MIG

Syns

Ave
FPKM
Ctrl

Ave
FPKM
Mut

Ave
MSI
Ctrl

Ave
MSI
Mut

MSI
Pvalue

∆MSI

Cell Cycle Function Description
… promoters during S phase, suggesting role in G1/S
phase transition (PMID: 23082233); in response to
DNA replication stress, E2f6 replaces activating E2fs
at promoters to repress transcription before G1/S
transition, and dissociation is driven by Chk
phosphorylation of E2f6 (PMID: 23954429)
cyclin G-associated kinase; in Nestin-cre conditional
knockout, observed morphological changes in
ventricular zones (cells less dense) and hypothalamus,
indicating proliferation defects (PMID: 18434600);
siRNA revealed importance of GAK for spindle
assembly and chromosome alignment during mitosis
(arrest during mitosis) (PMID: 20237935)

E2f6

E2f6b,
Ema

9.95

8.84

6.96

31.4

0.0006

24.5

Gak

Dnaj26,
Dnajc26

17.3

19.8

4.88

15.8

0.0012

10.9

Maea

Emp,
Emlp,
Gid9,
Pig5,
Hlc-10

16.3

17.3

1.20

4.79

0.0407

3.59

macrophage erythroblast attacher protein; localizes to
mitotic spindle and contractile ring during
mitosis/cytokinesis (PMID: 16510120)

7.86

sister chromatid cohesion factor required for loading
cohesin onto chromosomes (PMID: 16802858,
16682347); siRNA-mediated knockdown in HeLa cells
disrupted sister chromatid cohesion, resulting in
chromosome
mis-segregation
and
prolonged
prometaphase, at the expense of metaphase and
anaphase (PMID: 16682347)

7.03

centrosomal protein that is required for γ-tubulin ring
complex localization to the centrosome, with
knockdown
causing
defects
in
centrosomal
microtubule nucleation, aberrant mitotic spindles, and
inhibition of centriole duplication (PMID: 16461362)

Mau2

Nedd1

Scc4

Gcp-wd,
Tubgcp7

20.3

23.2

22.1

21.2

1.78

7.73

9.64

14.7

0.0129

0.0263
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MIG

Syns

Ave
FPKM
Ctrl

Ave
FPKM
Mut

Ave
MSI
Ctrl

Ave
MSI
Mut

MSI
Pvalue

∆MSI

Ppp2r2d

Pr55δ,
PP2AB55δ

13.9

11.1

5.06

17.2

0.005

12.2

Prim1

p48, p49

22.8

25.4

4.46

23.1

5E-06

18.6

Rfc5

Recc5,
36kDa,
36.5kDa,
p36

Uba3

Nae2,
Ube1c

Vash1

Zfp207

266

Bugz

22.4

14.6

4.95

12.8

0.0017

7.89

44.7

35.8

2.52

8.48

0.0199

5.96

6.94

6.49

2.45

6.43

0.0212

3.98

74.5

99.3

2.50

11.0

0.0003

8.58

Cell Cycle Function Description
phosphatase regulatory subunit; in cancer cell line,
knockdown enhanced T-cell proliferation and cytokine
production, and inhibited T-cell apoptosis (PMID:
24476824); work in Xenopus suggests PP2a-B55δ
inhibits CDK1 activation, thereby regulating mitosis
entry/exit (PMID: 19696736)
catalytic primase subunit of DNA polymerase αprimase (PMID: 20030400); generates an RNA primer,
followed by primer extension to produce RNA-DNA
primer, to initiate DNA replication (reviewed in PMID:
9759502)
component of the replication factor C complex, which
loads PCNA onto DNA at primer-template junctions or
onto nicked duplex DNA, in turn allowing for DNA
synthesis via DNA polymerase δ (PMID: 9759502)
in KO mouse, observe embryonic lethality ~E7, with
impaired growth of inner cell mass, inability of
trophoblast cells to enter S phase, with ICM cells
undergoing endoreduplication, with dysregulation of
cyclin expression and reduced degradation of Bcatenin (PMID: 11696557)
overexpression in ovarian cancer cells causes
inhibition of vascularization of tumor and of tumor
growth (PMID: 26460696); knockdown in cancer cells,
followed by transplantation into mice led to significantly
increased tumor growth and metastasis (PMID:
25797264)
microtubule-associated
factor
required
for
chromosome alignment in mitosis (PMID: 24462186,
24462187)

Table S6. The DNA damage response functions of 14 MIGs with significantly elevated minor intron retention in the mutant
pallium. Related to Figure 4.6. MSI=mis-splicing index. P-values were determined by two-tailed student’s t-test. Syns=synonyms,
ave=average.
Ave
FPKM
Ctrl

Ave
FPKM
Mut

Ave
MSI
Ctrl

Ave
MSI
Mut

MIG

Syns

Baz1b

Wstf,
Wbscr9,
Wbscr10

21.9

25.9

5.44

12.4

Ccnk

Cpr4,
CycK

55.3

5.32

5.05

27.0

Cep16
4

Cul1

Cul4a

Nphp15

5.06

41.6

11.1

5.32

47.3

12.0

5.90

2.80

3.60

30.0

16.1

15.7

MSI
Pvalue

∆MSI

DNA Damage Response Function Description

0.019

13.9

forms nucleosome remodeling complex with ISWI
(complex: WICH), which phosphorylates and
maintains this phosphorylation of H2AX (ɣH2AX),
thereby regulating important steps in the DNA damage
response process (PMID: 19092802)

0.0046

22.0

cyclin K; when complexed with Cdk9, accumulates on
chromatin in response to replication stress, and ssDNA
in stressed cells (PMID: 20930849)

24.1

centrosomal protein that is phosphorylated by the DNA
damage response proteins ATR and ATM; siRNAmediated knockdown in HeLa cells results in reduced
phosphorylation of multiple DNA damage response
proteins and chromosome missegregation (PMID:
18283122)

13.3

as part of the SCF E3 ubiquitin ligase complex,
ubiquitinates Ku80, a component of the initiating
complex of the NHEJ double-strand break DNA repair
pathway, thereby regulating this complex's removal
from DNA (PMID: 23324393)

12.1

cullin; ubiquitin ligase that targets Ddb1 (another MIG,
below) and Ddb2, both of which act to initiate the DNA
damage response, for ubiquitination and degradation,
thereby regulating the DNA damage response (PMID:
19481525)

0.0004

0.0018

0.0442
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MIG

Syns

Ave
FPKM
Ctrl

DNA Damage Response Function Description

12.6

due to 5’ to 3’ endonuclease activity, involved in
resection extension in homologous recombinationmediated DNA double stranded break repair (PMID:
28718810)

2.24

large subunit of DNA damage-binding complex, which
functions in nucleotide excision repair (PMID:
16951172); loss of Ddb1 in mouse brain results in
accumulation of cell cycle regulators and increased
genomic instability, ultimately causing apoptosis of
proliferating neuronal progenitors (PMID: 17129780)

E2f1

Rbp3,
Rbap1,
Rbbp3

6.06

6.48

12.9

53.2

0.001

40.3

upregulated in response to DNA damage, and
promotes DNA damage-induced apoptosis (PMID:
11459832); indirectly regulates the transcription of the
DNA damage response gene GADD45A (PMID:
20713352)

Ercc5

Xpg

5.36

6.27

1.33

7.64

0.048

6.30

single strand-specific DNA endonuclease involved in
the 3' incision step of nucleotide excision repair (PMID:
7657672)

Exo1

Msa,
Hex1

5.65

5’ to 3’ endonuclease involved in DNA mismatch repair
and resection extension in homologous recombinationmediated DNA double stranded break repair (PMID:
24705021)

9.92

recruited to sites of DNA damage and interacts with
SSB1, a DNA damage sensor recognized by ATM
(PMID: 21659603)
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4.42

8.82

4.14

8.81

3.73

3.59

2.70

9.38

13.5

0.015

∆MSI

Ddb1

0.46

17.4

MSI
Pvalue

XPE,
DDBA,
XAP1,
XPCE

88.3

4.80

Ave
MSI
Mut

Dna2l

86.0

3.75

Ave
MSI
Ctrl

Dna2

Ints7

3.92

Ave
FPKM
Mut

0.004

0.008

0.012

MIG

Syns

Parp1

Parp,
Ppol,
Adprt,
Artd1,
Adprt1

Usp10

UBPO,
Uchrp

Ave
FPKM
Ctrl

47.8

10.6

Ave
FPKM
Mut

47.6

8.05

Ave
MSI
Ctrl

0.77

4.47

Ave
MSI
Mut

14.7

17.2

MSI
Pvalue

0.002

0.012

∆MSI

DNA Damage Response Function Description

13.9

nuclear protein that promotes formation of poly(ADPribose) chains (PARylation), which transfers ADPribose group from NAD+ to target protein and forms a
scaffold around DNA breaks, allowing for recruitment
of essential DNA damage response factors (PMID:
21989215, 22431722)

12.7

after DNA damage, phosphorylated by ATM, resulting
in Usp10 stabilization and transport to the nucleus,
where it deubiquitylates p53, thereby stabilizing p53
(PMID: 20096447)
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Table S7. Primer sequences employed in Chapter 5.
Primer Name
Rnu11 cKO, 5' loxP
Rnu11 cKO, 3' loxP
Hist1h1a
expression
Cre genotyping
Emx1-Cre zygosity,
wild-type
Emx1-Cre zygosity,
mutant
Ai9 tdTomato Cre
reporter, wild-type
Ai9 tdTomato Cre
reporter, mutant
U11 expression
Neat1 expression
Coa3 minor intron
splicing
Pten minor intron
splicing
Parp1 minor intron
splicing
Sfrs10 expression
Spc24 expression
Intergenic primers
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Primer Direction
Forward (primer 1)
Reverse (primer 2)
Forward (primer 3)
Reverse (primer 4)
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse (intronic)
Reverse (exonic)
Forward
Reverse (intronic)
Reverse (exonic)
Forward
Reverse (intronic)
Reverse (exonic)
Forward
Reverse
Forward
Reverse
Forward
Reverse

Sequence (5' to 3')
ACCCTCCCCTACTGTTTTAC
AGGCTGCTACAGGATGACTC
CATGTGTTTGCTGGGAATTG
CTCATGAGGCAGATCTCTGAA
AGAAGAACAACAGCCGCATCAAACTGG
CTTGGACTCAGCCTTCTTGTTCAGCTT
TATCCAGCAACATTTGGGCCAGCT
AACATTCTCCCACCGTCAGTACGTGA
AAGGTGTGGTTCCAGAATCG
CTCTCCACCAGAAGGCTGAG
GATCTCCGGTATTGAAACTCCAGC
GCTAAACATGCTTCATCGTCGG
AAGGGAGCTGCAGTGGAGTA
CCGAAAATCTGTGGGAAGTC
GGCATTAAAGCAGCGTATCC
CTGTTCCTGTACGGCATGG
AAAGGGCTTCTGTCGTGAGTGGC
CCGGGACCAACGATCACCAG
AATTGGCCAGAAGACAACAGGGTTTGC
GTATTCAGTGGCAAAGCACTCATGAGG
CAGTTGCAGTTTATGCGGCAGGTG
CTAGCCACCCTTGCTGTTTTCCCAAA
CAGCTTTGGCTTCATCTTCCAGCTC
CTCCCAGACATGACAGCCATCATCAA
CTACTCCCACGTTATCAGAGTGACAGAA
CAAGTCTTTCTGCAGGAAATCCCATAGC
AAAACCACCCCTGACCCTTCG
GCACACAGCATAGCCAAGAAAGG
AATGTACCTGGGGAGGGCAGTT
AGCAGGTCTTACAGCCGAGATTATCG
CCAAACACGCCAAGACAACAGTTG
CTCATACCTTGCACAGAACTGGGGTT
AATAAAAAAGAAGCTGCAGGCCAGCC
GGATAGTTCATCTCCTGCAGGTCACAAG
GTCCCACCCATCTAGTTTAGCATCAGC

Table S8. Primer sequences employed in Chapter 6
Gene
TCP1
NEPRO
NCBP2
PFDN5
PHB2
VPS35
TGS1
NUP205
E2F3
PSMA1
SNRPE
Nup107
Arpc5l
Fam92a
Spc24
Dctn3
Pdpk1
Lsm5
Mysm1
Dram2
E2f3
Mlst8
Xist
Vps35
Xpo4

Forward primer

Reverse primer

TATCGCTGCCGTCAAGATGGAGG
GCAGTCCTTTACAGCAATCACAACAGA
ATGTCGGGTGGCCTCCTGAAG
GCTAGAAATGCTCAAGAACCAGCTGG
ATCACAGAGCTGAGCTTTAGCCGAGA
GGCTGTGAAGGTCCAGTCATTCCAA
CTGTGGAGTTGGAGGAAATACCATTCAG
GAGCAGCTTCCCCCAGATGAGATA
GGATTTGAACAAGGCAGCAGAAGTGC
TTGCGGGGCTTACTGCTGATGCTA
GCGGGTGTGCTCTTTGTGAAATTCCA
GCAGTCAAAGAGTTGCAAGGTTCTAGG
AACACACTGTCCTCACGCTTCCG
CGAAATCAACCTGTATGCCTCTACCGA
GATCAGTCATGGCGGCTTTCCG
AACGATGGCGGCTCTGACCGAT
GGGAAAATTCTTGGCGAGGGCTCTT
TGTCCTTAGCCACTTCCGGCGT
TGTGGATGTGGAAGGAGATGTTGCG
GCTGGCCTTGTACTTGGGATACTGA
TGCTCAAGGTGCAGAAGAGGAGGATT
CTAAGGCAGAGTGCAGAGCGTGTG
TTTGTGCTCCTGCCTCAAGAAGAAG
CCATCCAGGCTGTGAAGGTTCAGT
TTAGAGGACATGAGCCAGGACAAGC

AATAACATTGGCACCAGTTGCCAGGAT
TTGAATCCTAGCGACCTCTTGAAGCAAT
AGCAAATTCAACAGGCCAAAGGAGTGTTT
AGGGCTGTGAGCTGCTGAATCTTC
TGTGAGATAGATACGATTCTGTGATGTGG
CACACCACGGCACATTTCTACCAAATC
TGTTCTATTTCCACTTGCCCTCCAGG
TCACTATAGCCAGCCCACTTCTAAAATCT
ATGGGCCCTTGGGTACTTGCCAAAT
GGACAGGTTTGGAAAATGTGAGGGC
CTCATAGAGCCACACCTGAATCCG
AAGGCTGTCGAAAGGAGCTTGGC
AGTGACTGCACAGCCTGCTCAATTTC
TGCGGGTAGCATCAATCGTGGCT
TCAAGGCTCTGGCTCCCACGT
TCATTCCTCTGCTGGCTTCACTTGC
GCTCTCTGGGGATAACACTTTTGCTGT
GTCGAGGAAATCCATTCATACTTCAGGC
GTCCACTTTACTGAATGACTGGCTGGTT
CCATGTAAATTGGCTTCCACCCGC
CTGGACACAAGTAAACCTCAATGGGC
TATACATCCAGCGACCATCCTCGTGA
AATAGGTCGCCAGCACTGCAAA
ATCAGTCAGGTAGACCTCCAAGTAGTG
GCCTCGAGACAAAGCTGGCATACT
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Table S9. Mapping statistics for RNAseq datasets analyzed in Chapter 6.
Sample

# reads

# uniquely
% overall
% uniquely
mapped reads
alignment
aligned
19466800
86.71
67.51
33200119
84.79
65.41
30215926
86.13
65.52
18837623
87.01
70.31
24633711
84.56
65.69
32982354
84.75
69.16
29314075
85.09
67.36
21854595
83.83
66.67
28991726
86.52
65.68
33551643
85.9
64.87

E12_wt_rep1
E12_wt_rep2
E12_wt_rep3
E12_wt_rep4
E12_wt_rep5
E12_mutant_rep1
E12_mutant_rep2
E12_mutant_rep3
E12_mutant_rep4
E12_mutant_rep5

28834445
50753194
46113847
26790859
37497089
47691212
43518363
32780722
44137747
51721667

ControlMO_1
ControlMO_2
ControlMO_3
Ctrl_1
Ctrl_2
Ctrl_3
U12_1
U12_2
U12_3
U4atacMO_1
U4atacMO_2
U4atacMO_3
U6atacMO_1
U6atacMO_2
U6atacMO_3
U2MO_1
U2MO_2
U2MO_3

33116760
35792481
29427665
49668837
55938943
47818700
58239475
44042939
52855582
34823579
38824744
42208535
34823662
33126741
37175290
39956690
32938258
34873412

18405390
16642638
16194756
17057899
24854396
22386180
23654433
18180792
26110341
14813068
13585811
12188437
19989264
17113922
16586355
17503481
21211587
17589322

82.62
77.48
78.62
80.41
83.99
83.4
82.94
81.42
82.33
71.66
82.19
85.66
83.11
83.16
83.48
75.66
84.07
84.45

55.58
46.5
55.03
34.34
44.43
46.81
40.62
41.28
49.4
42.54
34.99
28.88
57.4
51.66
44.62
43.81
64.4
50.44

RS_patient
RS_control_1
RS_control_2
LWS_patient
LWS_control
Healthy_control_1
Healthy_control_2
Healthy_control_3

30836562
35629586
43593170
37332259
34296920
37186902
41634383
39611725

16884137
18560200
22090699
19236253
18777608
19714587
20816920
24539953

62.15
58.39
57.56
58.54
62.08
59.46
56.21
70.15

54.75
52.09
50.67
51.53
54.75
53.01
50
61.95
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Chapter 13 Appendix
#!/bin/bash
organism=Homo_sapiens
IntronType=MinorIntrons
if [[ ${organism} == Mus_musculus ]]
then
U12bedfileStrand=Bedfiles/mm10Ens95_${IntronType}_CanonicalIsoform.bed
ExonbedfileStrand=Bedfiles/mm10Ens95_BioMart_exons.bed
U125SSIntron=Bedfiles/mm10Ens95_${IntronType}_5SSIntronFinal.bed
U123SSIntron=Bedfiles/mm10Ens95_${IntronType}_3SSIntronFinal.bed
ROIbedfile=Bedfiles/mm10Ens95_${IntronType}_RegionOfInterestFinal.bed
elif [[ ${organism} == Homo_sapiens ]]
then
U12bedfileStrand=/Bedfiles/hg38Ens95_${IntronType}_CanonicalIsoform.bed
ExonbedfileStrand=Bedfiles/hg38Ens95_BioMart_exons.bed
U125SSIntron=Bedfiles/hg38Ens95_${IntronType}_5SSIntronFinal.bed
U123SSIntron=Bedfiles/hg38Ens95_${IntronType}_3SSIntronFinal.bed
ROIbedfile=Bedfiles/hg38Ens95_${IntronType}_RegionOfInterestFinal.bed
fi
awk '{print $1 "-" $2 "-" $3}' ${U12bedfileStrand} | sort > ${organism}OneField.txt
for sample in ControlMO Ctrl U12 U4atacMO U6atacMO U2MO
do
for replicate in 1 2 3
do
echo "Compute intron coverage" ${sample} ${replicate}
date
echo ""
if [ -e ../SAM_Files/${sample}_${replicate}_uniquereads_hisat2.sam ]
then
# Exclude spliced reads from sam file
awk -F"\t" -v OFS="\t" '{if ($6!~"N") print $0}' ${sample}_${replicate}_uniquereads_hisat2.sam >
${sample}_${replicate}_uniquereads_hisat2_ExclSplicedReads.sam
nice samtools view -bS ${sample}_${replicate}_uniquereads_hisat2_ExclSplicedReads.sam >
${sample}_${replicate}_uniquereads_hisat2_ExclSplicedReads.bam
nice samtools sort ${sample}_${replicate}_uniquereads_hisat2_ExclSplicedReads.bam -o
${sample}_${replicate}_uniquereads_hisat2_ExclSplicedReadsSorted.bam
# Determine intron coverage and number of reads mapped to intron
nice coverageBed -a ${U12bedfileStrand} -b ${sample}_${replicate}_uniquereads_hisat2_ExclSplicedReads.bam -s -split | awk -F"\t" -v
OFS="\t" '{print $1"-"$2"-"$3, $4, $5, $6, $7, $10}' > CoverageBedMinorIntrons${sample}_${replicate}.bed
# Determine presence of reads to exon-intron boundaries
nice intersectBed -wa -abam ${sample}_${replicate}_uniquereads_hisat2_ExclSplicedReads.bam -b ${ROIbedfile} -s >
IntersectBed${sample}_${replicate}_Exons.bam
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nice intersectBed -wa -abam IntersectBed${sample}_${replicate}_Exons.bam -b ${U125SSIntron} -s | intersectBed -wb -abam - -b
${U12bedfileStrand} -bed -s | awk '{print $13"-"$14"-"$15,$16,$17,$18}' | sort | uniq -c | awk '{print $2, $1}' | sort -k1,1 >
IntersectBed${sample}_${replicate}_Exon-5SSMinorIntronBoundaryFilter.bed
nice intersectBed -wa -abam IntersectBed${sample}_${replicate}_Exons.bam -b ${U123SSIntron} -s | intersectBed -wb -abam - -b
${U12bedfileStrand} -bed -s | awk '{print $13"-"$14"-"$15,$16,$17,$18}' | sort | uniq -c | awk '{print $2, $1}' | sort -k1,1 >
IntersectBed${sample}_${replicate}_Exon-3SSMinorIntronBoundaryFilter.bed
join -a1 -j1 ${organism}OneField.txt IntersectBed${sample}_${replicate}_Exon-5SSMinorIntronBoundaryFilter.bed | awk '{if (NF==2) print $1,
$2; else print $1, "0"}' > IntersectBed${sample}_${replicate}_Exon-5SSMinorIntronBoundaryFilterShortAll.bed
join -a1 -j1 ${organism}OneField.txt IntersectBed${sample}_${replicate}_Exon-3SSMinorIntronBoundaryFilter.bed | awk '{if (NF==2) print $1,
$2; else print $1, "0"}' > IntersectBed${sample}_${replicate}_Exon-3SSMinorIntronBoundaryFilterShortAll.bed
# Determine MSI for all Minor Introns for each sample
NumIntrons=`awk '{print $1"-"$2"-"$3}' ${U12bedfileStrand} | sort | uniq | wc -l`
for i in `seq 1 ${NumIntrons}`
do
Intron=`awk '{print $1"-"$2"-"$3}' ${U12bedfileStrand} | sort | uniq | head -n $i | tail -n 1`
ReadN=`awk -v intron=${Intron} '{if ($1==intron) print $5}'
CAT1/intersectBedSplicedReadsSpliceMinorIntronCanonical5SS3SS${sample}_${replicate}CAT1CountComplete.bed`
ReadA1=`awk -v intron=${Intron} '{if ($1==intron) print $2}' IntersectBed${sample}_${replicate}_Exon5SSMinorIntronBoundaryFilterShortAll.bed`
ReadA2=`awk -v intron=${Intron} '{if ($1==intron) print $2}' IntersectBed${sample}_${replicate}_Exon3SSMinorIntronBoundaryFilterShortAll.bed`
ReadAsum=`expr ${ReadA1} + ${ReadA2}`
Denom=`expr 2 \* ${ReadN} + ${ReadAsum}`
if [[ ${Denom} -gt 0 ]]
then
MSI=`echo ""${ReadAsum} / ${Denom}"" | bc -l`
Gene=`awk -v intron=${Intron} '{if ($1"-"$2"-"$3==intron) print $4}' ${U12bedfileStrand}`
echo ${Intron} ${Gene} ${ReadA1} ${ReadA2} ${ReadN} ${MSI} >> ${sample}_${replicate}_MSI_MinorIntrons.tmp
if [[ -n ${ReadA1} ]]
then
if [[ -n ${ReadA2} ]]
then
if [[ ${ReadAsum} -gt 4 ]]
then
Coverage=`awk -v intron=${Intron} '{if ($1==intron) print $6}'
CoverageBedMinorIntrons${sample}_${replicate}.bed`
PassCoverage=`echo "${Coverage} > 0.95" | bc`
if [[ ${PassCoverage} -gt 0 ]]
then
echo ${Intron} ${Gene} >>
${sample}_${replicate}_MinorIntronsPassFilters.tmp
fi
fi
fi
fi
fi
done
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fi
awk -v OFS="\t" '{print $1, $2, $3, $4, $5, $6}' ${sample}_${replicate}_MSI_MinorIntrons.tmp | sort -k1,1 > ${sample}_${replicate}_MSI_MinorIntrons.txt
sort -k1,1 ${sample}_${replicate}_MinorIntronsPassFilters.tmp > ${sample}_${replicate}_MinorIntronsPassFilters.txt
rm -f ${sample}_${replicate}_MSI_MinorIntrons.tmp
rm -f ${sample}_${replicate}_MinorIntronsPassFilters.tmp
done
done
cat `ls *_MinorIntronsPassFilters.txt` | awk '{print $1}' | sort -k1,1 | uniq > MinorIntrons_MSI_PassFilterIn1replicate.txt
for sample in ControlMO Ctrl U12 U4atacMO U6atacMO U2MO
do
for replicate in 1 2 3
do
join -a1 -j1 MinorIntrons_MSI_PassFilterIn1replicate.txt ${sample}_${replicate}_MSI_MinorIntrons.txt | awk '{if (NF==1) print $1, "gene", "x"; else print $1,
$2, $6}' > ${sample}_${replicate}_MSI_MinorIntrons_PassFilter.txt
done
# Merge values of replicates in one file
key-merge `ls ${sample}_*_MSI_MinorIntrons_PassFilter.txt` | awk '{print $1, $2, $3, $5, $7, $9, $11, $13, $15, $17, $19, $21}' >
${sample}_MSI_MinorIntrons_PassAllFilters.txt
done

275

